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2015 Statistics 
at a Glance 
MANUFACTURING LICENCES IN  
PLACE AT YEAR END FOR HUMAN  
AND VETERINARY MEDICINES
120
NEW MEDICINES FOR 
VETERINARY USE 
AUTHORISED
83
CLINICAL TRIALS WERE 
APPROVED TO COMMENCE IN IRELAND 
ON MEDICINES FOR HUMAN USE
108
VARIATIONS TO MARKETING 
AUTHORISATIONS ISSUED FOR 
HUMAN AND VETERINARY 
MEDICINES
17,122 
HPRA RANK IN EU FOR 
RAPPORTEURSHIPS FOR 
CENTRALLY AUTHORISED  
HUMAN PRODUCTS
7th
THE TOTAL NUMBER  
OF NEW HUMAN  
MEDICINES AUTHORISED
806
 
 
 
 
APPLICATIONS FOR CLINICAL 
INVESTIGATIONS OF MEDICAL DEVICES 
TO BE CONDUCTED IN IRELAND
  
10
EXPORT CERTIFICATES ISSUED
4,346 
HPRA ANNUAL REPORT 2015 3
i
RMPs FOR HUMAN MEDICINES 
SUBMITTED VIA NATIONAL, MUTUAL 
RECOGNITION, DECENTRALISED AND 
CENTRALISED PROCEDURES
356
THE NUMBER OF UNIQUE VISITORS 
WHO ACCESSED THE NEW HPRA 
WEBSITE
206,000  
NATIONAL AND FOREIGN 
INSPECTIONS AND AUDITS 
PERFORMED
344
MEDICAL DEVICE VIGILANCE 
REPORTS RECEIVED AND 
ASSESSED
2,126
SUSPECTED ADVERSE 
REACTIONS REPORTS FOR 
HUMAN MEDICINES RECEIVED
2,810 
YEAR OF HPRA PARTICIPATION 
AT THE BT YOUNG SCIENTIST AND 
TECHNOLOGY EXHIBITION
6th 
RECALLS OF HUMAN 
MEDICINES AND VETERINARY 
MEDICINES
116 
 
 
ENFORCEMENT CASES WERE 
INITIATED IN RESPECT OF 
POTENTIAL BREACHES OF HEALTH 
PRODUCTS LEGISLATION
3,677 S
COMPLIANCE CASES OPENED UNDER 
COSMETIC PRODUCTS MARKET 
SURVEILLANCE PROGRAMME
107
REPORTS OF SUSPECTED ADVERSE 
REACTIONS ASSOCIATED WITH USE 
OF VETERINARY MEDICINES 
RECEIVED
435
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The 12 months in review also represented the final year 
of the HPRA’s ambitious strategic plan for the period 
2011 to 2015 which set out clear goals and objectives 
to govern the organisation’s strategic direction and 
work programme. The development of a new plan, 
which outlines the strategic focus of the HPRA for the 
next five-year period, was overseen by the Authority in 
2015 and, importantly, involved extensive stakeholder 
consultation.   
The HPRA has a well established reputation as a 
highly capable and effective regulatory authority both 
internationally and at home. It has been a pleasure, 
along with my fellow Authority members, to support 
its operations and development over the past number 
of years as it continued to successfully deliver a world 
class regulatory regime for the health products sector 
in Ireland. 
This report highlights the many achievements delivered 
during the past year as a result of the commitment and 
hard work of HPRA staff, the active contributions of its 
Authority and advisory committee members, as well 
as the support of the many stakeholders who actively 
engaged with our organisation.
In carrying out its regulatory remit, the HPRA puts the 
safety and health of people and animals at the centre 
of all its activities and areas of remit. These include an 
extensive range of primary functions such as product 
authorisation, manufacturing and market compliance, 
product monitoring and safety communications. All of 
this work incorporates continued risk management and 
assessment across thousands of products on the market 
with the same overarching objective to protect and 
enhance public and animal health.  
We operate in a changing world where advances 
in medicines and new technologies are rapidly 
transforming treatments and ultimately leading to 
new health products. There is no doubt that these 
new products, whether medicines or medical devices, 
can improve the quality of life, and in many cases, 
extend the life expectancy of those who use them. Our 
important role is to ensure that these products are as 
safe as possible and that they work as intended. We 
do this through reviewing the pre-market evidence 
and data and by continuously monitoring the 
products once they are in actual use. In tandem, our 
organisational capabilities and skills must continue 
to keep pace with product innovation, new scientific 
data and developments in the regulatory environment 
so as to ensure the best possible health outcomes. 
The HPRA’s strategic plans over the last decade have 
acknowledged this and made provisions to ensure that 
the organisation continually has access to the most 
up-to-date information and expertise to appropriately 
support these continually evolving industries. 
Market diversification and reconfiguration also 
continues to be a feature of the pharmaceutical, 
medical device and cosmetic product sectors. In 
addition to the continuous up-skilling of the required 
expertise, and an efficient and robust risk-based 
regulatory model, the effective oversight of these areas 
requires co-operation at an EU and global level to 
enable both the sharing of safety information and the 
development of consistent regulatory practices. During 
2015, the HPRA continued to actively participate and 
provide its expertise and inputs into the European 
regulatory network where strategic decisions and 
actions are undertaken in respect of a huge number 
of health products on the Irish market. The HPRA 
contributes significantly to the work of the European 
Medicines Agency, where it is represented on all major 
decision-making committees, and we are also heavily 
active at the Heads of Medicines Agencies. In relation 
to medical devices, and specifically the new legislation 
being devised at EU level, the HPRA is playing a 
significant role through the contribution of our national 
experts. When completed, the recast of this legislation 
will provide significantly enhanced safeguards for users 
of medical devices across Europe. The HPRA is also 
very active within the network for medical devices in 
Europe and is a key participant through its experts 
Chairman’s Statement
The annual report of the Health Products Regulatory 
Authority (HPRA) details the extensive work programme 
undertaken by the national regulator during 2015 to 
deliver on its role to protect public and animal health. 
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within the many committees and working groups 
which have a role in the regulation of devices. At an 
international level, our agency continues to be one 
of the lead partners in the ongoing development of 
the International Coalition of Medicines Regulatory 
Authorities (ICMRA) and the International Medical 
Device Regulator’s Forum (IMDRF).
Our remit is comprehensive with responsibility 
for the regulation of clinical trials, human and 
veterinary medicines, medical devices, blood and 
blood components, tissues and cells, and cosmetic 
products. We play a role in the regulation of controlled 
substances and of organs intended for transplantation 
while also overseeing the regulation of animals 
used for scientific purposes. Looking at the key 
data from the HPRA’s 2015 output gives just some 
indication of the level of authorisation, assessment 
and safety monitoring work that is carried out across 
the organisation with increases in a number of work 
areas witnessed during the year. Close to 900 new 
human and veterinary medicines were authorised while 
over 17,000 variations to market authorisations were 
evaluated. We completed more than 370 inspections 
and audits across a range different sites and facilities to 
ensure that there was compliance in respect of relevant 
standards and legislation. 
A significant area of our work is the continuous 
monitoring of the safety and quality of products on the 
market. With many thousands of products available 
this involves our post market teams proactively and 
reactively taking action when appropriate to minimise 
risk for patients and consumers. In 2015, the HPRA 
assessed some 3,200 adverse reaction reports in 
relation to human and veterinary medicines. Our risk 
based sampling and analysis programme resulted in 
the assessment of 480 product samples with a total 
of 772 quality defects relating to medicines reported 
to, or identified by, the HPRA. As regards medical 
devices, over 2,100 vigilance reports were received. 
Each individual case arising from of our monitoring 
and vigilance activities is assessed by appropriate 
experts to review risks and actions if required. Where 
action is deemed necessary, the HPRA has a range of 
tools it can use to protect public and animal health. 
In 2015, for example, 116 medicine recalls were 
completed including the issuing of targeted safety 
communication to ensure that where stakeholders 
needed to be informed of new information, this was 
done so swiftly. The HPRA is grateful to those members 
of the public and healthcare professionals who take the 
time to inform us of their experiences, observations or 
concerns in respect of health products.  
During 2015, our Chief Executive, Mr Pat O’Mahony, 
moved to the Department of Health to take up 
the position of Deputy Secretary, Governance and 
Performance. On behalf of the outgoing Authority, 
I wish to express our sincere gratitude to Pat for his 
visionary leadership of this organisation for over a 
decade, during which time the HPRA’s remit expanded 
significantly. The Authority members wish his successor 
as Chief Executive, Ms Lorraine Nolan, former Director 
of Human Products Authorisation and Registration, 
well in her new role and are confident that under 
her leadership the HPRA will continue to be a highly 
effective regulatory agency. Particular thanks are due to 
Ms Rita Purcell who acted as Chief Executive during the 
interim period.
On behalf of the Authority, I would like to take this 
opportunity to thank the Minister for Health, the 
Minister for Agriculture, Food and the Marine, and the 
staff of their departments for their continued support of 
the HPRA in its endeavours and actions. 
Behind the extensive work outputs detailed in this 
report, are the highly skilled and experienced staff of 
the HPRA. At the beginning of my tenure as Chairman, 
I noted the vigour, passion and enthusiasm with which 
they approach their individual roles. I can assure all 
our stakeholders that this very much remains the case 
and on behalf of the Authority I thank all staff for their 
ongoing contribution and commitment. 
Additionally, on a personal note, I would like to thank 
my fellow Authority members, past and present, for 
their tremendous contribution to the strategic direction 
of the HPRA. I also wish to express my appreciation to 
those who have chaired the HPRA advisory committees 
and sub-committees. The contribution of all Authority 
and committee members is of huge value to the HPRA 
as it works to carry out its broad public and animal 
health remit. 
As outgoing Chairman of the Authority, I am pleased 
to have played my part in supporting everyone at the 
HPRA as we sought to drive high quality outputs across 
all areas of the organisation. It has been a privilege to 
serve as Chairman of this highly regarded public body 
and I wish my successor, Ms Ann Horan, the very best 
in her new role.
 
 
 
Michael D. Hayes 
Chairman
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* Term ended 31 December 2015
Authority Members
The Authority of the HPRA is appointed by the Minister for Health in accordance with the powers conferred by 
subsection 2 of section 7 of the Irish Medicines Board Act, 1995. There were nine Authority members up to 31 
December 2015.
Mr. Michael D. Hayes 
(Chairman)*
Mr. Pat Brangan
Mr. Wilfred J. Higgins Ms. Ann Horan  Prof. Mary Horgan Dr. Elizabeth Keane
Mr. Noel O’Donoghue* Prof. Caitriona O’Driscoll Dr. Diarmuid Quinlan
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Management Committee as of June 2016
Management Committee
Ms. Lorraine Nolan  
Chief Executive
 
Ms. Rita Purcell  
Deputy  
Chief Executive
Dr. J.G. Beechinor 
Director of  
Veterinary Sciences
Dr. Jayne Crowe  
Director of Human 
Products Authorisation  
and Registration
Dr. Caitríona Fisher 
Director of Quality, 
Scientific Affairs and 
Communications
Dr. Joan Gilvarry  
Director of Human  
Products Monitoring
Mr. Kevin Horan 
Director of ICT and 
Business Services 
Mr. John Lynch  
Director of Compliance
Ms. Lynsey Perdisatt 
Director of Human  
Resources and Change 
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Strategic Plan 2011 – 2015  
The layout of the annual report for 2015 is structured to 
ensure that the main chapters are closely aligned with 
the HPRA’s five high-level strategic goals.
These goals are to:
1. Enhance healthcare product safety and patient 
outcomes by effective risk management and market 
surveillance.
2. Deliver clear, relevant and timely communications to 
patients, consumers and healthcare professionals.
3. Improve service delivery within a high quality, risk-
based regulatory framework.
4. Influence legislation and policy development at 
European and international levels for the benefit of 
public and animal health.
5. Build future capabilities to meet evolving regulatory 
requirements, and scientific and technological 
advances.
Chief Executive’s Report
While I have written the report, I wish to acknowledge 
that it outlines the activities of a year under the 
leadership of my predecessor, Pat O’Mahony, and my 
colleague, Rita Purcell, who served as Acting Chief 
Executive during an interim period.  
The report, which is also the first full-year review 
under the HPRA name, outlines another year of high 
performance for our organisation and demonstrates 
again our absolute commitment to the protection and 
enhancement of public and animal health.  
It is a great pleasure to present  
my first Chief Executive’s Report  
on the annual activities of the 
Health Products Regulatory 
Authority (HPRA). 
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Significantly, the past year marked the end of 
our existing strategic plan for 2011 to 2015. The 
final implementation report showed significant 
achievements in respect of each of the five strategic 
goals, something that is reflected throughout this 
and previous annual reports. During the past year, we 
also commenced the process for developing our next 
strategic plan which covers the period from 2016 to 
2020. This plan was launched early in 2016 with the 
intention of building on the achievements of the past, 
while at the same time addressing future requirements 
and opportunities. 
 
Authorisation, Registration  
and Licensing Activities  
Our pre-market activities are a core regulatory 
function of the HPRA. They include the authorisation 
and registration of healthcare products, as well as the 
licensing of manufacturing, wholesaling and related 
activities. Our focus is on providing an effective and 
efficient regulatory framework that ensures the timely 
availability of appropriate health products. Among the 
activities and achievements of note during 2015 were 
the following:
• A total of 108 clinical trials for human medicines 
were approved to commence in Ireland compared 
with 80 the previous year. There were 10 
applications for clinical investigations of a medical 
device, which was the same number recorded in 
2014.
• In respect of human medicines, the HPRA 
assessed 137 new national applications (including 
parallel product authorisations), 67 applications 
via mutual recognition procedures (MRP) and 372 
via decentralised procedures (DCP).
• In continuing our active contribution to the 
European human medicines licensing system, 
we acted as reference (lead) Member State for 
the assessment of 17 MRP and DCP procedures. 
The HPRA was also allocated as rapporteur or 
co-rapporteur for 12 new marketing authorisation 
applications by the European Medicines Agency 
(EMA). Based on allocations for the year, the 
HPRA ranked as joint seventh in the EU for 
rapporteurships for centrally authorised human 
products. We acted as lead in 39 scientific advice 
procedures for medicines proposed for the 
treatment of a broad range of conditions.
• During the 12 months in review, the HPRA issued 
15,691 variations to marketing authorisations for 
human products authorised through the national 
or MR procedures. Of note, at a European 
level, we acted as rapporteur for one Article 
45 procedure and nine procedures relating to 
Paediatric Investigational Plans (PIPs).
• In the area of veterinary medicines, we authorised 
a total of 83 new product applications and 1,431 
variations to existing authorisations. 
• A total of 371 notifications of medical devices to 
the medical device register were recorded while 
43 organisations registered with the HPRA as Irish 
based manufacturers of medical devices.
• The number of manufacturing licences in place at 
year end for human and veterinary medicines was 
120 while there were 287 wholesale distribution 
authorisations for human medicines.
• There were 323 individual authorisations and 114 
project authorisations issued in respect of the use 
of animals for scientific purposes.
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Safety and Compliance 
Monitoring 
Monitoring the safety and quality of medicines, 
medical devices and other health products that have 
been licensed or registered for use in Ireland is a core 
public health function of the HPRA. Our regulatory 
decisions and actions in this regard are based on the 
best available information regarding benefit and risk.
It is also a function of the HPRA to monitor and 
inspect industry compliance with legislation, policies 
and procedures. Our focus is to make sure that 
all health products manufactured, processed or 
distributed in Ireland meet essential quality standards.
• A key part of our monitoring activity is the 
operation of a national pharmacovigilance scheme 
for adverse reactions, or side effects, associated 
with the use of human medicines. In the past 
year, the HPRA received a total of 2,810 valid new 
adverse reaction reports which is a figure broadly 
consistent with the reporting rates seen in the 
recent past. 
• In respect of human medicines, the HPRA again 
contributed to the work-sharing programme for 
signal detection within the EU. We acted as lead 
Member State for the detection and management 
of signals for 54 active substances authorised 
nationally. We also retained responsibility for 
assessing any signals arising as a result of signal 
detection for 27 centrally authorised active 
substances (or combination of active substances). 
In addition, the HPRA acted as concerned 
Member State in five newly initiated EU safety-
related referrals.
• Periodic safety update reports (PSURs) are 
vigilance reports submitted by marketing 
authorisation holders. For human medicines, as 
part of its contribution to the EU PSUR single 
assessment procedure, the HPRA contributed to 
the evaluation of 1,002 PSURs in 2015.
• The upward trend in the number of national 
reports of suspected adverse events to veterinary 
medicines continued in 2015 with 437 reports 
received by year end. We also completed 
the evaluation of 1,205 PSURs for veterinary 
medicines. 
• Post-market surveillance and vigilance activities 
are employed to monitor the safety and quality 
of medical devices. A total of 2,126 medical 
device vigilance reports were received and 
assessed during 2015 while we also commenced 
324 market surveillance cases. Both figures 
represented a slight increase compared to 2014.
• Over the course of 2015, 344 inspections and 
audits were performed compared to 260 in 2014. 
The figure for the past year included 124 Good 
Manufacturing Practice (GMP) inspections, 126 
Good Distribution Practice (GDP) inspections, 
15 Good Clinical Practice (GCP) inspections, 
16 medical device audits and 26 covering 
blood, tissues and organs. A full re-designation 
assessment of the Irish notified body, the 
National Standards Authority of Ireland, was also 
completed.
• As part of our risk-based sampling and analysis 
programme, we sent a total of 297 product 
samples for analytical testing while the packaging 
and labelling of a further 156 medicines and other 
products from the Irish market were examined. 
• In certain cases, it may be necessary to withdraw, 
or recall, products from the Irish market in order 
to protect public health. In 2015, 116 medicine 
recalls occurred. 
• In total, 3,677 enforcement cases were initiated 
with 1,136,494 dosage units of medicines being 
detained.
• The national sampling and analysis programme for 
cosmetics, which involves close co-operation with 
the Health Service Executive (HSE), resulted in 
the sampling of 469 such products. Of these, 398 
were analysed by year end with 71 being found to 
be non-compliant.
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Legislative and Regulatory 
Developments
The regulatory role of the HPRA continues to evolve 
and grow in line with new national and European 
legislation and in response to other changes and 
developments in our operating environment. 
Legislative Changes and Updates 
During the past year, representatives from across 
the HPRA were heavily involved in implementing, 
or preparing for the implementation of, new and 
updated EU directives which will typically result in 
significant changes to how specific health products 
are regulated across Europe.  
• As regards the ongoing implementation of the 
remaining aspects of Directive 2011/62/EU on 
falsified medicines, the HPRA continued to 
participate in the expert group convened by 
the Commission to assist with drafting of the 
Delegated Regulation in respect of proposed 
safety features on specified human medicines. It 
is expected that the Regulation will be finalised 
early in 2016 with a three-year period thereafter 
for implementation. We also liaised with industry 
and other stakeholder organisations in Ireland 
in relation to the establishment of a National 
Medicines Verification Organisation. 
• New clinical trials legislation (Regulation (EU) 
No. 536/2014) will come into effect in Europe 
in mid-2016. During the past year, the HPRA 
continued to progress the development of 
systems and procedures necessary to meet the 
new requirements. 
• The HPRA continued its work to support the 
phased implementation of EU pharmacovigilance 
legislation. This included participation in a pilot 
of a PSUR repository as well as user acceptance 
testing in preparation for mandatory use of the 
repository from June 2016. During 2015, the 
HPRA continued to contribute to three EMA / 
Member State project teams concerned with 
collection of key information on medicines, 
better analysis and understanding of data and 
information, and committees and communications 
with stakeholders. 
• Negotiations in respect of the European 
Commission’s proposals for Regulations on 
medical devices and in vitro diagnostic (IVD) 
medical devices reached a new phase with 
the adoption of a ‘General Approach’ on the 
legislative texts by the European Council. This 
allowed for the initiation of trialogue discussions 
with the European Parliament and the EU 
Commission on the dossiers, which is one of the 
key elements of the ordinary legislative process. 
The HPRA strongly supports the introduction 
of the revised legislation which we believe 
will represent a significant improvement and 
strengthening of the regulatory system for 
devices. Throughout 2015, the HPRA provided 
significant support to the Department of Health 
and the Permanent Representation of Ireland in 
Brussels for the purposes of negotiation of the 
legislation at the European Council Working Party 
and at various expert working groups. 
SCOPE Joint Action
The Strengthening Collaboration for Operating 
Pharmacovigilance in Europe (SCOPE) Joint 
Action is intended to support the operation of 
pharmacovigilance in Europe in light of requirements 
introduced by new pharmacovigilance legislation. 
During 2015, the HPRA contributed to both risk 
communications and lifecycle pharmacovigilance 
which are two of the eight work packages being 
implemented under SCOPE. The HPRA is the topic 
lead in respect of carrying out an impact assessment 
of risk communications under work package 6 (WP6). 
This incorporates the collection of information on 
risk communications practice in the EU network to 
better understand the communication channels and 
tools used. We also contributed in 2015 as a partner 
under work package 8 (WP8) relating to lifecycle 
pharmacovigilance.
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Existing Medical Devices Regulatory 
Framework
The HPRA has taken a leading role, along with a 
number of other European competent authorities and 
the European Commission, in enhancing the existing 
regulatory framework for medical devices in advance 
of the introduction of the revised legal framework. 
A key focus has been to improve the performance 
of notified bodies and their oversight by authorities. 
This was achieved by the development of an EU wide 
joint assessment scheme for notified body oversight 
by authorities and the HPRA continues to be part of a 
small expert group which oversees and co-ordinates 
its implementation. During 2015, the HPRA directly 
participated as experts in six joint assessments of EU 
notified bodies while the Irish notified body was also 
subject to an EU joint assessment.
In addition, throughout 2015, we progressed 
a number of initiatives to further enhance and 
strengthen our market surveillance and vigilance 
activities.  
Participation in the European and 
International Regulatory Systems
The health products and associated areas regulated 
by the HPRA are part of a dynamic and developing 
international industry. The HPRA is committed to 
playing its part in the global regulatory network thus 
ensuring that we represent and protect the interests of 
Irish patients and consumers.
Our participation and contribution at a European 
level continues to be significant with HPRA scientific 
and technical staff contributing to a broad range of 
committees and working parties at the EMA, the 
European Commission, the Heads of Medicines 
Agencies (HMA) and via other platforms. We also 
contribute where appropriate to relevant international 
organisations and initiatives. 
The following are some of main developments and 
HPRA contributions from the past 12 months which 
are in addition to those already outlined in my report.
• The HPRA continued in the role of Vice-Chair 
of the International Coalition of Medicines 
Regulatory Authorities (ICMRA). This group acts 
as a forum to support international co-operation 
among medicines regulatory authorities. It aims 
to avoid duplication and promote informed, risk-
based allocation of resources.   
• Our Pharmacovigilance Manager for human 
medicines continues to represent the World 
Health Organization (WHO) as a member of the 
Board of the Uppsala Monitoring Centre (UMC) 
and WHO Collaborating Centre for International 
Drug Monitoring. 
• The HPRA again served as a member of the 
European delegation on the Management 
Committee of the International Medical Device 
Regulators Forum (IMDRF). This forum seeks to 
promote the harmonisation of medical device 
regulation across the globe. In 2015, the HPRA 
hosted a meeting of the IMDRF Medical Device 
Single Audit Program (MDSAP) working group in 
Dublin.
• In July, the Irish Pharmacovigilance Risk 
Assessment Committee (PRAC) delegate was 
elected to serve a further three years as Vice-Chair 
of this important EMA public health committee. 
• The Pharmacovigilance and Risk Management Lead 
contributed to a number of strategies to support 
stakeholder engagement as well as to a range of 
other specialist topics at a European level. She also 
participated in a number of initiatives exploring 
development of the regulatory environment, 
strategies to facilitate access to innovative 
medicines for patients in need, and benefit-risk 
management through the product lifecycle.
• As a member of the Benchmarking of European 
Medicines Agencies (BEMA) steering group, the 
HPRA continued to work with other Member 
States to prepare for the fourth benchmarking 
cycle which is due to begin in 2016. 
• Our contribution to the veterinary medicines 
regulatory network is primarily through our 
involvement at the EMA, where our Veterinary 
Assessment Manager is the Vice-Chair of the 
Committee for Medicinal Products for Veterinary 
Use, and at the HMA. 
• The revision of the legal framework for veterinary 
medicines was again a key focus in 2015 and the 
HPRA provided practical support and advice to 
the Department of Agriculture, Food and the 
Marine during Council Working Party discussions.
• The HPRA contributed to deliberations in respect 
of a number key topics as part of the EU National 
Committees for the Protection of Animals used for 
Scientific Purposes.
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• At a European level, the HPRA was an active 
participant in the Medical Devices Expert Group 
(MDEG) and is the chair of three taskforces 
including the vigilance co-ordinating competent 
authority role.
• The HPRA is an elected member of the Executive 
Group of the Competent Authority for Medical 
Devices (CAMD). In November 2015, the 37th 
CAMD meeting was hosted in Dublin by the HPRA 
on behalf of the Luxembourg Presidency of the 
European Council.
Interchangeable Medicines
Under the Health (Pricing and Supply of Medical 
Goods) Act in June 2013, the HPRA was tasked with 
publishing a list of interchangeable medicines to 
facilitate generic substitution by pharmacists and to 
allow for the introduction of a reference pricing system 
by the HSE. This work continued during 2015 and 
by year end there was a total of 44 active substances 
included on the list. 
Legal Classification of Medicines
The HPRA has taken a proactive approach to the 
reclassification of the legal status of medicines. We 
have identified products which we consider could 
be safely made available without prescription in 
pharmacies, or made more widely available in general 
retail outlets such as supermarkets. Companies have 
been invited to make applications to have these 
medicines reclassified and, on foot of this proactive 
approach, a number of reclassification applications 
were completed in 2015. Further progress is 
anticipated during 2016.
Responding to Medicines Shortages
We continue to work closely with the Department 
of Health and other stakeholders in relation to the 
management of shortages of medicines impacting the 
Irish market. One mechanisms used by the HPRA to 
help alleviate shortages is the granting of a temporary 
authorisation for a batch of a product known as a 
‘batch specific request’. During 2015, the HPRA 
reviewed 115 such requests.
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Stakeholder Engagement  
and Communications
The HPRA is committed to ensuring that all our 
stakeholders have timely access to relevant safety and 
regulatory information and we continue to expand 
and develop our communications and engagement 
activities. In addition to ongoing meetings with key 
stakeholders, we implemented and further developed 
a number of significant communications programmes 
and initiatives during 2015. 
Events
HPRA information events and seminars, which are 
all organised and managed by an in-house events 
team, provide regulatory guidance and updates to 
a range of stakeholders and include presentations 
from HPRA staff and, where appropriate, external 
contributors. These events also enable attendees to 
submit questions, seek clarifications and network with 
colleagues. A number of information seminars were 
hosted during 2015 focused on topics such as herbal 
medicines, cosmetic products and the regulation 
of human tissues and cells. An animal welfare body 
training workshop and seminar was also organised on 
behalf of the National Committee for the Protection of 
Animals used for Scientific Purposes. Additionally, the 
HPRA also hosted one European and one international 
meeting focused on the regulatory system for medical 
devices.
In January 2015, thousands of students as well as 
teachers, parents and members of the general public 
from all over Ireland, visited the HPRA’s exhibition 
stand at the BT Young Scientist and Technology 
Exhibition 2015. This was the sixth year of HPRA 
participation and our stand again focused on building 
awareness of the significant role the HPRA plays in 
protecting public and animal health.
Publications
The HPRA continued to produce an extensive range 
of publications during 2015. As well as new and 
updated regulatory guides, we continued to publish 
our drug safety, medical devices and medicinal 
products newsletters which are focused on updating 
stakeholders in respect of key safety and regulatory 
issues. We also published specific safety warning and 
notices as required in respect of human and veterinary 
medicines, medical devices and cosmetic products. 
All these documents and notices are published online 
and we encourage stakeholders to subscribe to our 
e-mail alerting system to receive notifications of new 
content and information published on our website.  
During 2015, the HPRA also published an information 
leaflet highlighting the importance of reporting 
suspected adverse events following the use of 
veterinary medicines. Details on what information 
should be included in a report are also provided as 
are instructions on how to report. We also published 
a leaflet, developed with the input of the National 
Committee for the Protection of Animals used for 
Scientific Purposes, which is intended to support the 
work of the Animal Welfare Body in each research 
establishment in promoting the 3R principles 
(replacement, reduction, refinement), which provide a 
framework for humane scientific research.
HPRA Website
Our website continues to be a critical component 
of our communications programme and we are 
committed to its ongoing development and 
enhancement to ensure it remains an attractive and 
user-friendly resource. Over 200,000 unique visitors 
accessed the HPRA website during 2015 while there 
were in excess of 536,000 visits in total.
As well as the addition of new content and sections 
during the past year, we also implemented a search 
engine optimisation (SEO) and pay-per-click (PPC) 
campaign which resulted in both increased traffic 
to the HPRA website and improved rankings for the 
HPRA in search results. In addition, an online survey 
among the users of our website was completed in 
August. While the user satisfaction levels were at 
a high level overall, the specific feedback received 
will be used to guide the future development of our 
online presence.
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Parliamentary Affairs 
The HPRA engaged significantly with elected 
representatives and government officials throughout 
2015. We responded to 125 parliamentary questions 
during the year while more than 100 further requests 
for information were received from the Department of 
Health, other government departments and members 
of the Oireachtas. We also addressed the Oireachtas 
Joint Committee on Health and Children in December 
during a meeting to discuss the safety of the HPV 
vaccine. 
Organisational Management and 
Development
It is vitally important that our organisational 
capabilities continue to expand and evolve in line 
with regulatory and scientific developments while we 
must also display the flexibility required to adapt to 
changes in the environment in which we operate.
Change is something that we have constantly 
embraced in the HPRA and we are committed to 
ensuring that we have the requisite structures, systems 
and processes in place to deliver on our public health 
mission.
Human Resources and Change
The retention, engagement and continuing 
development of our highly skilled employees, is 
central to the HPRA delivering on its public health 
remit. Our new organisational competency of 
innovation and creativity, launched as part of the 2015 
Performance Development Programme (PDP) process, 
framed our approach to the development of many of 
our human resources initiatives during the past year. 
PDP continues to be one of our core platforms 
to support high performance, superior service 
delivery and the development of our staff. The 
programme was enhanced during 2015 with the 
full implementation of a range of tools designed to 
support employees and people managers in using the 
programme.
Our learning and development strategy continued 
to focus on staff development as one of our key 
motivation and retention tools. A full range of 
developmental in-house programmes were delivered 
in addition to new manager and PDP training. A group 
of HPRA managers also completed our externally 
accredited Leadership Development Programme.
During 2015, a number of projects requiring change 
management support were commenced. This 
included the creation of the Quality, Scientific Affairs 
and Communications directorate and the ongoing 
development of the EOLAS workflow system. The 
human resources and change team were also involved 
in the capacity building project that sees the HPRA 
contributing to the development of the Zambian 
medicines agency. As regards the public sector 
reform agenda, a comprehensive communications 
programme outlining the detail of the reforms and the 
associated impact on individuals was delivered to our 
employees. 
The HPRA continues to recognise the importance of 
supporting employee engagement and commitment. 
Building on the previous success of our wellness 
and health initiatives, we further developed this 
programme to deliver a range of initiatives during the 
year, with staff engagement levels for the programme 
remaining high. Our lunchtime learning programme 
operated in tandem with the wellness initiatives while 
we also reintroduced our organisational awareness 
programme with the purpose of highlighting the role 
and activities of individual departments and sections 
within the HPRA.
We are committed to managing our resources in 
line with public sector policy with a focus on internal 
skills development and the reallocation of tasks 
and responsibilities where possible. When required, 
recruitment of staff in specialist areas was completed 
in line with Department of Health approvals.
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Information Technology and Business 
Services 
Technology is recognised as a key component in 
supporting the regulatory activities of the HPRA at 
both national and international levels. We continue 
to actively contribute to, and in certain cases lead, a 
number of key national and pan-European technology 
projects. This includes the ongoing development and 
management on behalf of the wider EU regulatory 
community of the Common Electronic Submission 
Portal (CESP). The CESP activity levels again 
grew substantially in 2015, handling over 350,000 
submissions on behalf of more than 30 European 
regulatory organisations and the pharmaceutical 
industry.
The HPRA is also actively engaged at national level 
through its involvement with the National Health Data 
Standards Committee and we work closely with other 
relevant agencies including the HSE, NSAI, HIQA and 
eHealth Ireland on a number of mutually beneficial 
projects. During 2015, the HPRA also commenced 
development of a new registration system to support 
the implementation of new legislation to provide 
emergency access to certain prescription-only 
medicines.
An area of significant focus for our information 
technology and business services team, as well as 
many other colleagues across the organisation, 
is the ongoing development of a new workflow 
technology solution, known as EOLAS. The new 
system will enable the consolidation and replacement 
of a number of legacy solutions and will provide a 
new workflow and data management platform for 
the entire organisation. Considerable progress was 
achieved in respect of the the design and build of the 
system during 2015 with an initial launch expected in 
the second half of 2016.  
Financial Performance
In common with many of its peers internationally, the 
HPRA is primarily self-funded through a regulatory fee 
system. Fees are approved each year by the Minister 
for Health following a public consultation. The HPRA is 
committed to the highest standards of independence 
and governance so as to ensure quality of service 
combined with value for money. Throughout the past 
12 months, we continued to successfully manage the 
affairs of the HPRA in line with our statutory obligation 
that income at least meets costs.
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The Future
To ensure that we continue to deliver on our mission 
to protect and enhance human and animal health, the 
HPRA must be prepared for both the challenges and 
opportunities that will no doubt arise during 2016 and 
beyond. Our new strategic plan for the years 2016 
to 2020, which was launched early in 2016, will be 
central to our future planning and provides a clear 
roadmap for the future focus and development of 
the HPRA. The strategy also reflects the key issues 
and work areas highlighted during an extensive 
consultation process and we look forward to working 
in collaboration with all our stakeholders to deliver on 
our plan in the years ahead.
As regards 2016 specifically, we can expect that the 
overall workload for the organisation will continue to 
expand and diversify in response to legislative and 
regulatory developments as well as advances in new 
innovative products and technologies. The former 
includes the ongoing development of new legislation 
in respect of both veterinary medicines and medical 
devices which we know will result in quite significant 
changes to how these product areas are regulated. 
We will maintain a risk-based approach to our 
regulatory work. We will continue to review and assess 
our own processes and will adopt changes across the 
organisation where these are deemed necessary and 
beneficial. We will continue to enhance our quality 
management systems and our IT capabilities with 
the latter incorporating the launch of the HPRA’s new 
workflow and data management platform. A new 
communications strategy will also be developed 
to support our stakeholder engagement activities 
and to build further awareness of our public health 
role. There will be an ongoing review of our funding 
provision and management of our cost base so as 
to ensure optimal use of resources. Of note, we 
anticipate that a fee model that reflects our regulatory 
role in respect of medical devices, will be introduced. 
Finally, in parallel with the development of our new 
strategic plan, we will also finalise and launch a new 
human resources strategy. This broad, long-term plan 
will focus on a number of key elements including 
the critical area of staff retention and engagement. 
Learning and development will also be a priority area 
as we endeavour to maintain and enhance the skills 
that are required in an increasingly complex regulatory 
environment.
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AUTHORISATION,  
REGISTRATION AND  
LICENSING ACTIVITIES  
The authorisation and registration of health 
products is a core public health function 
of the HPRA. These are the regulatory 
actions which are carried out before a health 
product can be marketed and supplied in 
Ireland. Ensuring timely approval of new 
product applications in particular, following 
a positive assessment of safety, quality and 
effectiveness, gives patients and users access 
to a range of appropriate treatments.
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The HPRA is responsible for the authorisation of 
human and veterinary medicines, of clinical trials 
and for the registration of certain medical devices. 
We licence manufacturers and wholesalers of human 
medicines, manufacturers of veterinary medicines 
as well as blood and tissue establishments and 
organ transplant centres. We also grant relevant 
authorisations under scientific animal protection 
legislation and we are responsible for issuing export 
certificates for medicines, medical devices and 
cosmetics.
In addition, the HPRA provides a classification service 
to assist stakeholders in clarifying whether products 
should be categorised as human medicines, veterinary 
medicines, medical devices, cosmetics or none  
of these.  
Human 
Medicines
Borderline Product Classification
The HPRA regularly receives queries in regard to the 
correct classification of human medicines, veterinary 
medicines and medical devices. Products in these 
categories fall under the remit of the HPRA from a 
regulatory perspective and are distinct from other 
products which are outside the HPRA’s remit. For 
products for human use, a classification service is 
operated for products which are on the borderline 
between medicines and other products such as food 
supplements, cosmetics and medical devices. 
Requests for classification, whether external 
or internal, are presented to an internal, multi-
disciplinary, human medicine classification committee. 
This committee met 11 times in 2015 and considered 
a total of 80 new products. In addition, there were 16 
products revisited from pre-2015.
The committee has a close working relationship with 
the Food Safety Authority of Ireland (FSAI). During 
the course of 2015, the FSAI notified the HPRA of 59 
products which had been brought to its attention and 
which it considered to fall more appropriately under 
the HPRA’s remit. Where this turned out to be the 
case, these products were followed up by the HPRA.
Clinical Trials
The role of the HPRA is to assess applications from 
sponsors to conduct clinical trials in Ireland. Sponsors 
include pharmaceutical companies and / or research 
institutions. The HPRA approves the clinical trial 
protocols which describe in detail how each trial is to 
be conducted and outlines the steps that will be taken 
to protect the health of volunteers or patients.
In 2015, 108 clinical trials were approved to 
commence in Ireland. This is an increase compared 
with the total of 80 trials approved in the previous 
year. The key areas of interest for clinical research 
continue to include cancer and blood disorders.
Voluntary Harmonisation Procedures
A voluntary harmonisation procedures (VHP) is a 
co-ordinated work sharing assessment procedure 
for multinational clinical trials. This procedure was 
established by the national competent authorities for 
clinical trials from across the EU.
The HPRA participated in 15 VHPs for clinical trials 
during 2015, compared with seven during the 
previous year. The HPRA acted as lead Member State 
for the assessment of eight of these VHPs in 2015. 
This compares with a figure of two in the previous 
year.
The VHP is similar to the approval process for clinical 
trials under planned new legislation. For this reason, 
it is popular with sponsors wishing to gain experience 
and the HPRA continues to actively participate in this 
procedure.
New Marketing Authorisation 
Applications  
Prior to a new medicine being placed on the Irish 
market, it must be assessed and authorised (licensed) 
by the HPRA or by the European Medicines Agency 
(EMA) in conjunction with the European Commission. 
The assessment involves establishing that a medicine’s 
health benefits outweigh its known risks. Where this is 
the case, it may be granted a marketing authorisation.
There are a number of routes through which a product 
can be authorised by the HPRA. These include the 
national procedure, the mutual recognition procedure 
(MRP) and the decentralised procedure (DCP). Both 
MRP and DCP involve the simultaneous submission of 
applications in a number of EU Member States. The 
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assessment involves the input from all of the relevant 
competent authorities in evaluating the benefit / risk 
of the product(s). The DCP route differs from the MRP 
in that the product has not previously been authorised 
within the EU. 
The following applications were assessed by the HPRA 
during 2015:  
• 137 new national applications (including parallel 
product authorisations); 
• 67 applications made under the MRP; 
• 372 applications made under DCP. 
 
The HPRA acted as reference (lead) Member State 
for the assessment of 17 of the MRP and DCP 
procedures.
The centralised route is another mechanism whereby 
products can be authorised in Ireland. In this 
procedure, the assessment is carried out by Member 
States (MS) appointed as lead assessor (rapporteur) 
and joint lead assessor (co-rapporteur), with input 
also from all other Member States and is co-ordinated  
by the EMA. The authorisation is granted by the 
European Commission. The centralised route involves 
the submission of a single application to the EMA, and 
the authorisation once granted is valid in all Member 
States. In 2015, the HPRA was allocated as rapporteur 
/ co-rapporteur for 12 new marketing authorisation 
applications by the Committee for Medicinal Products 
for Human Use (CHMP) at the EMA. These included 
treatments for respiratory, musculoskeletal and orphan 
diseases, such as Cushing’s syndrome, as well as for 
rare corneal diseases. The HPRA was also responsible 
for the assessment of radiopharmaceutical products.
Based on 2015 allocations, the HPRA was ranked joint 
seventh in the EU for rapporteurships for centrally 
authorised human products.
The total number of new products authorised in 
2015 was 806. This figure also includes 218 products 
authorised through the centralised route where 
the HPRA was not rapporteur or co-rapporteur. In 
overall terms, the number of products authorised has 
increased relative to 2014 when the total number of 
new products authorised was 615.
Traditional Herbal and 
Homeopathic Medicinal Products
During 2015, seven traditional herbal medicinal 
products (THMPs) were authorised by the HPRA. 
This is a simplified registration scheme which takes 
into account the tradition of use of these products. 
Legislation requiring registration for THMPs came 
into effect in full in 2011. The number of applications 
received by the HPRA since that time has remained 
low. A total of 40 THMPs are now authorised for sale.  
There were no homeopathic medicinal products 
authorised during 2015 under the simplified rules 
scheme. As a result, the total number of products 
registered remained at 98.
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Transfer Applications 
The HPRA processed a total 245 human medicine 
transfer applications in 2015. Of these, 197 related to 
the transfer of an existing marketing authorisation to a 
new marketing authorisation holder while the balance 
related to a transfer of a marketing authorisation 
holder prior to authorisation.
Variations 
After a medicine has been authorised, the terms of its 
marketing authorisation may need to be changed and 
the process whereby such changes are implemented is 
known as a “variation”. Examples of variations include 
the addition of a new indication, a new potential side 
effect, or updates to the company’s manufacturing 
or contact details. In the past year, the HPRA issued 
15,691 variations to marketing authorisations for 
products authorised through the national or MR 
procedures. The figure compared with a total of 
13,205 variations during the previous year. The HPRA 
also issued 283 work-sharing variations in 2015 
through national or MR procedures. For five of these 
procedures, the HPRA acted as lead Member State.
Articles 45 and 46 - Variations to  
Update Product Information
During the past 12 months, the HPRA acted as 
rapporteur for one paediatric Article 45 procedures 
and nine procedures relating to Paediatric 
Investigational Plans (PIPs). These are important 
procedures from a public health viewpoint as they 
increase the availability of medicinal products 
specifically indicated for use in children.
Renewals 
A total of 108 renewals to marketing authorisations for 
products authorised through the national (43), MR (19) 
or centralised (46) procedures were assessed in 2015. 
In general, the numbers of renewals are decreasing, 
reflecting the lifecycle of the products in question.
Scientific Advice 
Scientific advice is a pre-authorisation activity which 
assists product and technology innovation and 
development. The EMA operates a scientific advice 
system for innovative products which will ultimately 
be the subject of applications under the centralised 
authorisation system. During 2015, the HPRA acted 
as lead in 39 EMA scientific advice procedures 
for medicines proposed for the treatment of a 
broad range of conditions. Areas of focus included 
medicines to treat respiratory disorders, inflammatory 
diseases, cancers and blood disorders.
39
EMA SCIENTIFIC 
ADVICE PROCEDURES 
FOR HUMAN MEDICINES 
LED BY THE HPRA
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Veterinary Medicines
The HPRA, through its veterinary medicines licensing 
activities, is committed to protecting the welfare of 
treated animals, including fish, poultry, bees and 
domestic animals, as well as ensuring the safety 
of foodstuffs obtained from animals treated with 
veterinary medicines. The assessment of veterinary 
products also includes an evaluation of any possible 
risks to the user as well as the elaboration of risk-
management measures to control any risks. Finally, we 
also evaluate the potential impact of new veterinary 
medicines on the environment.
Product Classification Requests 
As the competent authority, the HPRA has an 
important role in deciding which types of products 
fall within the scope of the veterinary medicines 
legislation. Products that are regarded as medicinal 
but which do not have a marketing authorisation are 
deemed illegal in Ireland and may be seized by the 
Department of Agriculture, Food and the Marine. 
HPRA work in this area is largely driven by the 
monitoring activities of the Department which polices 
the market. 
During 2015, 21 product classification queries were 
received in respect of veterinary medicines. A total of 
49 queries had been received the previous year.
 
New Applications
Ensuring timely approval of new products 
applications, following a positive assessment of their 
safety, quality and effectiveness, ensures a range of 
medicines and vaccines are available to prevent and 
treat diseases in animals. The HPRA is responsible for 
authorising the majority of new products coming to 
83
NEW PRODUCT 
APPLICATIONS FOR 
VETERINARY MEDICINES 
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the market in Ireland, with a smaller number (relating 
to innovative or high-tech veterinary medicines) being 
authorised centrally under the responsibility of the 
EMA.
The accompanying graph shows new product 
authorisations in respect of veterinary medicines 
during the past five years.
Variations
After a medicine has been authorised, the terms of 
the marketing authorisation may subsequently be 
varied. Examples of variations include the addition of 
a new indication or potential side effect, an alteration 
to the method of manufacture or a change in active 
substance suppliers.
Under European legislation, such variations must 
be notified to the competent authority which must 
evaluate and approve any significant changes. The 
goal is to ensure that medicines are produced in a 
robust and standardised manner, thus safeguarding 
against sub-standard products. This requirement, 
together with a more global manufacturing 
environment, has led to in an increasing number 
of variations in recent years as shown in the 
accompanying graph. This activity now represents 
approximately half of the total number of applications 
for veterinary medicines processed annually.
Work-in-Progress Applications
The HPRA actively monitors work-in-progress data 
as an important indicator of our customer service 
levels. The overall figure for work-in-progress at the 
end of the year relevant to veterinary medicines was 
621 units (comprising various application types). The 
overall work-in-progress overdue figure was down to 
24. It follows that, everything else being equal, the 
greater the volume of business being conducted, the 
greater will be the levels of work-in-progress.
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Scientific 
Animal 
Protection
This relatively new area for the HPRA represents a 
very important opportunity to improve the welfare 
of animals used for scientific purposes and to ensure 
that animals are used only when there is no alternative 
to their use and the use itself is properly justified. 
Our regulatory approach is specifically focused 
on adherence with the 3R principles (reduction, 
refinement and replacement of animal testing).
One of the primary functions of the HPRA is to perform 
evaluations of applications for the authorisation of 
research establishments and projects. The HPRA also 
evaluates applications from individuals to allow them to 
conduct procedures or euthanasia of animals. 
While the total number of projects authorised during 
2015 was similar to the previous year, there was 
quite a significant fall in the number of applications 
for individual authorisations. This reduction was 
anticipated and was due to the legal requirement 
for existing establishment personnel to apply for 
individual authorisations before the end of 2014. 
Hence, there were a large number of applications for 
individual authorisations, which are valid for five years, 
during the previous 12-month period. It is likely that 
the application numbers for 2015 mainly reflect new 
individuals joining the sector.
Medical 
Devices
Classification Requests
The HPRA received 35 applications for classification 
of medical devices or products queried as medical 
devices in 2015. The queries emanated from other 
medical device competent authorities in Europe 
/ the European Commission, from medical device 
manufacturers and from distributors.
The HPRA circulated one enquiry relating to a medical 
device classification issue to other European medical 
device competent authorities with a view to seeking 
a consensus opinion in Europe on the classification or 
qualification of a specific product. 
Clinical Investigation 
Applications
The HPRA received 10 applications for clinical 
investigations of a medical device to be conducted in 
Ireland in 2015. The investigations were received in 
areas such as closure devices, cardiac and software. 
This level of activity was broadly similar to the 
previous 12-month period. 
In addition, three compassionate use procedures were 
completed during 2015.
Product Registrations
The HPRA received 371 notifications of medical devices 
to the medical device register. These relate to class I, 
in-vitro diagnostic and custom made medical devices 
and to system and procedure packs. Registration 
of these devices in the Member State in which the 
manufacturer or their authorised representative is 
based is required by legislation as there is a self-
declaration of conformity made by the manufacturer. 
During 2015, 43 organisations registered with the 
HPRA as Irish based manufacturers or authorised 
representatives of class I, custom-made, in-vitro 
diagnostic medical devices, as manufacturers of 
system or procedure packs, or as sterilisers of medical 
devices. This was an increase of over 60% on the 
number of organisations registered in 2014.
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Controlled Substances 
Controlled Drugs
Import, export and holding of controlled drugs (for 
legitimate purposes) are subject to licensing. The 
Department of Health is the licensing authority while 
the HPRA handles the administrative aspects of the 
application and licensing process.
Licensing activity, which consists primarily of export 
and import licences and letters of no objection, has 
increased somewhat during recent years. 
 
Precursor Chemicals 
Precursor chemicals are legally used in a wide variety 
of industrial processes and consumer products, such 
as medicines, flavourings and fragrances.
The HPRA has been the licensing authority for 
precursor chemicals since 2010. Precursor chemicals 
are subject to different licensing requirements, 
dependant on the category.  
Controlled Drugs Licensing
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Authorisation / Licensing  
of Sites and Facilities
The authorisation / licensing of manufacturers 
and wholesalers of medicines, of blood and tissue 
establishments and the approval of contract 
laboratories permits those facilities to carry out 
specified activities. The authorisation is based on 
satisfactory outcomes to HPRA inspections (see also 
under Safety Monitoring and Surveillance) during 
which adherence to relevant European guidance is 
evaluated.
The total number of licences / authorisations in place 
at year end for the past five years is presented by 
category in the accompanying table. 
Variations to authorisations / 
licences for sites and facilities
Applications from authorisation and licence holders 
to vary the information on which the authorisation / 
licence is based are processed regularly by us. These 
variations, including updates and amendments, are 
classified as either administrative or technical.  
  
4
Total Number of Licences/Authorisations (Sites) 2011 2012 2013 2014 2015
Manufacturers of Medicines for Human Use 88 87 89 92 95
Manufacturers of Veterinary Medicines 24 23 24 25 25
Investigational Medicinal Products for Human Use 50 47 49 53 52
Wholesalers of Medicines for Human Use 243 258 269 272 287
Blood Establishments 4 3 4 4 3
Tissue Establishments 22 21 23 24 24
Laboratory Approvals 16 17 16 16 12
Total 447 456 474 486 498
Total number of Variations 2011 2012 2013 2014 2015
Total  684 1068 947 815 1091
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Registrations for Active 
Pharmaceutical Ingredients 
and Brokers of Medicinal 
Products 
Under amendments (via the so-called ‘Falsified 
Medicines Directive’) to the Medicines Directive, 
2001/83/EC, that came into force at the beginning 
of 2013, manufacturers, importers and distributors of 
active substances are required to register with us. 
The total numbers of registrations in place at year end 
is outlined by category in the accompanying table. 
Brokers of medicines for human use are also required 
to register with us. One new broker registration 
was issued, meaning that there was a total of two 
registrations in place at year end. 
Total Number of Registrations for Active Pharmaceuticals Ingredients 2013 2014 2015
Manufacturers  22 22 22
Importers  35 37 37
Distributors 38 36 37
Total  95 95 96
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Export Certificates 
Export certificates are required by health authorities 
in many so-called third country markets as an 
indication that a product registered, authorised 
and / or manufactured in the country of origin is of 
appropriate quality. The inspection and authorisation 
/ registration programmes operated by us form the 
basis on which certificates are issued. Where possible, 
certificate formats, as published by the World Health 
Organisation, are used.
There was an output of 4,346 export certificates as set 
out below. 
Export certificates can also be required to facilitate the registration of cosmetics in third countries. The certificates 
issued by us are based on the product concerned having a valid registration in the EU. 
Product Certification Activity  2011 2012 2013 2014 2015
Certification of Documents 239 272 223 231 134
Certificates of Good Manufacturing Practice  272 276 252 255 221 
for Active Substance and Finished Product  
Manufacturers 
Certificates for Medicinal Products  1416 1350 1510 2112 1358
Medical Device Free Sale Certificates 1780 1522 1987 2535 2601
Other  51 16 50 86 32
Total  4146 3436 4022 5219 4346
Product Certification Activity  2011 2012 2013 2014 2015
Cosmetics Free Sale Certificates 388 210 242 246 216
4,346
EXPORT CERTIFICATES 
ISSUED
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SAFETY AND  
COMPLIANCE  
MONITORING   
Post-market surveillance, which refers to the safety 
monitoring of medicines, medical devices and other 
healthcare products that have been authorised, 
licensed or registered for use in Ireland, is a primary 
function of the HPRA. 
There are a range of tools employed to monitor the 
safety of health products while quality issues may also 
arise at the post-market stage. Where changes to how 
a product is used are required to enhance safety, we 
work closely with stakeholders to ensure such changes 
are introduced in a timely and effective manner.
Pharmacovigilance 
Pharmacovigilance is defined as the science and 
activities relating to the detection, assessment, 
understanding and prevention of adverse reactions, or 
side effects, associated with the use of medicines. 
The HPRA, in co-operation with pharmacovigilance 
professionals in Europe and further afield, monitors 
adverse reaction reports to look for new types of 
reactions or changing trends in reporting. If there 
appears to be a new and serious risk emerging, the 
issue must be assessed to determine the impact 
on the overall benefit-risk profile of the medicine 
concerned and consideration is given as to how any 
new risks should best be managed and communicated 
to healthcare professionals and patients.
During 2015, the HPRA received a total of 2,810 new 
adverse reaction reports associated with the use of 
human medicines in Ireland. While this represents 
a slight decrease when compared with the 2,884 
reports received in 2014, overall reporting rates have 
remained quite consistent in recent years. In addition, 
2,615 follow-up reports were also received during 
the past 12 months with any duplicate case reports 
reconciled with previously submitted cases and invalid 
/ nullified reports managed appropriately.
 
Source of Suspected New Adverse  
Reaction Reports % 
Pharmaceutical company 67
Patient/Consumer 8
Community Care doctor 4
Community Pharmacist 4
General Practitioner 4
Hospital Pharmacist 4
Nurse 4
Hospital Doctor/Specialists 3
Clinical Trial reports 1
Other 1
 
The majority of adverse reaction reports are notified 
to the HPRA by pharmaceutical companies marketing 
the medicines, also known as marketing authorisation 
holders. It is important to note that reports submitted 
by pharmaceutical companies to the HPRA, in the 
context of their regulatory reporting obligations, will 
have initially been notified to them by healthcare 
professionals, patients or consumers.
Medicines subject to additional monitoring accounted 
for 25% of the reports submitted during 2015. The 
requirements for additional monitoring, introduced 
in the context of the pharmacovigilance legislative 
revisions in 2012, highlight the importance of 
reporting all suspected adverse reactions associated 
with the use of these products which are identifiable 
by a black inverted triangle included on the 
accompanying package leaflet (PL) and the summary 
of product characteristics (SmPC).
Human Medicines
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Reports submitted to the HPRA in many instances arise 
from suspicions occurring during observation of an 
unexpected and / or unwanted event, in the context of 
use of a medicine. They also include adverse reactions 
known to occur in association with medicines such as 
those described in the product information.
The medicines most frequently included in reports 
to the HPRA accounted for over 55% of the adverse 
reaction reports received during 2015 (see table). It is 
important to note that the place of a medicine on this 
list cannot be taken as an indicator of safety or risk. 
The number of reports received cannot be used as a 
basis for determining the incidence of a reaction as 
neither the total number of reactions occurring, nor 
the number of patients using a medicine, is known.  
Suspect Medicine(s)/ 
Class of Medicines
Number of 
Reports in 
2015
Protein kinase inhibitors 258
Antipsychotic medicines 223
Selective immunosuppressant  
medicines
207
Antithrombotic agents 181
Systemic antiviral medicines 158
Anti-TNF inhibitors 156
Vaccines used in the primary  
immunisation programme
148
HPV vaccine 112
Medicines used in the treatment of 
bone disease
87
Systemic antibiotics 87
 
Of the reports received by the HPRA, 147 patients 
were reported to have died while on treatment. The 
accompanying table outlines the medicines / class 
of medicines associated with the highest number of 
reports.
In many of these cases, the patients concerned had 
significant underlying illness and were treated with 
multiple medicines and / or surgery, which may also 
have contributed to the outcome. In addition, many 
of these cases were influenced by disease progression 
or other complications unrelated to the medicine. 
The majority were associated with medicines used in 
the context of products subject to close monitoring, 
those used in the management of severe underlying 
medical conditions, in patient support programmes 
and special patient monitoring programmes. 
Suspect Medicine(s)/  
Class of Medicines
Number of 
Reports in 
2015*
Antineoplastic medicines 50
Antipsychotic medicines 22
Antithrombotic agents 19 
Systemic antiviral medicines 16 
Selective immunosuppressant 
medicines
15 
Systemic antibiotics 9
Analgesics  
(including NSAIDs and Opioids)
9
Antiepileptic medicines 7
Medicines used in the treatment 
of bone disease
5
Immunostimulant medicines 4
 
* Please note that in some cases treatment may have 
involved more than one medicine from the above 
groups.
Online and Electronic Reporting 
The online reporting system, available to healthcare 
professionals and patients / consumers, continued to 
be used during 2015 with some 484 reports submitted 
via our website by year end. This was a significant 
increase when compared to the 391 reports submitted 
online during the previous year. As part of this 
increase, the submission of reports directly by patients 
and consumers grew in annual terms by over 5%.  
The HPRA continued to increase both receipt and 
transmission of individual case safety reports (ICSRs) 
electronically during 2015 and actively engaged with 
companies to encourage and facilitate testing to 
support additional electronic reporting throughout  
the year.
 
Monitoring Compliance with  
Pharmacovigilance Obligations
Company / sponsor compliance with 
pharmacovigilance obligations continued to be 
monitored throughout 2015, with follow up and 
feedback provided as appropriate. See Inspections 
and Audits on page 49 for details of the associated 
inspection programme.
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Vigilance Assessment  
and Risk Management
The HPRA plays a key role in monitoring the safety 
of medicines available on the Irish market through 
the regular assessment of signals and emerging 
safety issues, and via routine and urgent benefit-risk 
evaluations. The HPRA also proactively participates in 
evaluating and approving risk management plans for 
medicines throughout their life cycle and serves as a 
key source of advice and information on the safe and 
effective use of medicines. The HPRA is represented 
at a European level on the Pharmacovigilance 
Risk Assessment Committee (PRAC) and works 
continuously with the EMA and other Member States 
within the EU to ensure robust and timely decision-
making on safety-related issues.
Signal Management Activities
Signal detection and management activities allow 
for enhanced detection of new or changing safety 
issues relating to medicines thus allowing for more 
rapid action when necessary to protect public 
health. Throughout 2015, the HPRA continued its 
participation in the work-sharing initiative for signal 
detection within the EU acting as lead Member State 
in the detection and management of signals for 54 
active substances authorised nationally. Serving as the 
PRAC rapporteur, the HPRA was also responsible for 
the further management of any signals detected in 
relation to 27 centrally authorised active substances / 
combination of active substances. Labelling changes 
were also implemented for nationally authorised 
products during the past year following PRAC 
recommendations thus ensuring improved medicines 
information was provided to healthcare professionals 
and patients.  
The HPRA continued its participation in the Signal 
Management Review Team at the EMA which focuses 
on improving tools, methods and processes for signal 
detection as well as developing methodological 
guidance.
Periodic Safety Update Reports
Periodic safety update reports (PSURs) are 
pharmacovigilance documents submitted by 
marketing authorisation holders at defined time 
points following authorisation of products. PSURs 
are intended to provide a continuous cumulative 
update and analysis on the benefit-risk profile of a 
medicine throughout its lifecycle. The outcome of 
these procedures may lead to automatic harmonised 
regulatory action if considered necessary such as a 
variation, suspension or revocation. During the year 
in review, the HPRA contributing to the evaluation 
of 1,002 EU PSUR single assessment (PSUSA) 
procedures and consistently ranked in the top 10 
for appointments as lead Member State for PSUSA 
evaluation for nationally authorised products at EU 
level.
Safety Referrals
In a safety related referral, the EMA conducts a 
scientific assessment of a particular medicine or 
class of medicines, through the PRAC, on behalf of 
the EU. Following this assessment, PRAC makes a 
recommendation for a harmonised position across the 
EU which is ultimately implemented nationally by the 
HPRA.
The HPRA participated as concerned Member State 
in five newly initiated safety referrals in 2015 and a 
further four safety referrals which reached a conclusion 
during the year. The HPRA ensures that the final 
outcomes of referrals are implemented nationally and 
communicated to stakeholders.
1,002
THE NUMBER OF EU PSUR 
SINGLE ASSESSMENT 
PROCEDURES 
EVALUATED WITH  
HPRA INPUT
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Risk Management Plans and Post  
Authorisation Safety Studies  
All new applications for drug marketing authorisations 
now include a risk management plan (RMP) 
documenting the proposed risk management system 
to be implemented once a marketing authorisation is 
granted. During 2015, the total output was 356 RMPs 
(newly approved or updated) submitted via national, 
mutual recognition, decentralised and centralised 
procedures. The HPRA ranked 10th amongst the 
EU Member States for PRAC rapporteurship / co-
rapporteurship appointments for initial marketing 
authorisation applications. These products include 
treatments for orphan diseases including cystic fibrosis 
as well as other innovative products. 
The HPRA also provided assessment input to 263 
post authorisation safety study (PASS) procedures 
(protocols, reports and other post authorisation 
safety-related measures). PASS are non-interventional 
studies carried out as part of a risk management plan 
in order to further evaluate the safety and benefit-risk 
profile of a medicine in the post-authorisation phase, 
or to measure the effectiveness of risk minimisation 
activities that have been introduced.
Risk Communications
As part of its role to promote and support the safe 
and effective use of medicines, the HPRA reviewed 
and approved 21 direct healthcare professional 
communications (DHPCs) which provided new safety 
information or risk minimisation advice to prescribers 
and published these on the HPRA website. During 
2015, the HPRA also commenced online publication 
of educational materials and tools which have been 
developed by marketing authorisation holders 
as additional risk minimisation measures for their 
medicines. In total, 70 suites of educational materials 
were approved by the HPRA by year end. 
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Haemovigilance
The HPRA is the competent authority for legislation 
concerning blood and blood components. 
Haemovigilance refers to a set of organised 
surveillance procedures relating to serious adverse or 
unexpected events or reactions in donors or recipients 
and the epidemiological follow-up of donors.
The HPRA continued its interaction with the National 
Haemovigilance Office (NHO) during 2015, including 
discussion of issues of mutual interest and concern at 
bilateral quarterly meetings. 
Following collaboration with the NHO, the HPRA 
submitted an annual report of serious adverse 
reactions and events to the European Commission 
during 2015. The report reflected information 
received from January to December 2014 and 
included information on 64 serious adverse reactions 
and 201 serious adverse events which met the 
mandatory legislative reporting requirements. 
The HPRA continued to work closely with the Irish 
Blood Transfusion Service (IBTS) and the Department 
of Health in respect of haemovigilance activities and 
developments. This included a contribution to the 
review of options proposed by the IBTS / NHO for 
the online reporting system to facilitate simultaneous 
submission of mandatory reports to both the NHO 
and HPRA. Pending finalisation of these formalised 
arrangements, and access to an online reporting 
system, the interim arrangements, first agreed for 
reporting to the HPRA in 2008, continued to operate 
throughout the past year. These arrangements have 
facilitated consistency and timeliness in reporting 
allowing appropriate regulatory oversight. 
Tissue and Cell Vigilance
The HPRA is the competent authority in Ireland for the 
purposes of the EU tissues and cells legislation. The 
legislation focuses on standards of quality and safety 
for donations, procurement, testing, processing, 
preservation, storage and distribution of human 
tissues and cells.
The HPRA submitted an annual report on serious 
adverse reactions and events associated with tissues 
and cells to the EU Commission during 2015. The 
report reflected information received in 2014 and 
consisted of some 42 reports, 29 of which met the 
legislative reporting requirements, including two 
serious adverse reactions and 27 serious adverse 
events.   
Human Organs for  
Transplantation
During 2015, the HPRA continued to liaise closely 
with the Health Service Executive (HSE) lead and 
colleagues responsible for this area in relation to 
the development of report forms and guidance to 
facilitate serious adverse reaction and event reporting. 
During the past year, the HPRA received 12 reports of 
serious adverse reactions and events associated with 
organ donation / transplantation. These reports have 
been followed up with the HSE in the context of its 
regulatory role as the competent authority for clinical 
and transplant related matters. 
Blood, Tissues  
and Cells, Organs
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Pharmacovigilance
The operation of a national pharmacovigilance system 
which is based on the receipt and review of reports 
of suspected adverse events is a primary role of the 
HPRA. An effective system enables us to monitor the 
continued safety and efficacy of veterinary medicines 
under actual use conditions. Where necessary, 
the HPRA will intervene and introduce new risk 
management measures for a product. In so doing, we 
strive to prevent adverse effects in other animals as 
well as in humans exposed to the medicine.
The effectiveness of the system is dependent on the 
submission of reports by veterinarians, pharmacists, 
licensed merchants and others involved in dispensing 
or using the products concerned. These reports may 
be submitted either directly to the HPRA or to the 
companies’ marketing the products. The companies, 
in turn, must relay the data to the HPRA.
During the 12 months under review, the HPRA 
received 437 national reports of suspected adverse 
events to veterinary medicines. The vast majority of 
reports (95%) were received from pharmaceutical 
companies.
The quite significant increase in the number of 
reports received in 2015 is due to greater reporting 
of suspected lack of expected efficacy. One of the 
factors for the increase in such reports is a change in 
reporting practices whereby a number of companies 
marketing products are now reporting non-serious 
reports in addition to the serious reports required 
under legislation.
 
Periodic Safety Update Reports
Evaluating PSURs on individual products accounts for 
approximately 38% of the HPRA’s overall veterinary 
medicines workload currently and is evidence of 
our commitment to the ongoing assessment of 
benefits and risks. Our work includes the assessment 
of individual medicines on the market in Ireland as 
well as a work-sharing initiative where we lead, or 
contribute to, the assessment of a class of veterinary 
medicines for the European Union.
The HPRA completed the evaluation of 1,205 PSURs 
in 2015 which was a notable increase on the figure of 
852 in the previous 12-month period.  
 
Use of Veterinary  
Antimicrobials in Ireland
The HPRA collects annual information on the 
consumption of veterinary antibiotics from each 
marketing authorisation holder. This information is 
important as it allows us to benchmark our usage 
rate against those of our European neighbours. The 
data for the period 2009 to 2014 show that there 
are significant fluctuations in consumption levels 
annually and, consequently, that a clear trend is not 
yet evident. This is likely due to a variety of factors, 
such as seasonal disease patterns, fluctuations in the 
classes of antibiotics being prescribed, end of year 
sales activities, the numbers of animals slaughtered 
and exported as well as changes in breeding policy 
for the national herd. 
The HPRA continues to work with other EU veterinary 
medicines agencies and the EU Commission to help 
ensure that veterinary antibiotics are used responsibly 
in accordance with their approved conditions of use.
Veterinary Medicines
500 
450 
400 
350 
300 
250 
200 
150 
100 
50 
0 
2011
Reports Received
2012 2013 2014 2015
244 271
300
435
228
Consumption 
of Antibiotics 
2009 2010 2011 2012 2013 2014
Tonnes sold 88.3 93.9 85.2 97.4 100.2 90.2
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This relatively new area represents a very important 
opportunity to improve the welfare of animals used 
for scientific purposes and to ensure that animals are 
used only when there is no alternative to their use and 
the use itself is properly justified.
Inspection Programme 
A key component of our work involves inspection of 
animal facilities to monitor animal welfare standards 
and compliance with legislation. Our inspections, 
which may be announced or unannounced, follow a 
risk-based approach.
During 2014, the focus of the HPRAs inspection 
programme had been determined by the legislative 
requirement to complete the authorisation of all 
relevant national establishments previously licensed 
by the Department of Health. There were therefore a 
particularly high number of inspections conducted in 
2014, as, in addition to the compliance inspections 
conducted that year, every establishment (including 
those deemed to be very low risk) had to be inspected 
for the purposes of granting an establishment 
authorisation. The focus for 2015, however, was on 
carrying out compliance inspections, a significant 
proportion (28%) of which were unannounced 
inspections. These inspections help us to ensure the 
welfare of animals used in scientific studies as well as 
ensuring that unauthorised animal experiments cannot 
take place in this country.
Scientific Animal Protection
Number / Category of Inspections  2013 2014 2015
Total  30 38 29
Advisory inspections  22 1 0
Establishment authorisation inspections  1 23 0
Announced compliance inspections  2 11 21
Unannounced compliance inspections  3 3 8
% of unannounced inspections  10% 8% 28%
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The HPRA is responsible for a number of risk-based 
market surveillance programmes. These include 
proactive activities such as the sampling and 
analysis programme and the advertising compliance 
programme, and reactive activities such as the quality 
defect and recall programme. 
We also operate an exempt medicines notification 
scheme designed to monitor the importation and 
supply of unauthorised medicines. In addition, we 
carry out a programme of regulatory compliance 
inspections at the premises of marketing authorisation 
holders. The latter is designed to assess the level of 
compliance against national legislation relating to the 
placing on the market and advertising of medicines.
Sampling and Analysis  
Programme
The risk based sampling and analysis programme 
is part of our monitoring of the quality and safety 
of medicines and our identification of borderline 
medicinal / non-medicinal products that may be on 
the Irish market. This is achieved through analytical 
testing and / or examination of packaging and 
labelling of medicines, active substances, borderline 
medicinal / non-medicines and enforcement-related 
samples. 
A total of 480 product samples were sent for analytical 
testing / examination work. Details are provided in the 
accompanying tables.
Examination of Packaging and Labelling 
The packaging and labelling of 156 medicines and 
other products available on the Irish market were 
examined. Individual checks were carried out on the 
samples including reviews of the safety information 
contained in the package leaflets.   
Authorised medicines accounted for 96% of the 
products examined and all of these were examined 
for signs of falsification and tampering. No issues 
were identified. Of the products examined, 30% were 
parallel imported or parallel distributed products 
and a small number were products supplied via the 
exempt medicines route. Braille compliance checks 
were also carried out on 31% of the products. 
The following table outlines the type of examinations 
that were carried out:
Analytical Testing 
During the past year, 297 medicinal and other 
product samples were sent for analytical testing. 
These included 234 samples sent to governmental 
laboratories in Ireland and 69 samples sent to 
governmental laboratories in other countries as part  
of European working-sharing arrangements. 
A breakdown of the types of samples tested is 
outlined in the accompanying table. In summary, 
53% were authorised medicines, 27% related to 
enforcement and borderline medicines / non-
medicines, while 19% were actives and other 
substances.
Market Compliance – Human 
and Veterinary Medicines
Categories of products 
examined for packaging and 
labelling attributes
Number 
of samples 
examined
Authorised medicines (including 
samples for Braille compliance 
checks)
102
Authorised parallel imported and 
parallel distributed medicines
47
Exempt medicines 7
Total 156
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Participation in EU Co-ordinated Market 
Surveillance Activities 
The HPRA is an active participant in EU surveillance 
programmes that involve the sampling and analysis of 
medicines. This is achieved by its active participation 
in the Official Medicines Control Laboratories (OMCL) 
network, co-ordinated by the European Directorate for 
Quality of Medicines (EDQM) in Strasbourg. 
 
The 2015 programmes included: 
• Centrally authorised medicines: 29 sampled in 
Ireland for testing at OMCLs in other Member 
States and seven tested at the HPRA’s OMCL 
(Public Analyst’s Laboratory, Galway).  
• MRP / DCP: 11 medicines sampled in Ireland and 
analysed at other Member State OMCLs. 
• Other products: A number were analysed at our 
request at OMCLs in other Member States. For 
example, 16 products underwent microbiological 
analysis at the Finnish and Czech OMCLs.
Principal Findings 
Analysis Findings
Laboratory 
analysis
While the majority of samples 
tested were compliant with their 
specifications, 12 of out-of-
specification results were obtained. 
Nine deficiencies were identified 
in the analytical methods and 
specification documents used by 
manufacturers of medicines.
Packaging 
and labelling
In total, 15 non-compliances, 
including 11 braille-related issues, 
were identified across samples of 
a number of human and veterinary 
authorised medicines.
 
Appropriate follow-up actions were taken in each 
case. 
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Product categories selected for analytical testing in 2015 Number of samples analysed
Physico-chemical Analysis / Biological Analysis:
Enforcement-related products for human use 83
MRP / DCP authorised medicines for human use 61
Centrally authorised medicines for human use  36
Nationally authorised medicines for human use 35
Active / Intermediate pharmaceutical ingredients 33
Parallel imported medicines for human use  10
Other product categories 23
Microbiological Analysis:
Nationally authorised medicines for human use 10
Other product categories 6
Total 297
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Quality Defects and Recalls
The HPRA’s quality defects and recalls programme 
investigates, on the basis of risk to public and 
animal health, reports of suspected quality defects 
in both human and veterinary medicines and in their 
related active substances. We also co-ordinate any 
subsequent recall actions on the Irish market. 
Number and Types of Quality Defects 
A total of 772 quality defects were reported to, or 
identified by, the HPRA during the past 12 months 
representing a decrease of 5% on the figure for 2014. 
The accompanying table outlines the corresponding 
risk classification applied to each report.
Overall, 633 reports (82%) were determined to 
affect Ireland meaning that the defective batch or 
batches were either on the Irish market and / or were 
manufactured in Ireland. Medicines for human use 
accounted for 737 quality defect reports with 35 
reports concerning veterinary medicines.
Critical quality defects, which are those defects 
defined as potentially life-threatening or a serious 
risk to health, accounted for 214 of the total reports 
received. Of these, 118 were deemed to affect 
Ireland. These included 49 reports relating to 
lack of sterility assurance, 41 reports of potential 
contamination and 14 reports of a falsified medicine.
The most common categories / causes of defects 
were:
• Stability issues (150 reports)
• Contamination issues (125 reports)
• SmPC / printed artwork issues (68 reports)
• Lack of sterility assurance (57 reports)
 
Of the 150 stability issues investigated, 124 cases 
affected Ireland, with 61 of those products having 
been manufactured in Ireland for the home and other 
markets. The figures for lack of sterility assurance and 
contamination include four separate events at one 
compounding facility that affected 85 products.
In relation to each instance of lack of sterility 
assurance / potential contamination, it was 
subsequently confirmed that there was no evidence of 
contamination in any of the concerned medicines. The 
14 falsified medicine issues were classified as affecting 
Ireland because in each case the genuine products, of 
which falsified representations were detected on other 
markets, were manufactured in Ireland.
 
Year 2011 2012 2013 2014 2015
Minor Quality Defects 314 236 230 248 214
Major Quality Defects 364 303 300 199 226
Critical Quality Defects 231 189 235 365 326
Number of Quality Defect Reports  
Not Justified
8 13 9 4 6
Total Number Quality Defects 917 741 774 816 772
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Sources of Quality Defects 
As in previous years, pharmaceutical companies 
and other competent authorities accounted for the 
majority of reports of quality defects received. 
Recalls of Human and Veterinary 
Medicinal Products 
In certain cases, so as to protect public or animal 
health, it is deemed necessary to withdraw, or recall, 
products from the Irish market. During the year in 
review, 116 medicine recalls occurred. Of these, 113 
related to human medicines and three to veterinary 
medicines. 
As regards the level of recall, 44% were to patient / 
user level, 22% to pharmacy / retail level and 34% to 
wholesale level. The proportion of recalls to patient 
level is high compared with recent years. This can be 
attributed to four recalls of compounded products 
affecting 48 different products (41% of all recalls). 
Consequently, 67 (58%) of the products recalled 
from the Irish market were manufactured in Irish 
manufacturing facilities, compared with 24 (24%) 
in 2014. These were mainly precautionary recalls 
of compounded products for human use. Exempt 
medicines accounted for 12% of human medicine 
recalls.
The most common causes of a human medicine recalls 
were:
• Lack of sterility assurance (27)
• Contamination issues (25)
• SmPC / printed artwork issues (11)
• Cold-chain issues (8)
• Stability issues (8)
• Non-compliance with GMP (6)
In respect of veterinary medicines, two of the recalls 
related to stability issues while the remaining recall 
was due to a lack of therapeutic efficacy.
Retail Sales Monitoring 
 
General Retail Sale Investigations
The sale of consumer healthcare products by retail 
outlets such as grocery shops, health food shops 
and, where necessary, pharmacies, is monitored 
by the HPRA using a proactive and reactive, risk 
based, retail monitoring programme. During 2015, 
69 cases, some of which involved multiple products, 
were investigated. Of these, 36 related to the sale 
of medicines that did not carry a valid registration 
number or authorisation number for the Irish market. 
An additional 32 cases related to the sale of medicines 
that had been incorrectly classified as non-medicines 
by those placing them on the market while one case 
related to the sale of a pharmacy-only medicine by a 
non-pharmacy retailer. A total of 143 products that did 
not carry a valid registration or authorisation for the 
Irish market were removed from sale.
MEDICINE RECALLS  
Source of Reports Human  Veterinary 
 Medicines Medicines
Companies  490 32 
(Manufacturers, distributors  
and / or authorisation holders)  
Other Competent Authorities  147 3 
(Regulators)  
HPRA Staff Members  41 
Community Pharmacists 32 
Hospital Pharmacists 20 
Other Health Care Professionals 4
Patients and / or Members  2 
of the Public
116
MEDICINE RECALLS 
OCCURED
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Exempt Medicines Programme
Medicines placed on the Irish market must be 
authorised by the HPRA or, in the case of centrally 
authorised products, by the European Commission. 
However, European and Irish legislation provide for 
an exemption to this rule. In this case, authorised 
healthcare professionals are permitted to prescribe 
unauthorised medicines for individual patients under 
their direct responsibility in order to fulfil the special 
needs of those patients. Such products are referred 
to in Irish law as ‘exempt medicines’. Under Irish 
medicines legislation, wholesalers and manufacturers 
of medicines are obliged to notify certain information 
to us in relation to any exempt products that they 
source. This is done by submitting electronic 
notification to a HPRA database. This information 
facilitates, when required, the effective recall of any 
defective exempt medicine from the Irish market.
In 2015, 1,639,312 packs of exempt medicines 
were notified to us. In addition, we responded to 
approximately 200 queries related to the exempt 
medicinal products programme. 
Note: The figure in the 2014 Annual Report for the number  
of packs notified during that year was significantly higher  
than that for 2015. However, the HPRA has since become  
aware that the 2014 figure, which was in excess of three 
million packs, was overstated due to an error in the way that  
the database counted pack numbers.
Regulatory Compliance Inspections 
These risk-based inspections are carried out at the 
premises of marketing authorisation holders. The 
inspection seeks to determine the level of compliance 
with the legal requirements for the marketing and 
advertising of medicines. Three inspections were 
carried out at the premises of marketing authorisation 
holders and a number of non-compliances were 
identified. These were followed up and we monitored 
the implementation of corrective actions at the 
companies concerned. This inspection activity is linked 
to the HPRA’s advertising compliance programme.
Human Medicines Advertising 
Compliance Programme
It is the role of the HPRA to monitor and review 
advertising and promotion activities by the industry 
for compliance with the requirements of the Medicinal 
Products (Control of Advertising) Regulations, 
2007. Some 152 advertisements were reviewed for 
compliance.
The five aspects to the programme are shown in the 
table below:
In all cases of non-compliance identified under the 
different elements of the programme, the HPRA 
supervised the adoption of the necessary corrective 
and / or preventative actions by the marketing 
authorisation holder.   
5
 
Total Advertisements Reviewed Non-Compliances Identified
Proactive Monitoring:  
Pre-planned Projects 4 48
Seven individual advertisements were 
non-compliant.
Proactive Monitoring:  
Includes Randomly  
Selected Projects
1 1
This advertisement was found to be 
compliant.
MAH Inspections Performed 3 Multiple
Five major and other deficiencies 
identified across a number of areas with 
one major deficiency related directly to 
advertising activities.
Complaints Received 22 45
14 with seven complaints upheld as 
being valid. Six advertisements in total 
were non-compliant.
Queries Received 66 58 18 advertisements were non-compliant.
*Note: Some of these figures are approximate. They may include website advertisements, and each page of a website is counted as 
one advertisement, because multiple pages can have multiple advertisements. Additionally, the data exclude advertisements that were 
reviewed during the regulatory compliance inspections work. Numerous advertisements were reviewed during those inspections.
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Vigilance 
The medical devices vigilance system which was 
established under European medical device directives 
aims to minimise risks to the safety of patients, users 
and others. Vigilance activities include the following:
• The submission of vigilance reports by 
manufacturers and users to the relevant 
competent authorities (the HPRA in Ireland); 
• The evaluation of reported incidents by the 
competent authorities; 
• The dissemination of information, which may be 
used to prevent recurrence of the incident, or to 
alleviate the consequences of such incidents, in 
cases when it is necessary to do so; 
• A device being updated, modified or taken off the 
market in cases when it is necessary to do so. 
In 2015, there was a particular HPRA focus on 
the dissemination of medical device safety 
communications.  
2015 Reports in Summary  
A total of 2,126 medical device vigilance reports were 
received and assessed representing a slight increase 
on 2014. Manufacturers accounted for 57% of all 
vigilance reports received in 2015 while 24% were 
received from competent authorities. Of the incidents 
reported, 35% were as a result of an incident on the 
Irish market. Of the Irish Incidents, 30% were related 
to an ongoing field safety corrective action. 
Concerning the regulatory response to the reports 
received, 62% resulted in an action being taken in 
Europe. In Ireland, the HPRA published online 474 
manufacturer’s field safety notices directly affecting 
the local market. These notices are intended to inform 
users of safety issues relating to medical devices. In 
addition, there were 160 product removals conducted 
in Ireland in 2015.
Safety information was also highlighted to the public 
through HPRA safety notices. There were 33 such 
notices sent to relevant interest groups and published 
on our website. During the year in review, we issued 
76 national competent authority reports.
Medical Devices
2500
2000
1500
1000
500
0
Number of Vigilance Reports
1,335
2009 2010 2011 2012 2013 2014 2015
1,687 1,775
2,1132,225 2,126
2,268
HPRA ANNUAL REPORT 2015 45
2015 Reports by Product Type
Orthopaedic, surgical devices and infusion devices accounted for a large proportion of vigilance reports received.  
Reports were again received relating to software issues associated with medical devices. The HPRA continued to 
receive reports relating to revision procedures associated with the ASR Articular Surface Replacement and ASR XL 
Acetabular system manufactured by DePuy.  
In the area of in-vitro diagnostic (IVD) devices, the largest number of vigilance reports received related to clinical 
biochemistry. Field safety corrective actions relating to clinical biochemistry reagents and analysers continued to have 
a high impact on the number of IVD vigilance cases.
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Market Surveillance
Medical device surveillance activities are focused 
on protecting the health and safety of those who 
use medical devices. Our role includes continuous 
surveillance of the market to monitor the regulatory 
compliance of medical devices after they are placed 
on the market.
Surveillance Cases
During 2015, the HPRA continued to develop 
its lifecycle approach to market surveillance and 
investigated 324 market surveillance cases. It is 
expected that market surveillance activity will increase 
further in the future due to ongoing increases in 
both the number of European Compliance and 
Enforcement (COEN) requests from other Member 
States and the number of certificate notifications from 
notified bodies. COEN requests serve as a method 
for communication between European authorities on 
market surveillance issues.
Other market surveillance activities conducted in 2015 
include: 
• The development of the system and procedure 
guidance pack;
• The development of a Medical Device Information 
Notice for communicating market surveillance 
issues;
• Review of food intolerance products available on 
the Irish market;
• Review of the standalone software on the HPRA 
register; 
• Proactive reviews of respiratory and ophthalmic 
manufacturers based in Ireland;
• Review of bio resonance products;
• Development of specific test methods implant 
analysis;
• Reviews of clinical data presented as part of 
clinical evaluations of high risk medical devices.
The HPRA also initiated a program of sampling and 
analysis in 2015 which included testing of several 
types of implants.
Certificate Withdrawals
There was an increasing trend of certificate refusals, 
withdrawals and suspensions from notified bodies 
during 2015 reaching 959 by year end. The number 
of notifications received highlights the impact of the 
joint assessment process for notified bodies which 
may affect the scope of activities and potentially 
the ongoing validity of certificates issued. The 
number also reflects the continued improvements in 
performance and consistency of notified bodies. The 
HPRA investigated those certificate notifications with 
implications for the Irish market, those arising from 
identified safety concerns and major non-compliances, 
and those arising from a reduction in the designation 
scope or de-designation of notified bodies.  
Technical File Reviews
In 2015, the HPRA continued its increased focus 
on review of technical documentation both in the 
context of market surveillance activities and notified 
body oversight. A total of 17 technical file reviews 
were completed in 2015. The proactive technical file 
reviews were requested as part of reactive market 
surveillance with a particular emphasis on the areas of 
software, respiratory and ophthalmic devices as well 
as files associated with the Irish notified body.
Clinical Evaluation Review
During 2015, the HPRA increased its activities further 
in the assessment of clinical data presented by 
manufacturers to support the safety and performance 
of their device. A total of 32 clinical evaluation reviews 
were conducted. This work was undertaken reactively 
in response to a number of specific device issues 
highlighted during the year and proactively as part 
of our ongoing market surveillance activities. This 
work also formed a significant part of our notified 
body designation and oversight activities both at 
national level and European level as part of EU joint 
assessment activities.  
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Designation and Monitoring of 
the Irish Notified Body 
A key activity for the HPRA in 2015 was the 
assessment of an application from the NSAI which 
resulted in the renewal of its designation as a notified 
body for medical devices in accordance with the new 
European Regulation (920/2013). The assessment 
was conducted as part of a joint assessment team led 
by the European Commission’s Food and Veterinary 
Office (FVO). National experts from the Turkish and 
UK regulatory agencies also participated. Both the 
HPRA and NSAI received positive feedback from the 
FVO following the assessment.
In addition, one observed audit was conducted by 
the HPRA of NSAI staff auditing medical device 
manufacturing sites.
The HPRA provided technical, clinical and quality 
system experts to support six joint assessments of 
medical device notified bodies in other European 
countries during 2015.
The HPRA received 69 certification notifications from 
NSAI during the past year. These notifications were 
uploaded, as required, to the European EUDAMED 
database.
324
MARKET 
SURVEILLANCE CASES 
INVESTIGATED
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Proactive Market Surveillance
Post market surveillance of cosmetic products includes 
a national sampling and analysis programme and 
involves close co-operation between the HPRA 
and the HSE’s Environmental Health Service and 
Public Analyst Laboratories in Galway, Cork and 
Dublin. During 2015, 469 cosmetic products were 
included in the sampling programme. Analysis was 
carried out in respect of 398 of these products by 
year-end with 71 (18%) found to be non-compliant. 
The largest areas of non-compliance related to skin 
whitening products containing prohibited substances, 
sunscreens containing undeclared UV filters, hair dyes 
missing appropriate label warnings and microbial 
contamination of baby powders, face paint creams 
and hand cleaning products.
Reactive Market Surveillance
Reactive surveillance includes investigation of quality 
related complaints (compliance cases), reports of 
adverse events relating to the use of cosmetics 
(vigilance cases) and RAPEX serious risk alerts. 
During the past year, 107 compliance cases were 
opened and 99 closed. Of these, 90 involved cosmetic 
products that were deemed to be non-compliant with 
the EU Cosmetics Regulation 1223/2009. The majority 
of non-compliances were in the areas of labelling, the 
presence of prohibited substances, contamination 
(mainly microbiological or heavy metals) and 
unsupported efficacy claims. A total of four products 
were withdrawn from the Irish market as a result of 
stability issues, contamination or the presence of 
prohibited substances. 
Eleven vigilance cases were investigated relating to 
different product types such as hair dyes, face masks, 
moisturisers and shampoos.
During the year, 55 RAPEX serious risk alerts were 
received from other European Member States 
regarding non-compliant cosmetic products. One of 
these products was found on the Irish market and 
removed from sale.
Market Compliance  
of Cosmetics 
Reactive Market Surveillance 2013 2014 2015
Compliance cases opened 145 105 107
Compliance cases closed 139 109 99
Vigilance cases opened 17 21 11
Vigilance cases closed 19 14 20
RAPEX alerts received 102 100 55
Recalls / withdrawals from the Irish market - 1 4
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As part of our regulatory role, the HPRA is focused on 
ensuring industry compliance with relevant standards 
and legislation. Our inspections and audits work 
programme includes:
• Regular inspections of manufacturers and 
wholesalers of medicines to check for compliance 
with EU guidelines on Good Manufacturing 
Practice (GMP) and Good Distribution Practice 
(GDP), respectively. 
• Inspection of manufacturers of active substances 
for compliance with EU guidelines on GMP.
• Inspection of clinical trial sites for compliance 
with EU and International Conference on 
Harmonisation (ICH) guidelines on Good Clinical 
Practice (GCP). 
• Inspection for compliance, by marketing 
authorisation holders, with Good 
Pharmacovigilance Practice.
• Regular audits of the NSAI, the notified body for 
medical devices that is designated by the HPRA. 
• Proactive audit of manufacturers of Class I devices 
and ‘for cause’ audits as required, for example, as 
part of the follow-up to a defect.
• Inspection of blood, tissue and cells, and organ 
establishments for compliance with applicable 
EU guidelines on the quality and safety of blood, 
blood products, tissues and cells, and human 
organs intended for transplantation. 
• Inspection, often in conjunction with the Garda 
National Drugs Unit, of manufacturers and 
wholesalers of medicines containing controlled 
drugs (CD) and of precursors (chemicals that can 
be used in the preparation of illicit drugs). 
• Inspection, primarily based on risk assessment, of 
manufacturers of cosmetic products.
Overview of the 2015  
Inspection Programme
During the 12 months under review, 344 inspections 
and audits were performed compared to 260 in 
2014 and 313 in 2013. The average number of days 
required to close-out inspections and audits was 106.
Inspections and Audits 
Performance Results and Statistics 2011 2012 2013 2014 2015
No. of national inspections and audits performed 271 289 279 229 319
No. of foreign inspections and audits performed 29 26 34 31 25
% inspections and audits closed on time (≤ 90 days) 66 61 63 61 67
Average time for close-out (days) 79 76 103 112 106
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In the past year, there were:
• 124 GMP inspections carried out at manufacturing 
sites. These included 21 inspections in non-
EEA countries, 14 of which were carried out at 
the request of the EMA for centrally authorised 
products. Of the GMP inspections carried out, 15 
were of active substance manufacturers.
• 126 GDP inspections of wholesalers were 
performed. There were also 26 inspections of sites 
that handled controlled substances (controlled 
drugs or precursor chemicals), two inspections 
of medicines brokers and two inspections of 
registered distributors of active substances.
• 15 GCP inspections were carried out at 
investigator sites in Ireland. 
• Two pharmacovigilance inspections were 
conducted. The first was at the facility of an Irish 
based marketing authorisation holder while the 
second inspection, relating to centrally-authorised 
medicines, was conducted at the request of the 
EMA.  
• Medical devices / Notified Body Assessment: A 
full re-designation assessment of the Irish notified 
body, the NSAI, was completed. This assessment 
was also part of the EU joint assessment program 
and was carried out alongside representatives of 
the European Commission’s Food and Veterinary 
Office and national experts (as outlined earlier on 
page 47).
 
• An observed assessment of an NSAI auditor at a 
class III implantable medical device manufacturer 
based in the US was also conducted. 
• 16 audits were performed at both medical device 
manufacturer and authorised representative 
facilities. Of these, two were for-cause audits 
(one of which was at a US based facility), eight 
were reactive audits based on vigilance / market 
compliance issues, four were proactive audits 
based on proactive market surveillance projects 
while the remaining two audits were of authorised 
representatives of medical device manufacturers.
• Seven blood establishment inspections were 
completed. These included six inspections of 
facilities maintained by the IBTS and one routine 
inspection of a holder of blood and tissue 
establishment authorisations. 
• 16 tissue establishment inspections were carried 
out.
• Three inspections were carried out to assess 
applications for authorisation for establishments 
involved in organ transplantation.
• Three inspections were also carried out under 
cosmetic products legislation. Two of these 
inspections were of distributors while one was 
of a manufacturer. These were the first cosmetic 
product inspections to be carried out by us. 
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Illegal activity involving the manufacture, supply and 
sale of medicines or medical devices can have adverse 
consequences for public health. It is the role of the 
HPRA to investigate potential breaches of human 
medicines, medical device and the majority of other 
legislation within its remit. Where necessary, we will 
take the appropriate corrective action, including the 
possibility of legal proceedings.
Enforcement Cases and  
Medicines Detained
During 2015, 3,677 enforcement cases were initiated, 
compared to 3,703 in the previous year. There were a 
total of 1,136,494 dosage units detained, an increase 
from 730,056 units in 2014.
Sedative products accounted for almost two-thirds 
(64%) of all detentions. Erectile dysfunction products 
and illegal cosmetic products accounted for 9% and 
6% of detentions, respectively. Other categories of 
products detained in smaller quantities included 
anabolic steroid, slimming and pain relief.
A summary of the HPRA enforcement data is provided 
in the accompanying table.
 
Inter-Agency Co-operation  
and Pangea VIII
The HPRA continues to liaise and work closely 
with other enforcement agencies both nationally 
and internationally, in combating, detecting and 
preventing the unauthorised flow of medicines, 
medical devices and other health products. 
National co-operation between the HPRA, the 
Revenue’s Customs Service and An Garda Síochána 
continued in 2015 incorporating Operation Pangea 
VIII. During this operation, the inter-agency approach 
resulted in the detention of 142,000 tablets and 
capsules, with an estimated value of over €430,000. 
Pangea VIII was a global initiative which involved 
236 agencies drawn from health product regulatory 
authorities, police and customs across 115 countries. 
The operation, which was co-ordinated by INTERPOL, 
targeted criminal networks behind the sale of falsified 
and illegal medicines via illicit websites. 
Throughout 2015, the HPRA worked in co-operation 
with the Pharmaceutical Society of Ireland, the HSE 
and the Food Safety Authority of Ireland across areas 
of common interest to address offending behaviours 
in the market. The HPRA also liaised with Sport Ireland 
regarding substances that could be used in doping.
Prosecutions
The policy of the HPRA is to prosecute where it is 
considered necessary in order to protect public health 
and where a compliance based approach is not 
considered appropriate. 
During the past year, one prosecution was initiated 
while four prosecutions that commenced prior to 2015 
were concluded. These cases related to products 
containing active substances that had the potential to 
be used for mood stabilisation, sports performance 
enhancement, erectile dysfunction and weight loss.
Enforcement
Year 2011 2012 2013 2014 2015
Product detained (dosage units) 762,641 758,276 919,965 730,056 1,136,494
Cases Opened 4,549 3,911 3,932 3,703 3,677
Prosecutions 9 11 9 10 1
Product destroyed 4,519kg 1,065kg 4,194kg 3,440kg 0kg (at year end)
Voluntary Formal Caution (VFC) 12 6 27 13 14
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LEGISLATIVE AND  
REGULATORY  
DEVELOPMENTS  
The remit and role of our organisation continues 
to develop and expand in line with national and 
European legislative changes and in response to 
the addition of further competencies. 
This section of the 2015 annual report outlines 
the most significant legislative and regulatory 
developments during the past year by product 
type, how these changes influenced the work of  
the HPRA and, where relevant, the associated 
impact on stakeholders.
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Falsified Medicines 
Work continued towards implementation of the 
remaining aspects of Directive 2011/62/EU on falsified 
medicines, which amended Directive 2001/83/EC 
(relating to medicinal products for human use). 
Of note, the European Commission issued a draft 
Delegated Regulation for consultation in respect 
of proposed safety features on specified human 
medicines. It is expected that this will be finalised 
early in 2016 with a three-year period thereafter 
for implementation. The HPRA continued to 
participate in the expert group convened by the 
Commission to assist with drafting of the Delegated 
Regulation. We also liaised with industry and other 
stakeholder organisations in Ireland in relation to the 
establishment of a National Medicines Verification 
Organisation. The tasks of this organisation will 
include development of a repository system to 
hold batch data and permit authentication of packs 
of medicines carrying safety features at point of 
dispensing and at earlier points in the distribution 
chain.
Also during 2015, regulations amending the Medicinal 
Products (Prescription and Control of Supply) 
Regulations 2003 and the Pharmacy Act 2007, were 
put in place. These provide for legitimate supply of 
authorised non-prescription medicines by entities that 
apply, and are listed by, the Pharmaceutical Society of 
Ireland. 
New Clinical Trials Regulation 
The new clinical trials legislation (Regulation (EU) 
No. 536/2014) was adopted and published in May 
2014. It will come into effect in Europe in 2018. The 
new Regulation is intended to increase the number 
of clinical trials conducted in Europe and provide for 
improved transparency. 
The HPRA has been working to progress the 
development of systems and procedures to meet 
the new requirements. The existing voluntary 
harmonisation procedure (VHP) is similar to the 
approval process for clinical trials under the new 
legislation and the HPRA continues to increase its 
involvement in this procedure.  
Human Medicines
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Interchangeable Medicines
Following commencement of the Health (Pricing and 
Supply of Medical Goods) Act in June 2013, the HPRA 
was tasked with publishing a list of interchangeable 
medicines to facilitate generic substitution by 
pharmacists and to allow for the introduction of a 
reference pricing system by the HSE. By the end of 
2015, the list included a total of 47 active substances.
Legal Classification of Medicines
Medicines are classified, in law, as prescription or 
non-prescription. Since 2014, the HPRA has taken a 
proactive approach to the reclassification of the legal 
status of medicines, with the aim of increasing the 
number of medicines available without prescription, 
where it is safe to do so. The HPRA has identified 
medicines which we consider could be safely made 
available without prescription in pharmacies, or made 
more widely available in general retail outlets such as 
supermarkets, and has invited the industry to make 
applications to have these medicines reclassified. 
On foot of this proactive approach, a number of 
reclassification applications were completed in 2015 
and further progress is anticipated during 2016.
Responding to Medicines 
Shortages
The HPRA works closely with all relevant stakeholders 
to limit the impact of human medicines shortages on 
the Irish market. One of the mechanisms used by the 
HPRA to aid continuity of supply to the market place 
in the event of a shortage includes the granting of 
a temporary authorisation for a batch of a product 
known as a ‘batch specific request’. During 2015, 
the HPRA reviewed 115 batch specific requests to 
facilitate continuity of supply of medicinal products 
in Ireland and prioritised other applications where 
expedited review was required to avoid shortages. It 
also worked with marketing authorisations, including 
suppliers of alternative products, to avoid or mitigate 
shortages.
Innovative Medicinal Products 
and New Manufacturing 
Technologies
The HPRA continues to support the development of 
innovative medicinal products and new manufacturing 
technologies, and recognises the need to ensure 
the appropriate regulation of such products. In the 
past year, it was an active participant in European 
groups which aim to support such innovation and the 
ongoing training and development of staff in these 
areas remains a priority for the HPRA.
Working towards Full 
Implementation of EU 
Pharmacovigilance Legislation
The HPRA continued its work with stakeholders 
including the EMA, other national regulators and 
industry to support the phased implementation of EU 
pharmacovigilance legislation. 
Under this legislation, there is a requirement for the 
EMA to set up a repository of PSURs and assessment 
reports. This allows for centralised PSUR reporting 
and enhances access to data and information, 
thereby supporting benefit / risk assessments of 
medicines. During 2015, the HPRA participated in a 
pilot of the PSUR repository with the EMA and other 
Member States as well as user acceptance testing in 
preparation for mandatory use of the repository in 
June 2016.
The HPRA continued to contribute to three EMA / 
Member State project teams (PT) concerned with:
• collection of key information on medicines (PT1);
• better analysis and understanding of data and 
information (PT2); 
• committees and communications with 
stakeholders (PT3). 
The HPRA’s Pharmacovigilance and Risk Management 
Lead contributed to the project oversight governance 
through membership of the Project Co-ordination 
Group and the European Risk Management Strategy 
Facilitation Group.  
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SCOPE Joint Action
The Strengthening Collaboration for Operating 
Pharmacovigilance in Europe (SCOPE) Joint Action 
was established to optimise the operation of 
strengthened pharmacovigilance legislation in Europe 
which was brought into effect in June 2012. The 
SCOPE Joint Action is being implemented via eight 
work packages which target discrete elements to 
support the overall project. During 2015, the HPRA 
contributed to the risk communications and lifecycle 
pharmacovigilance work packages. 
The HPRA is the topic lead in respect of carrying out 
an impact assessment of risk communications under 
work package 6 (WP6). Information is being collected 
on risk communications practice in the EU network 
to better understand the communication channels 
and tools used. During 2015, a web-based survey 
on safety communications and their effectiveness for 
healthcare professionals was delivered and distributed 
to general practitioners, cardiologists and pharmacists 
across the Member States which are partners in 
WP6, including Ireland. The survey was designed to 
assess different means of communicating drug safety 
updates with particular focus on Direct Healthcare 
Professional Communications (DHPCs), national 
competent authority communications and product 
specific educational materials. Analysis of results has 
commenced with a consolidated report anticipated by 
the final quarter of 2016. These results, together with 
input from patient organisations, consumer groups 
and national regulators, will inform the development 
of good practice recommendations for use in EU 
Member States.
The HPRA also actively contributed in 2015 as a 
partner under work package 8 (WP8) relating to 
lifecycle pharmacovigilance. A survey of national 
competent authorities was undertaken in 2015 and 
the results will be used to develop recommendations, 
guidance and training for regulators to support EU 
pharmacovigilance work. 
Contributing to the European 
and Global Regulatory Network
 
Europe
The HPRA continues to actively participate across 
the European medicines regulatory network. HPRA 
scientific and technical staff contribute to a broad 
range of committees and working parties, preparing 
papers as appropriate, at the EMA, the European 
Commission, the HMA, and at other fora.
In addition to our regular participation at a European 
level, highlights from the past year included the 
following:  
• An active contribution to the work of the PRAC, 
with the Irish PRAC delegate being re-elected as 
Vice-Chair of the committee for a further three-
year term.
• The Pharmacovigilance and Risk Management 
Lead participated in a number of initiatives 
exploring development of the regulatory 
environment, strategies to facilitate access to 
innovative medicines for patients in need and 
benefit-risk management through the product 
lifecycle.
• The Pharmacovigilance and Risk Management 
Lead contributed to a number of strategies to 
support stakeholder engagement and to specialist 
topics such as risk management planning, 
benefit-risk evaluation, pharmacovigilance impact 
evaluation, post authorisation efficacy studies and 
pharmacovigilance as an enabler for innovation.
• During 2015, the HPRA transferred the secretariat 
function for the Benchmarking of European 
Medicines Agencies (BEMA) to Halmed, the 
regulatory agency for human medicines in Croatia. 
The BEMA programme provides assurance to the 
heads of the EU medicines agency network with 
respect to the quality of the systems and practices 
in place in agencies for regulating human and /
or veterinary medicines and is a resource for 
sharing of best practices. As members of the 
BEMA steering group, the HPRA continued to 
work with other Member States to prepare for 
the fourth benchmarking cycle which is due to 
begin in 2016. Visits will take place over a three-
year period to all agencies regulating human and 
veterinary medicines in the EU and EEA countries.
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• HPRA delegates attended three meetings of 
the European Pharmacopoeia (Ph. Eur.) and 
participated in a number of the working parties 
and groups which provide expert advice in respect 
of the pharmacopoeia.  
• The HPRA presented at a meeting of the FOAM 
(Forum on the Advertising of Medicines) network 
on advertising. The network is a mechanism 
whereby those within the EU competent 
authorities responsible for monitoring advertising 
of medicines share information on their 
advertising compliance programmes and related 
activities.  
World Health Organization
The HPRA’s Pharmacovigilance Manager continued 
to represent the World Health Organization (WHO) 
as a member of the Board of the Uppsala Monitoring 
Centre (UMC) and WHO Collaborating Centre for 
International Drug Monitoring during 2015.
The HPRA participated at the annual meeting of 
national centres participating in the WHO international 
drug monitoring programme in November and 
continued to provide details of reports received 
nationally to the WHO for inclusion on its international 
database. As outlined in the accompanying graph, 
the volume of adverse reaction reports from 
Ireland continued to fall within the top 20 countries 
participating in the programme with Ireland ranked 
as the thirteenth highest reporter (population based) 
during 2015. There are currently 123 countries with 
full programme membership and 28 countries with 
associate membership.
Health Systems Strengthening 
Programme
The HPRA was part of a successful consortium selected 
to provide ‘Technical Assistance to the Ministry 
of Health and the Zambia Medicines Regulatory 
Authority’. This followed a tender process under 
the EU funded Health Systems Strengthening (HSS) 
programme. Planning for the delivery of regulatory 
and capacity building support by the HPRA to the 
Zambian agency began in 2015 while the project itself 
is expected to commence in quarter two 2016.
Sub-Committees to the 
Advisory Committee for Human 
Medicines
 
There are a number of sub-committees appointed by 
the Advisory Committee for Human Medicines. These 
include the Clinical Trials Sub-Committee which met 
12 times in 2015 and the Herbal Medicines Sub-
Committee which met once in the same period.
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Two Commission Directives were published during 
2015. These were:
• Directive (EU) 2015/565, amending Directive 
2006/86/EC as regards certain technical 
requirements for the coding of human tissues and 
cells; 
• Directive 2015/566, implementing Directive 
2004/23/EC as regards the procedures for 
verifying the equivalent standards of quality and 
safety of imported tissues and cells.   
Member States are required to transpose the 
provisions of these Commission Directives during 
2016 and the requirements will apply from 29 April 
2017. The HPRA hosted two information sessions to 
highlight the requirements of these Directives and 
the presentations and other relevant information were 
made available online to stakeholders. 
Contributing to the European 
Regulatory Network
The European regulatory network is the backdrop 
for reaching a common view on medicines and their 
regulation. Given that most medicines are supplied 
to multiple European markets, it is clear that in 
order for us to maximise our influence, we must 
have an input in decisions taken at a European 
level. This we do through our involvement across 
the EU network which includes active participation 
at the EMA, where our Veterinary Assessment 
Manager is the Vice-Chair of the Committee for 
Medicinal Products for Veterinary Use (CVMP), and 
the HMA. 
Key regulatory issues discussed during 2015 were: 
• The new proposal for a regulation on veterinary 
medicines. The HPRA provided practical support 
and advice to the Department of Agriculture, 
Food and the Marine during Council Working 
Party discussions; 
• The European surveillance strategy on 
pharmacovigilance work-sharing;
• The implementation of the HMA Action Plan on 
antimicrobial resistance.
Veterinary 
Medicines
Tissues 
and Cells
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Contributing to National Health 
Initiatives
During 2015, the HPRA participated in a working 
group of the FSAI tasked with preparing a report 
on the risk of antibiotic resistance transfer posed by 
food. The HPRA also participated in two meetings 
of the National Interdepartmental AMR Consultative 
Committee.  
Throughout the year, support was provided to the 
Department of Agriculture, Food and the Marine in 
relation to matters of mutual interest.
Advisory Committee for 
Veterinary Medicines 
The Advisory Committee for Veterinary Medicines 
is the HPRA’s independent expert committee that 
advises on matters relating to the authorisation of 
veterinary medicines in Ireland. It met twice during the 
course of 2015 and considered such matters as:
• Regulatory developments affecting medicines 
in the European network;
• A report of suspected adverse reactions to 
veterinary medicines in Ireland for 2014;
• A report on the consumption of veterinary 
antibiotics in Ireland for 2014;
• Various applications that had been considered 
by the agency previously but were submitted 
for peer review by the committee. 
Medical 
Devices
Revision of European Medical 
Devices Legislation
The European Commission’s proposals for Regulations 
on medical devices and in vitro diagnostic (IVD) 
medical devices are intended to develop and 
reinforce the European legislative framework to ensure 
a high level of protection for patients and healthcare 
professionals. At the same time, the proposed 
changes are focused on ensuring that the regulatory 
system enables safe innovation of new products 
and access for patients and healthcare professionals 
to new therapeutic and diagnostic options. The 
proposals are subject to the ordinary legislative 
process which involves examination by both the 
European Council and the European Parliament.
During 2015, negotiations in respect of the proposals 
reached a new phase with the adoption of a ‘General 
Approach’ on the legislative texts by the European 
Council. This allowed for the initiation of trialogue 
with the European Parliament and the EU Commission 
on the dossiers, which is one of the key elements of 
the ordinary legislative process. 
The two proposed Regulations represent a significant 
development and improvement in comparison to the 
existing system which has been in place for over 20 
years. However, the negotiations are complex and 
time-consuming due to the volume and technical 
intricacy of the legal text. The final compromise text 
will likely represent a delicate balance of the views of 
the Member States, the European Parliament and the 
EU Commission. However, the HPRA considers that 
the revised legislation is necessary and will represent 
significant improvement and strengthening of the 
regulatory system for devices. 
During the year, the HPRA provided significant 
support to Department of Health and the Permanent 
Representation of Ireland in Brussels for the 
purposes of negotiation of the legislation at the 
European Council Working Party and at various 
expert working groups. This includes advising on the 
2
NEW MEDICAL DEVICES 
REGULATIONS PROPOSED 
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COMMISSION
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further development of the legal texts, compromise 
proposals, assistance with relevant stakeholder 
consultation and provision of input to the Department 
as it finalises a national position on the proposals.
The trialogue negotiations will continue during 2016 
when it is anticipated that final agreement can be 
reached under the Dutch Presidency. When the final 
texts are agreed and the legal texts start to come 
into effect, the HPRA will conduct an information 
campaign to provide information, guidance and 
advice to affected stakeholders on implementation of 
the legislation.
Ongoing Development 
and Strengthening of the 
existing European Regulatory 
Framework 
Along with a number of other European competent 
authorities and the European Commission, the 
HPRA has taken a leading role in development and 
strengthening of the existing regulatory framework 
for medical devices in advance of the revised legal 
framework being agreed and implemented. In 
particular, the HPRA is keen to promote co-ordination 
and co-operation between authorities to increase 
safety, effectiveness and reduce duplication.
Oversight and Performance of Notified 
Bodies for Medical Devices
One of the central components of the European 
Commission’s joint action plan of 2012 was to 
improve the performance of notified bodies and 
their oversight by authorities. This was achieved 
by implementation of an EU wide joint assessment 
scheme for notified body oversight by authorities 
which led to the implementation of the 2013 
Regulation on notified bodies. The HPRA, having 
contributed to the development and implementation 
of this assessment scheme, continues to be part of a 
small expert group which oversees and co-ordinates 
its continued implementation. During 2015, the HPRA 
directly participated as experts in six joint assessments 
of EU notified bodies. In addition, the Irish notified 
body was also subject to an EU joint assessment 
audit during 2015 as part of its application for re-
designation as a medical device notified body.
Market Surveillance and Vigilance
Another key element of the joint plan, which was 
further highlighted by the EU Commission in its 2014 
report, was the strengthening of market surveillance 
activities by national regulatory authorities across 
Europe. In response, the HPRA has developed its 
range of market surveillance activities throughout the 
medical device lifecycle and has a planned continued 
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development process towards the new legislation. In 
particular, the HPRA’s key emphasis is on proactive 
surveillance. Areas of proactive market surveillance in 
2015 are outlined in Chapter 2 of this report.
The HPRA continues to encourage healthcare 
professionals and other device users to submit reports 
of incidents which occurred when using a medical 
device. In addition, the HPRA has revised our methods 
for safety reporting to ensure the information is clear 
and targeted to the correct user group.
As part of the strengthening of medical device 
regulation, the HPRA has also been focused on 
improving the functioning of the vigilance system 
both nationally and at an EU level. This has been in 
the form of:
• systematic access for notified bodies to reports of 
adverse events; 
• developing an internal system for signal detection 
and trend analysis;
• encouraging healthcare professionals and 
empowering patients to report adverse events; 
and
• enhancing co-ordination in analysing reported 
incidents in order to pool expertise and expedite 
necessary corrective actions.
In respect of enhanced co-operation, the HPRA has 
been participating in the development of a centralised 
European databases for vigilance. These will also 
be an area for consideration and further attention in 
2016.
During the past year, the HPRA was an active 
participant in Medical Devices Expert Group (MDEG) 
vigilance meetings and vigilance teleconferences. 
The HPRA continued to chair three taskforces which 
included the vigilance co-ordinating competent 
authority role and was an active participant in 
eleven other taskforces relating to specific devices / 
manufacturers and to the development of guidance 
such as device specific vigilance guidance.
Contributing to the European 
and Global Regulatory Network
Competent Authority for Medical 
Devices
During 2015, the HPRA continued to engage actively 
and develop its partnerships with other European 
competent authorities. The HPRA is an elected 
member of the Competent Authority for Medical 
Devices (CAMD) Executive Group. The objective 
of this group is to build mechanisms and structures 
to enable co-operation between authorities and to 
identify key work items and priorities for focus at 
European level. The EU Commission also participates 
in the group’s discussions.
In November 2015, the 37th CAMD meeting was 
hosted in Dublin by the HPRA on behalf of the 
Luxembourg Presidency of the European Council. The 
meeting was attended by over 60 delegates from 25 
countries and included representatives from the EU 
Commission’s DG GROW, the Food and Veterinary 
Office (FVO) and the Joint Research Centre (JRC). 
The meeting focused on developing the regulatory 
system further in preparation for the anticipated 
revision of the medical devices legislation. One of the 
key focus areas was to agree priorities and work plans 
for co-funded joint actions in medical device market 
surveillance under the European Health Programme 
2016-2020.
60+
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International Medical Device  
Regulatory Forum
During 2015, the HPRA continued as a member of the 
European delegation on the Management Committee 
of the International Medical Device Regulators Forum 
(IMDRF). This forum aims to develop and promote 
harmonisation of the regulation of medical devices 
across the globe. In addition to contributing to the 
Management Committee, the HPRA continued in the 
role of secretariat for the IMDRF National Competent 
Authority Report (NCAR) Exchange mechanism which 
allows for the exchange of reports and key safety 
information from each global region. The HPRA also 
participated in the IMDRF working groups on NCAR 
and on developing Regulated Product Submission 
(RPS) standards (which facilitate standard formats for 
technical documentation for submission to regulatory 
authorities). As part of this working group the HPRA 
acted as Chair for the Table of Contents Workstream 
in 2015 to establish a pilot for regulatory submissions. 
In 2015, the HPRA hosted a meeting of the IMDRF 
Medical Device Single Audit Program (MDSAP) 
working group in Dublin. The EU is a formal observer 
to the ongoing MDSAP pilot programme. The 
programme allows recognised auditing organisations 
(such as notified bodies) to conduct a single quality 
system audit of a medical device manufacturer that 
will satisfy the relevant requirements of the regulatory 
authorities participating in the programme. The 
HPRA is also committed to providing experts to 
conduct MDSAP audits in Europe as part of the pilot 
programme.
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Bilateral Meetings
During 2015, the HPRA held bilateral meetings 
with the US Food and Drug Administration (FDA), 
Australia’s Therapeutic Goods Administration (TGA), 
the EU Commission’s Joint Research Centre (JRC) 
and the EU Commission’s Food and Veterinary 
Office. Meetings were also held with other national 
authorities in Europe including the UK’s Medicines and 
Healthcare products Regulatory Authority (MHRA), 
the Croatian competent authority (HALMED), the 
Netherlands healthcare inspectorate (IGZ) and the 
Netherlands National Institute for Public Health and 
the Environment (RIVM).
Contributing to National Health 
Initiatives
As outlined earlier in this report, the HPRA has also 
been focused on improving the functioning of the 
vigilance system nationally. Throughout 2015, we 
worked closely with the HSE to develop a system 
for the dissemination of medical devices safety 
information. This also included the identification of 
a designated person within all HSE and voluntary 
hospital acute and community settings. Further work 
will be carried out in these areas during 2016.
Advisory Committee for Medical 
Devices 
The Advisory Committee for Medical Devices 
met three times in 2015. Regular updates were 
provided on key medical device issues, regulatory 
developments, the revision of the medical devices 
legislation and HPRA activities in regulating medical 
devices. The term of the current committee concluded 
at the end of 2015. A new committee was appointed 
by the Minister for Health to commence in 2016.
Scientific 
Animal 
Protection
In relation to the EU network on scientific animal 
protection, the HPRA contributed to deliberations in 
respect of a number key topics and played an active 
role as part of the EU National Committees for the 
Protection of Animals used for Scientific Purposes.
Nationally, the HPRA published its second annual 
statistical report on the use of animals for scientific 
purposes in Ireland. We also provided support to the 
National Committee for the Protection of Animals 
used for Scientific Purposes in relation to their role 
to nurture the creation of a culture of care at the 
establishments concerned. The committee met twice 
during 2015.
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STAKEHOLDER  
ENGAGEMENT AND  
COMMUNICATIONS  
The HPRA continues to deliver a comprehensive 
programme of communications and engagement 
activities so as to provide all our stakeholders 
with timely access to relevant safety, licensing and 
regulatory information. Ensuring effective and 
timely communications is one of our core strategic 
goals and will continue to be an area of focus and 
development over the coming years.
A number of significant communications 
programmes and initiatives took place during 2015.
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Stakeholder Engagement
Meetings with Stakeholders –  
Human Medicines
During 2015, there were a number of meetings 
held with industry representative groups including 
the Association of Pharmaceutical Manufacturers in 
Ireland (APMI), the Irish Pharmaceutical Healthcare 
Association (IPHA), the Healthcare Enterprise Alliance 
(HEA), the Irish Generic Medicines Association (IGMA) 
and Pharmachemical Ireland. These meetings provide 
a forum for discussion of items of mutual interest. 
There was also one meeting of the Advertising 
Compliance Technical Group which includes 
representatives from the HPRA and pharmaceutical 
industry. Issues of mutual interest were discussed with 
a goal of promoting good practice and compliance in 
this area.
Meetings with Stakeholders –  
Veterinary Medicines
During 2015, the HPRA met with the Department 
of Agriculture, Food and the Marine in relation to 
ongoing matters of mutual interest, including the new 
proposal for the regulation of veterinary medicines 
in the EU and the shortage of a particular medicinal 
product. Meetings were also held with a number of 
stakeholders from the veterinary medicines industry. 
In addition, an update on the changing regulatory 
requirements for veterinary medicines was provided at 
an award ceremony for new graduates of the course 
for licensed merchants.
Meetings with Stakeholders –  
Scientific Animal Protection 
There was one meeting held in 2015 with 
the Department of Health in relation to the 
implementation of Directive 2010/63/EU regarding 
the protection of animals used for scientific 
purposes. A large number of presentations on the 
implementation of the Directive were also delivered to 
the research community throughout Ireland. 
Meetings with Stakeholders –  
Medical Devices 
Regular meetings with key industry stakeholder 
groups continued during 2015. These meetings 
provide the HPRA with an opportunity to update 
stakeholders on regulatory developments at national 
and European level. They also enable the HPRA to 
be kept up-to-date on issues affecting the medical 
devices industry. A key topic for discussion during 
2015 was the ongoing revision of the medical devices 
legislation and the introduction of national fee 
structures for medical device regulation.
In the past year, meetings were held with the NSAI, 
the Irish Medical Devices Association (IMDA), the Irish 
Medical and Surgical Trade Association (IMSTA) and 
Eucomed (European Medical Technology Industry 
Association). 
As part of the negotiations of the ongoing revision of 
the medical devices legislation, the HPRA, along with 
colleagues from the Department of Health, met with 
Members of the European Parliament to discuss the 
proposed legislation. This topic was also discussed 
in a meeting between the HPRA and the Industrial 
Development Authority (IDA).
In November, the HPRA hosted the 37th meeting 
of the CAMD in Dublin (see page 61). The agenda 
incorporated a meeting between the CAMD Executive 
and representatives from the European industry 
associations AESGP, COCIR, EDMA and EUCOMED. 
In addition, during the plenary meeting, a session was 
held with representatives from the EU Notified Body 
representative associations. 
Also in November, the HPRA, together with the HSE, 
launched the eAlert IT system and complementary 
designate person role to facilitate the dissemination 
of key medical device safety information from the 
HPRA to the HSE, voluntary hospitals and community 
settings. This event, which was held at the Royal 
College of Physicians in Ireland, was attended by a 
large number of healthcare professionals and included 
a range of speakers and a panel discussion.   
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Meetings with Stakeholders –  
Cosmetic Products
During 2015, meetings were held with the Irish 
Cosmetics, Detergent & Allied Products Association 
(ICDA), the Department of Jobs, Enterprise and 
Innovation (DJEI) and the NSAI.
Presentations to Stakeholders
As in recent years, the HPRA invested significant 
time in delivering a programme of presentations 
and talks at a range of external stakeholder events 
such as meetings, seminars, conferences and training 
courses. In addition, a programme of presentations 
was delivered to undergraduate and post graduate 
students studying courses related to the role of the 
HPRA.
Such presentations contribute to the HPRA goal 
of providing stakeholders such as healthcare 
professionals and regulatory professionals with 
access to relevant, up-to-date information. The 
presentations are delivered by HPRA staff from across 
the organisation and cover all products and functions 
under our remit. While some are general in nature and 
primarily focused on explaining the role of the HPRA, 
others are more specific and deal with specialist areas 
and / or new regulatory developments. A full list of 
all presentations delivered during 2015 is provided in 
Appendix 2.
Events
Information Days and Seminars 
HPRA information seminars provide regulatory 
guidance and updates to a range of stakeholders. 
As well as presentations from HPRA staff and, where 
appropriate, external contributors, the events enable 
all attendees to submit questions, seek clarifications 
and network with colleagues. 
In addition to the meetings outlined earlier in this 
report, the following events were also held during 
2015:
• In January, the HPRA hosted an information 
seminar on the regulation of herbal medicines. 
The meeting focused on a number of topics 
including traditional herbal medicinal products 
(THMPs) and focused on both pre and post 
authorisation / registration requirements.
• Three cosmetic information evenings were 
hosted, free of charge, in Dublin, Cork and 
Galway during September and October. These 
events were aimed at small to medium sized 
cosmetic businesses, both manufacturing and /
or distributing cosmetics, and provided guidance 
on the regulatory compliance required of the 
industry.    
• An animal welfare body training workshop and 
seminar was held in September. The HPRA 
organised this event on behalf of the National 
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Committee for the Protection of Animals used 
for Scientific Purposes and also presented on 
relevant topics. This was the first such meeting in 
Ireland and represented an important networking 
opportunity for those involved in the sector. It 
also afforded the Committee an opportunity to 
establish direct communication links with the 
establishments concerned. 
• A meeting of the International Medical Device 
Regulators Forum (IMDRF) Medical Device Single 
Audit Program (MDSAP) working group was 
hosted by the HPRA in Dublin.
• The HPRA hosted two information sessions to 
highlight the requirements of two Commission 
Directives published during 2015 relating to the 
regulation of human tissues and cells. 
• A regulatory information session was hosted in 
conjunction with TOPRA (The Organisation for 
Professionals in Regulatory Affairs) in November.
Industry Events
The Professional Beauty Show held in the RDS, Dublin 
in October, featured an information stand operated 
by HPRA staff members. Details were provided on 
the regulatory requirements for the cosmetic and 
medical device industries to beauty professionals both 
participating in and attending the event.
BT Young Scientist and Technology 
Exhibition 2015
The BT Young Scientist and Technology Exhibition 
2015 took place in January in the RDS, Dublin. 
Thousands of students as well as teachers, parents 
and members of the general public from all over 
Ireland visited the HPRA’s exhibition stand in the 
Industries Hall. This was the sixth year of HPRA 
participation and our stand again focused on building 
awareness of the significant role the HPRA plays in 
protecting public and animal health. In particular, 
the safe and appropriate use of medicines, medical 
devices and cosmetic products was highlighted. As in 
previous years, the stand also focused on the many 
interesting science related career opportunities that 
are available in the health products industry.
Publications
Guidance Documents
HPRA guidance documents provide stakeholders, 
primarily from the industry sectors we regulate, with 
advice and direction in respect of legislation and 
regulatory requirements. New and updated HPRA 
guidance documents are published regularly on our 
website with alerts issued to website subscribers. 
A number of new guidance documents were 
published during 2015 with a significant number of 
existing documents also being updated. Among the 
new documents published during the past year were:
• Guide to Good Manufacturing Practice for 
cosmetic products;
• Guide to applying for a manufacturer’s / importer’s 
authorisation;
• Guide to biosimilars for healthcare professionals 
and patients.
All of the HPRA guidance documents can be accessed 
via the publications section of www.hpra.ie. 
6th
YEAR OF HPRA 
PARTICIPATION AT THE 
BT YOUNG SCIENTIST 
AND TECHNOLOGY 
EXHIBITION
HPRA ANNUAL REPORT 2015 69
Newsletters
The HPRA produces three newsletters with a number 
editions of each published throughout the year. 
 
Medicinal Products Newsletter
This newsletter provides regulatory updates for those 
working in the pharmaceutical and cosmetics sectors 
on Irish and European legislation, new / revised HPRA 
regulatory publications and stakeholder events such as 
information days. 
Three editions of the Medicinal Products Newsletters 
were published during 2015. Topics covered included:
• Human Medicines
- Updates to good vigilance practice (GVP) 
guidelines;
- Electronic reporting of ICSRs to marketing 
authorisation holders;
- Proactive approach to reclassification (switching);
- New EU Clinical Trials Regulations.
• Veterinary Medicines
- Using the HPRA as Reference Member State;
- Changes to requirements for product literature;
- Certificates of suitability and retest periods;
- Use of animals for regulatory testing of medicinal 
products.
• Compliance
- Reporting the theft or unaccounted loss of 
controlled drugs and precursor chemicals to the 
HPRA;
- New tools for manufacturers to help prevent 
medicines shortages;
- Pilot inspection programme for distributors of 
medical devices;
- Methylisothiazolinone (MI) in cosmetic products.
The newsletter is published on the HPRA website and 
is issued to those who subscribe to the HPRA alerts 
system. 
Drug Safety Newsletter
The Drug Safety Newsletter continues to provide 
important safety information to healthcare 
professionals in respect of human medicines and 
incorporates hyperlinks to product information 
and other relevant documents on the HPRA and 
EMA websites. Seven issues of the newsletter were 
published on our website and made available 
electronically to registered doctors, dentists, nurses 
and pharmacists during 2015. An overview of the 
topics covered during the past year is included in 
Appendix 3.
Medical Devices Newsletter 
This newsletter provides regulatory and safety updates 
for those working in the medical devices sector and 
professionals working in the health area who regularly 
use or purchase medical devices. It provides updates 
on Irish and European legislation, on safety issues as 
well as details of HPRA medical devices publications 
and stakeholder events. There were two editions 
of this publication issued in 2015 in addition to a 
feedback survey aimed at reviewing the content of the 
newsletter to ensure it meets the expectations of our 
stakeholders. 
The following were some of the main topics covered:
• Proposals for new regulation on medical devices 
and in vitro diagnostic medical devices;
• The Medical Device Single Audit Programme 
(MDSAP);
• An overview of transcranial Direct Current 
Stimulation (tDCS);
• Supplier qualification and management;
FEBRUARY 2016
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In this Edition
Educational materials-optimising the safe and effective 
use of medicinal products 
Medicines use may be complex and ensuring that medicines are used safely and effectively may also be a challenge for those involved in the prescribing, dispensing and using medicines in clin-ical practice. The HPRA would like to highlight the availability of educational materials and tools for certain medici-nal products which should be used to support their rational prescribing and use in clinical practice. 
The use of risk minimisation measures to help support the safe and effective use of medicines has evolved over the years. Risk minimisation measures asso-ciated with medicinal products are a set of interventions designed to prevent or reduce the occurrence of adverse re-actions associated with exposure to a medicine, or to reduce their severity or impact on the patient should such ad-verse reactions occur.
Risk minimisation measures may con-sist of ‘routine’ measures or ‘additional’ measures. 
Routine risk minimisation measures are applicable to all medicinal prod-ucts and include the product infor-mation (i.e. the summary of product characteristics (SmPC), which the basis of information for healthcare professionals (HCPs) on how to use 
the named medicinal product safely and effectively, the package leaflet (PL), which is primarily aimed at the patient and drawn up in accordance with the SmPC, and the product label), the pack size and design and the legal (prescrip-tion) status of the product (e.g. avail-able on prescription only, available through pharmacies, available thor-ough general sales outlets). 
It is usually adequate to address safety concerns relating to medicinal prod-ucts by these ‘routine’ risk minimisa-tion measures, e.g. safety warnings and risk minimisation advice, advice on interactions, in the product informa-tion (SmPCs for products authorised in Ireland are available through the HPRA website).
However, in some cases, it is consid-ered that ‘additional’ risk minimisation measures are necessary in order to manage certain key risks and to further optimise the safe and effective use of a medicinal product throughout its lifecy-cle. The aim of these additional meas-ures is to further support optimal use of a medicinal product in clinical prac-tice by focusing on the most important, preventable risks in a way that does not introduce an undue burden on the healthcare delivery system, HCPs or patients. 
Examples of additional risk minimisa-tion measures include direct healthcare professional communications, educa-tional programmes, pregnancy preven-tion programmes and controlled access systems for certain medicines.Direct Healthcare Professional Com-munications (DHPCs) are commu-nications used to convey important safety information to HCPs and to in-form them of the need to take certain actions or adapt their practices in rela-tion to a medicinal product. They are all approved by the HPRA and are deliv-ered directly to HCPs by the Marketing Authorisation Holder (MAH) respon-sible for marketing the product. They also may be disseminated when there is a need to take immediate action or change current practice in relation to a medicinal product, e.g. an impor-tant change to the use of a medicine due to the restriction of an indication, a new contraindication, or a change in the recommended dose, due to safety reasons. They may also be distributed when a new product is being launched onto the Irish market in order to high-light specific risk minimisation advice to HCPs. The HPRA also publish all ap-proved DHPCs on the HPRA website and highlight them via our Drug Safety Newsletter (DSN).Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland. 
T: +353 1 676  4971    E: medsafety@hpra.ie    www.hpra.ie       
• Educational materials-optimising the safe and effective use of medicinal products 
• Adverse Reaction  Reporting-Reminder
• Direct Healthcare Professional Communica-tions published on the HPRA website since the last Drug Safety Newsletter
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• European pilot on vigilance reporting;
• Registration and classification;
• Regulatory Science Ireland.
Scientific Animal Protection – Regulatory Updates 
These updates, which were issued on four occasions 
during the year, are intended to provide the research 
communities with updates on latest developments, 
including:
• New and updated HPRA guidance documents, 
forms and procedures;
• Information on education and training;
• Information on the 3Rs, best practices, compliance 
with the legislation and other relevant details.
External Articles
In respect of human medicines, there were 22 articles 
provided for inclusion in MIMS Ireland and two articles 
were provided for inclusion in the Irish Medicines 
Formulary. The full list of topics covered in these 
articles is included in Appendix 3. All articles were 
also published on the HPRA website. An article was 
also submitted for inclusion in the Irish PharmaChem 
Yearbook and Directory. This followed a request from 
PharmaChemical Ireland to provide information on the 
issue of falsified medicines and the work being done 
by the HPRA in this area.
Consistent with our objective to improve stakeholder 
knowledge of the appropriate use of veterinary 
medicines, we contributed four articles to the 
specialist It’s Your Field publication. Additionally, an 
article entitled Medical device vigilance: A competent 
authority perspective was published in the Journal of 
Medical Device Regulation while the Irish Forum for 
Global Health published an online article highlighting 
the HPRA’s participation in the BT Young Scientist and 
Technology Exhibition.  
Safety Warning and Notices 
Throughout 2015, in addition to the Drug Safety 
Newsletter, the HPRA continued to publish important 
safety information and the outcomes of benefit-risk 
evaluations of human medicines. Following HPRA 
review and approval, 21 Direct Healthcare Professional 
Communications were published on the HPRA website 
and issued to subscribers. The PRAC published 
monthly agendas, minutes, meeting highlights, 
notifications of safety reviews and signals throughout 
the past year and these were also made available via 
our website. 
We also published two advisory notices in respect 
of veterinary medicines. The first notice related to 
reported lack of efficacy of a sheep vaccine while 
the second notice concerned the updating of safety 
information on specific injectable products.  
Separately, a total of 33 HPRA safety notices 
concerning medical devices were published on the 
HPRA website and issued to subscribers. These 
notices were also circulated through the HSE eAlert 
system. We also published 474 manufacturer field 
safety notices on our website and a monthly listing 
was sent to subscribers. In addition, medical device 
information notices were issued during 2015 on food 
intolerance testing and on specific medical devices 
affected by regulatory actions in other global regions.
Reporting Adverse Events – Veterinary 
Medicines Leaflet
The receipt by the HPRA of reports of suspected 
adverse events following the use of veterinary 
medicines is central to the operation of an effective 
pharmacovigilance system. This leaflet, copies of which 
were distributed to all registered veterinary practitioners 
in Ireland, highlights the importance of reporting and 
explains how the information received by the HPRA 
is used to monitor the continued safety and efficacy 
of veterinary medicines. Details on what information 
should be included in a report are also provided as are 
Welcome to the first edition of the medical devices newsletter for 2015. In this edition, we introduce an article from our Director of Scientific Affairs, Dr J. M. Morris on a new regulatory initiative, Regulatory Science Ireland (RSI). RSI is a network comprised of academia, industry, regulators and government agencies involved in health products that are committed to the development of an integrated response in the fields of research, education and leadership in the global regulatory science effort. RSI strives to: create an environment that facilitates Irish contributions to an effective response to the increasing complexity of health care products and their regulatory systems; create a cohort of Irish based regulatory science experts; and strengthen the value proposition of Ireland as an attractive location for health care product related activities.
We feature an article from Ms Kimberly Trautman, Chairperson of the working group of the Medical Device Single Audit Program (MDSAP) of the International Medical Device Regulators Forum (IMDRF) and the US Food and Drug Association’s (FDA) Associate Director of International Affairs at their Centre for Devices and Radiological Health (CDRH). The working group is developing a system and standard set of requirements for third party auditing organisations to conduct regulatory audits of medical device manufacturers’ quality management systems on behalf of multiple regulatory regions. In February 
2015, the HPRA as members of the IMDRF Management Committee hosted a meeting of the working group in Dublin.
We would also like to raise awareness to the communication of information notices to stakeholders. To this end we feature two information notices recently published on our website regarding food intolerance testing and guidelines regarding the use of medical devices in the home.
The discussions on the revision of the medical devices legislation are continuing to progress at the European Council Working Party and we provide an update on its progress in this newsletter. Additionally, we have included regulatory updates on the recent European working group meetings namely the Medical Device Expert Group, MDEG Vigilance, Compliance and Enforcement Group, the In-vitro Diagnostics Technical Group and also on the activities at the International Medical Devices Regulators Forum. As always, the HPRA welcomes feedback on the content of our newsletter and encourages readers to submit suggestions for articles that would be  of interest by contacting us at  devices@hpra.ie
Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland 
T: +353 1 676  4971    E: devices@hpra.ie   www.hpra.ie       
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instructions on how to report. Copies of the leaflet can 
be downloaded from the HPRA website while printed 
versions can be ordered from leaflets@hpra.ie.
Animal Welfare Body Information 
Leaflet
This information leaflet, which was distributed to all 
establishments authorised to use animals for scientific 
purposes during the year, was developed with the 
input of the National Committee for the Protection 
of Animals used for Scientific Purposes. The leaflet is 
intended to support the work of the Animal Welfare 
Body in each establishment in promoting the 3R 
principles and to provide practical information 
on creating a culture of care. The leaflet can be 
downloaded from our website while printed versions 
can be ordered from sap@hpra.ie.
Public Information Campaign
In early 2015, HPRA announced its intention to 
develop a public information campaign that will 
communicate important safety messages to those 
who take, use and / or purchase health products such 
as medicines and medical devices. It is envisaged 
that the campaign, which should also contribute to 
increased awareness of the role of the HPRA, will run 
over a number of years beginning in 2016. During 
the past year, the HPRA conducted a procurement 
process which resulted in the appointment of media 
buying and creative advertising agencies.  
HPRA Website
Our website www.hpra.ie is a key component of the 
HPRA’s communications programme. The site outlines 
the primary functions and activities of the HPRA 
and facilitates the dissemination of information to a 
wide variety of audiences including healthcare and 
industry professionals as well as patients and other 
members of the public. As new content is regularly 
added to the website, we are focused on its continued 
development and enhancement to ensure it remains 
an attractive and user-friendly resource.
Developments in respect of the HPRA website during 
2015 included the following:
• The launch of a new human medicines information 
resource featuring educational materials for 
healthcare professionals and/or patients and 
care-givers. Educational materials are intended to 
promote the safe and effective use of individual 
medicines. The materials provide clear information 
on specific safety risks and describe concisely 
what actions are required to prevent and minimise 
such risks. 
• The publication of a dedicated list of vaccines 
authorised and marketed in Ireland for human use. 
This information complements the immunisation 
guidelines issued by the National Immunisation 
Advisory Committee (Royal College of Physicians 
of Ireland). Information is provided in respect 
of the product (and common) name, the 
authorisation number and the relevant marketing 
authorisation holder. A link to an online version of 
the most recently approved patient information 
leaflet is also provided for each vaccine. 
• The implementation of a search engine 
optimisation (SEO) and pay-per-click (PPC) 
campaign. SEO is a marketing tool focused on 
growing visibility in organic (non-paid) search 
engine results. PPC is a model of internet 
marketing which is designed to increase visits to 
a site rather than relying solely on organic visits. 
As part of the HPRA campaign, both technical 
and creative elements were applied to improve 
rankings, increase traffic and expand awareness in 
search engine results. We also placed a number of 
adverts to appear on search engine results pages. 
Overall, the SEO and PPC campaign resulted in 
increased traffic to the HPRA website and improved 
rankings for the HPRA in search results. HPRA 
content is now returned as the number one search 
result for a number of key regulatory topics.
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2015 Statistics
• Almost 206,000 unique visitors accessed the 
HPRA website during the past twelve months. 
There were in excess of 536,000 visits in total.
• Of those who accessed the site, 36% were new or 
first time users. 
• Among the most popular sections of the website 
were the human and veterinary medicines listings, 
and the medicines regulatory information sections 
(which include publications and forms).
Media Communications
The HPRA implements a proactive media 
communications campaign annually so as to 
communicate important safety messages and build 
awareness of the role of the HPRA. We prepared 35 
press releases and statements which in a number of 
instances resulted in national and regional media 
interviews with a HPRA spokesperson. 
Among the issues highlighted through press releases 
and statements during the past year were:
• Advice on seasonal maintenance of automated 
external defibrillators (AED) including a call for 
owners to ensure all defibrillators have received 
import software updates. 
• The suspension of medical devices manufactured 
by Silimed.
• HPRA participation in, and the outcome of, an 
EMA review of the safety of HPV vaccines.
• The dangers of consuming illegal slimming 
products containing Dinitrophenol (DNP).
• Advice to consumers on the importance of using, 
and correctly applying, sunscreen products. 
• The dangers of counterfeit cosmetics and how to 
identify such products. 
In addition, we responded to almost 500 queries from 
national, local and specialist media during the year. 
Drafting responses to such queries involves subject 
matter experts from across the organisation. 
Research 
 
Third National Consumer Survey
In late 2015, the HPRA commissioned Behaviour and 
Attitudes to carry out national consumer research to 
examine how Irish consumers source information about 
the medicines they take. The research will also examine 
the use of the internet as a source of medicines 
information and supply, and will explore the use of 
long-term and generic medication. The results of the 
research will be published in the first half of 2016.
Website User Satisfaction Survey
In August, the HPRA carried out an online survey 
among the users of our new website which by that 
time had been live for just over 12 months. The 
goal of the survey was to identify potential areas 
for improvement as well as any new content or 
features that users feel should be included on the 
site. The survey was highlighted via the homepage 
while a link and request to participate were also sent 
to key stakeholder groups. Overall, the feedback 
received was very positive in nature and the specific 
comments submitted will be used to guide the future 
development of our online presence.
Public Consultations
Public consultations enable the HPRA to identify the 
needs and expectations of stakeholders so that we 
may incorporate their views into the way our services 
are planned and delivered.
During 2015, the HPRA completed two public 
consultations. The first was in respect of the regulatory 
fees proposed for 2016 while the second related 
to the draft Guide to Biosimilars for Healthcare 
Professionals and Patients. A consultation on the 
introduction of a fee based funding model to support 
the conduct of medical device regulatory activities by 
the HPRA was also commenced in 2015. 
The HPRA also makes submissions to third party 
consultations where the topic is related to or impacts 
our regulatory functions and the broader public 
health agenda. In 2015, we provided comments in 
respect of 22 public consultations from government 
departments, including the Department of Health, 
other national agencies and international bodies such 
as the European Commission, EMA and World Health 
Organization.
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Freedom of Information
The HPRA is subject to the Freedom of Information 
Act 2014. The Act asserts the right of members of 
the public to obtain access to official information to 
the greatest extent possible consistent with public 
interest and the right to privacy of individuals. During 
2015, the HPRA received 18 Freedom of Information 
requests none of which related to requests for 
personal information.
Parliamentary Affairs 
Oireachtas Joint Committee on Health  
and Children
In December 2015, the HPRA was invited to address 
the Oireachtas Joint Committee on Health and 
Children. The Committee met to discuss the safety of 
the HPV vaccine. The Department of Health, the HSE 
and the National Immunisation Advisory Committee 
(NIAC) were also in attendance. 
Parliamentary Questions 
The HPRA received and responded to 125 
parliamentary questions. There were also a further 
106 requests for information from the Department of 
Health, other government departments or members 
of the Oireachtas during the year. Of the total number 
of queries (231), the largest category related to human 
medicines (163) and concerned topics such as adverse 
reactions, the availability or supply of products, 
clinical trials, exempt medicines, market shortages, 
reclassification, orphan status and vaccines.
Customer Services
Almost 2,700 queries were received and actioned 
by the customer services team during 2015. These 
included queries from industry representatives, 
healthcare professionals and members of the public. 
Queries were received primarily via email and by 
phone. 
In addition to the queries managed by customer 
services staff, a range of stakeholder queries are 
addressed by specialist staff across the organisation. 
Many of these queries come from healthcare 
professionals requesting information about specific 
medicines. In 2015, 200 queries were also received in 
respect of the exempt medicines programme while 
the medical devices team received in excess of 500 
regulatory queries.
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ORGANISATIONAL  
MANAGEMENT AND  
DEVELOPMENT 
The HPRA is committed to having the 
necessary corporate functions, systems 
and supports in place to deliver on our 
public health mission. We must ensure that 
our organisational capabilities continue to 
expand and evolve in line with regulatory and 
scientific developments and that we adapt to 
other changes in our operating environment. 
We must also apply and maintain the highest 
possible levels of corporate governance. 
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Human Resources and Change
The retention, engagement and continuing 
development of our highly skilled employees, the 
HPRA’s key resource, continued to be the overarching 
focus of a range of initiatives delivered by the Human 
Resources and Change department in 2015. While 
conscious of further advancing the public sector 
reform agenda, the new organisational competency 
of innovation and creativity launched as part of the 
2015 Performance Development Programme (PDP) 
process, framed our approach of actively pursuing 
opportunities for improvement, thinking creatively 
when generating new solutions and building on 
existing successes.  
Performance Development
The further development and enhancement of our 
PDP continued in 2015 with the full implementation 
of a range of tools designed to support employees 
and people managers in using the programme. 
Awareness of the development planning guides, 
forms and additional aids was achieved through a 
communications programme which highlighted at each 
stage of the PDP cycle the relevant supports available.  
Learning and Development 
Our learning and development strategy continued to 
focus on delivering initiatives to support the retention 
of staff. A full range of developmental in-house 
programmes were delivered covering courses such as 
time management, presentation skills and dignity and 
respect. On the people management side, the new 
manager training programme was delivered alongside 
interview skills training and PDP training. Our learning 
and development team worked in tandem with IT 
colleagues to provide training support for the update 
of the Microsoft Office suite of applications.  
The HPRA’s accredited Leadership Development 
Programme (LDP) continues to be an effective 
development tool for our managers and a second 
group completed the programme in 2015. The HPRA 
also continues to support all staff members in meeting 
various development needs through providing support 
for third level qualification and technical training.
Externally we continued our collaboration with the 
EU Network Training Centre, providing input and 
expertise while also attending a number of fora.
Change Management
A number of projects commenced in 2015 which 
required change management support. The Human 
Resources and Change department were involved 
in the creation of the Quality, Scientific Affairs and 
Communications directorate which required input into 
the scoping of the new directorate structure and the 
development of an internal communications strategy 
surrounding this change. Support continues to be 
provided in respect of resourcing the new directorate. 
Significant input was provided to the ongoing EOLAS 
workflow system project with the provision of a senior 
resource from the department to the project to lead in 
the area of change management supports and impact 
assessment.
The department also took a leading role in the 
capacity building project with the Zambian medicines 
agency (ZAMRA). The main areas of work involved 
development of the requirements for short term 
experts to resource the project and communications 
with HPRA employees about the scope of the project 
and opportunities for involvement.
The public sector reform agenda continued to have 
a direct impact on employment terms and conditions 
during 2015. In this regard, a comprehensive 
communications programme outlining the detail of 
the reforms and the associated impact on individual 
employees was delivered by the Human Resources 
and Change department which included general and 
one-to-one advice sessions.
2nd
ACCREDITED LEADERSHIP 
DEVELOPMENT 
PROGRAMME 
COMPLETED
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Employee Engagement and 
Commitment
Building on the success of our wellness and health 
initiatives in previous years, we further developed 
our programme to deliver support in five main health 
areas. These were physical, financial, nutritional, 
emotional and general health awareness. The 
programme resulted in the delivery of a range of 
initiatives during the year, with staff engagement 
levels for the programme remaining high. In particular, 
the step challenge, run in conjunction with the Irish 
Heart Foundation, achieved our highest uptake since 
its inception in 2010 with 30% of our staff taking part. 
The HPRA went on to achieve a silver ‘Active at Work’ 
award from the Irish Heart Foundation. 
Our lunchtime learning programme operated in 
tandem with the wellness initiatives and focused 
on providing further support for the creativity and 
innovation competency which was part of our PDP 
for 2015. Seminars to unlock and boost personal 
creativity and for learning practical applications for 
creativity in a business environment were delivered.
In 2015, we also reintroduced an organisational 
awareness programme with the purpose of providing 
employees with an understanding of the activities 
of each directorate within the HPRA. Each month 
a directorate is responsible for holding a number 
of different information sessions to highlight key 
activities in its area.  
Resourcing
We continue to develop and manage our resources 
in line with public sector policy by focusing where 
possible on internal skills development and the 
reallocation of tasks and responsibilities in response 
to specific challenges. Recruitment of staff in specialist 
areas was completed in line with Department of 
Health approvals. One of the most important roles 
recruited for in 2015 was that of Chief Executive. This 
process concluded in December with the appointment 
of Ms. Lorraine Nolan. 
The benefits of our new human resource IT system 
continued to be realised with significant gains 
in process efficiency and effectiveness with work 
continuing to further develop the system.  
Finally, the development of a human resources 
and change strategy to align with and support the 
requirements of the HPRA’s new five-year strategic 
plan began during 2015. Quarter four saw the 
commencement of research with stakeholders to 
inform this strategy. 
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Information Technology and 
Business Services 
The Information Technology and Business 
Services department is responsible for all 
aspects of organisational technology, data and 
telecommunications. The department also manages 
the business services unit that is responsible 
for delivering specialist business services to the 
organisation, including business analysis and 
project management for both internal and external 
stakeholders. A core function of the business services 
unit is the management of the organisational Project 
Management Office (PMO) that formally manages 
projects and provides HPRA management with the 
necessary information to support the planning process 
while ensuring that organisational initiatives are fully 
aligned with corporate strategy.
Technology is recognised as a key component in 
supporting regulatory activities at both national 
and European levels and during 2015 a number of 
significant projects and initiatives were progressed. 
 
National Developments 
Work commenced on the design and build of the 
HPRA’s new workflow technology solution EOLAS 
that will provide the organisation with a single 
workflow and data management system to support its 
regulatory activities. A planned implementation date 
of 2016 will coincide with implementation of new EU 
standards for regulatory data management.
In October of 2015, the HPRA commenced 
development of the new Emergency Medicines 
Registration System to support the implementation 
of legislation (S.I. No.449 of 2015) to widen access to 
certain prescription-only medicines. This system will 
provide external organisations with a mechanism to 
register online for the procurement and storage of 
emergency medicines under the legalisation.   
In keeping with the government strategy for shared 
service provision, the HPRA also provides hosting 
services to a number of organisations and works 
closely with agencies such as the Office of the 
Revenue Commissioners. The HPRA is also actively 
engaged at national level through its involvement with 
the National Health Data Standards Committee and in 
liaison with other relevant agencies such as the HSE, 
NSAI, HIQA and eHealth Ireland. During 2015, the 
HPRA continued to contribute to the development of 
data set standards for ePrescribing and an electronic 
medicinal product reference catalogue. 
The IT and business services team was also active 
in the development of processes and technology 
interfaces to support the exchange of information 
between stakeholders in areas such as the medical 
products database for both human and veterinary 
products, interchangeable medicines for the generic 
substitution programme and data for clinical and 
pharmacy systems.
European Initiatives
During the past year, the HPRA continued to play 
a significant role in the development of European 
telematics strategies, standards and technologies 
through its engagement with programmes at the 
EMA, the European Commission and the HMA 
forum. The HPRA is represented on the EU telematics 
management board, the network data board and the 
eSubmisson group and leads on a number of key 
initiatives relating to single submission portals and 
data standards. 
As part of a European consortium, the HPRA is 
participating within the European Commission’s 
Horizon 2020 research programme on the 
openMedicine project. We are leading a significant 
work package within this project which is called 
Identification of Branded Medicinal Products and 
this work will continue throughout 2016. The project 
addresses drug identification and substitution 
challenges to better enable cross-border healthcare 
delivery particularly the exchange of ePrescriptions 
and safe dispensation of prescribed medicinal 
products. The openMedicine global initiative 
advances the unique identification of medicinal 
products and thereby patient safety in cross-border 
settings.
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Common Electronic Submission Portal
A key activity for the HPRA is the development and 
management of the Common Electronic Submission 
Portal (CESP) on behalf of the wider EU regulatory 
community. We provide technical support through the 
operation of a helpdesk facility and we work with all 
relevant stakeholders throughout the year to deliver 
an optimum solution. 
In 2015, version 2 of the system was launched 
providing stakeholders with online tracking of 
submissions and enhanced reporting capabilities. 
Participation and activity levels again grew 
significantly during the year with the portal now 
handling over 350,000 submissions, compared to 
100,000 back in 2013, and supporting over 2,500 
pharmaceutical companies and 8,000 users. More 
than 30 regulatory agencies across Europe are using 
the system which is available 24 hours a day over a 
seven day period.
A new version of the system will be designed and built 
in 2016 to enable the European regulatory network 
to capture data from online forms based on the new 
ISO Identification of Medicinal Products (IDMP) data 
standards.
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The corporate affairs team is responsible for 
the delivery of a number of key service areas to 
the organisation. These include building and 
accommodation management as well as the provision 
of reception, canteen, travel, library and event 
management services. The department also manages 
legal matters, international co-operation and Freedom 
of Information requests. In addition, it provides 
secretarial support to the Authority and committees 
and ensures adherence to best practice in the area of 
corporate governance.
Event Management
The HPRA held six events in 2015 all of which were 
organised and managed in-house. This approach 
ensures cost effective delivery of events while also 
allowing HPRA staff to deal directly with stakeholders. 
This has resulted in very positive feedback from 
attendees via event questionnaires. Details of these 
events are provided on page 67.
Freedom of Information
During 2015, the HPRA received 18 Freedom of 
Information requests (as per page 73). 
Authority and Committees
The corporate services section provides secretarial 
support to the Authority and committees of the HPRA 
and ensures adherence to best practice in the area of 
corporate governance.
• The Authority of the HPRA met 11 times in 
2015 and considered a number of strategic 
matters including corporate policy, planning and 
finance matters. The latter included monthly 
management accounts, annual budgets and 
the financial statements for 2015. The Authority 
also reviewed update reports from the Statutory 
Advisory Committees and the Audit Committee. 
In addition, it reviewed the licences for all 
medicinal healthcare products as approved by the 
Management Committee.
 The number of meetings attended by each 
Authority member during 2015 is as follows:
Corporate Affairs
Authority Member
Number of meetings 
held during the period the 
member was on the Authority
Number of meetings 
attended during the period the 
member was on the Authority
Mr. Michael D. Hayes (Chair) 11 11
Mr. Pat Brangan 11 11
Mr. Wilfred J. Higgins 11 10
Ms. Ann Horan 11 10
Prof. Mary Horgan 11 5
Dr. Elizabeth Keane 11 10
Mr. Noel O’Donoghue 11 0
Prof. Caitriona O’Driscoll 11 11
Dr. Diarmuid Quinlan 11 7
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• The Audit Committee, a subcommittee to the 
Authority, met four times in 2015. Further details 
are provided in the HPRA’s Financial Statements. 
• Also during the year in review, the Advisory 
Committee for Veterinary Medicines met twice 
while the Advisory Committee for Medical Devices 
met three times.
• The Herbal Medicines Sub-Committee, a sub-
committee to the Advisory Committee for Human 
Medicines, met once in 2015. The Clinical Trials 
Sub-Committee is also a sub-committee to the 
Advisory Committee for Human Medicines and it 
met twelve times in the past year.
• The National Committee for the Protection of 
Animals Used for Scientific Purposes, a statutory 
committee to provide guidance to the regulator 
and those working in this area, met twice in 2015.
Finance
The HPRA’s finance section is responsible for 
managing and safeguarding the finances of the 
HPRA. It must ensure that the organisation fulfils its 
legislative requirements and applies best practice 
to the governance of its affairs. All procedures are 
carried out using standard operating procedures 
under the quality management system. 
The 2015 financial statements presented in this 
report were prepared by the finance section and 
submitted for audit to the Comptroller and Auditor 
General. All financial transactions during the period 
under review are reflected and reported upon 
in these statements as is our commitment to the 
highest standards of corporate governance.
Legal
The legal section advised on the implementation 
of new legislation in addition to other relevant 
issues. The section dealt with various legal queries 
from across the organisation and attended and 
presented at the European meeting of lawyers held 
under the European Presidency.
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Quality Management
During 2015, the HPRA’s quality management 
system continued to be extended with the 
deployment of policies, guidelines and procedures 
for clinical field trials. As part of the development 
of the new workflow system, we also began to 
develop a new document management policy and 
procedures.
In September, we reported to the European 
Commission on internal audits of our 
pharmacovigilance system, as required under the 
Pharmacovigilance Directive, 2010/84/EU. A copy 
of the report was published on our website.
Overview of Energy  
Usage in 2015
Since 1 January 2011, the HPRA, as a public 
sector body, has been required to report annually 
on its energy usage and actions taken to reduce 
consumption in accordance with the European 
Union (Energy Efficiency) Regulations 2014 (S.I. No. 
426 of 2014).
The HPRA uses electricity for lighting, air 
conditioning or heating as required and the 
provision of hot water. Natural gas is used for 
central heating.
In 2015, the HPRA consumed 1066 MWh of energy 
consisting of:
• 733 MWh of electricity; 
• 333 MWh of fossil fuels;
• 0 MWh of renewable fuels.
Actions Undertaken in 2015
In the past year, the HPRA continued to focus on 
energy performance by maintaining framework 
agreements for the supply of both electricity and 
natural gas. Both of these framework agreements 
were established by the Office of Government 
Procurement for the supply of electricity and natural 
gas to the Irish public sector. The agreements 
are intended to maximise volume discounts and 
provide for reductions in administrative and 
transaction costs for suppliers and public sector 
purchasers. During 2015, HPRA cost savings were 
in the region of 2.7% for electricity and 10.7% for 
gas (compared to the cost of going directly to the 
market).
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Total Energy Savings
The HPRA has been highly focussed on reducing 
energy usage for the past number of years. This 
is evidenced by the 2015 Sustainable Energy 
Authority of Ireland (SEAI) report for the HPRA 
which confirmed that the organisation has 
improved its energy usage by 23% since 2009.
Actions Planned for 2016
The HPRA is committed to reducing its energy 
usage by 33% by 2020 in accordance with S.I. 
No. 426 of 2014, the National Energy Efficiency 
Action Plan 2014 and the European Energy 
Efficiency Directive (2012/27/EU). As a result, we 
have entered into a partnership agreement with 
the Office of Public Works (OPW) to roll out the 
Optimising Power @ Work programme across the 
organisation. The HPRA has also signed up for the 
SEAI sponsored Energy Map programme and is 
seeking a partnership arrangement with the SEAI.
During 2016, the HPRA intends to maintain energy 
performance by continuing its participation in 
newly contracted framework agreements for the 
supply of both electricity and natural gas to the 
public sector. It is anticipated that both these 
framework agreements, accessed via the Office 
of Government Procurement, will deliver savings 
when compared to the costs of going directly to 
the market. It is important to note that the Office of 
Government Procurement contract rates are fixed 
until early 2017 for electricity and gas.
4
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FINANCIAL STATEMENTS 
FOR THE YEAR ENDED  
31 DECEMBER 2015
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Authority Members  
and Other Information
 
 
 
Authority: Mr. Michael Hayes  term expired 31/12/2015, Chairman
  Mr. Pat Brangan  term expired 31/12/2013, re-appointed 22/05/2014
  Mr. Wilfrid Higgins term expired 31/12/2013, re-appointed 22/05/2014
  Ms. Ann Horan  appointed Chairman 01/01/2016
  Prof. Mary Horgan *
  Dr. Elizabeth Keane ** term expired 31/12/2013, re-appointed 22/05/2014
  Mr. Noel O’Donoghue term expired 31/12/2015
  Prof. Caitriona O’Driscoll
  Dr. Diarmuid Quinlan ***
  The Authority was appointed by the Minister for Health on 18/01/2011.
  *      Prof. Mary Horgan was appointed on 08/11/2011.
  **    Dr. Elizabeth Keane was appointed on 24/10/2012.
  ***  Dr. Diarmuid Quinlan was appointed on 22/05/2014.
Bankers: Allied Irish Bank
  1-3 Lower Baggot Street
  Dublin 2
  Bank of Ireland Corporate
  2 Burlington Plaza
  Burlington Road
  Dublin 4
Solicitors: Eugene F. Collins
  Temple Chambers
  3 Burlington Road
  Dublin 4
Head Office: Kevin O’Malley House
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The Health Products Regulatory Authority (the HPRA) 
was established under the terms of the Irish Medicines 
Board Act, 1995 (as amended), and is governed by 
an Authority which was appointed by the Minister 
for Health. The Authority of the HPRA (the Authority) 
consists of a chairman and eight unremunerated non 
executive members. On 1 July 2014, the organisation 
changed its name from the Irish Medicines Board, as 
provided for in Section 36 of the Health (Pricing and 
Supply of Medical Goods) Act 2013 and SI (205/2014) 
Health (Pricing and Supply of Medical Goods) Act 
2013 (Commencement) order 2014. 
The HPRA is committed to the highest standards 
of Corporate Governance and has implemented 
the “Code of Practice for the Governance of 
State Bodies” issued by the Department of Public 
Expenditure and Reform. This Code of Practice 
incorporates many of the principles under which the 
HPRA operates, taking account of the size and legal 
nature of the organisation. 
The HPRA has in place an extensive Code of Conduct 
and conflicts of interest policy for all staff, committees 
and Authority members. The HPRA applies the 
highest standards of disclosure and transparency in 
respect of interests held by staff, committees and 
Authority members.
Audit Committee
The HPRA has an audit committee comprising three 
Authority members, which met on four occasions 
during 2015. This committee is responsible for 
reviewing internal control matters, together with 
any other issues raised by the external auditors, the 
Authority or management. The external auditor is 
invited annually to meet with the audit committee 
to brief them on the outcome of the external audit 
and the audit committee also meets annually with 
the internal auditor. During 2015, the internal 
auditor carried out internal audits on the areas of 
income and travel/subsistence. They also carried out 
reviews of the project management office and of the 
implementation of the new finance system in HPRA. 
The audit committee has also been involved with the 
review of the quality systems as described below.
Quality Systems
During 2015, the finance section of the HPRA 
continued the process of implementing and reviewing 
standard operating procedures (SOPs) under the 
quality management system. This process involved 
a critical review and analysis of internal controls and 
processes throughout the section with particular 
emphasis on risk management. This system now 
underpins the internal control environment and feeds 
into the internal audit process and ultimately into the 
audit committee.
Remuneration Policy - Authority 
Members and Executive Directors
Remuneration and travel expenses paid to Authority 
members are disclosed in note 17 to the financial 
statements. The Chairman receives remuneration 
as directed by the Minister for Health in accordance 
with the Irish Medicines Board Act, 1995. Other 
Authority members receive travel expenses in 
accordance with circulars issued by the Department 
of Health. The Chief Executive is remunerated in 
accordance with guidelines issued from Government 
and other Executive Directors are paid in accordance 
with Department of Health pay scales. The Chief 
Executive’s remuneration is disclosed in note 18 to the 
Financial Statements.
Internal Control
The Authority is responsible for the HPRA’s systems 
of internal control. Such systems can only provide 
reasonable and not absolute assurance against 
material misstatement or loss. The systems of internal 
controls in use in the HPRA are described more fully in 
the Chairman’s report on page 88.
Corporate Governance
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1. I, as Chairman, acknowledge that the Authority 
is responsible for the body’s system of internal 
financial control.
2. The HPRA system of internal financial control 
can provide only reasonable and not absolute 
assurance against material error, misstatement or 
loss.
3. The Authority confirms that there is an ongoing 
process for identifying, evaluating and managing 
the significant risks faced by the HPRA. The HPRA 
maintains a risk register which is reviewed and 
updated by management, considered by the audit 
committee and presented to the Authority.
 Management are responsible for the identification 
and evaluation of significant risks applicable to 
their areas of business together with the design 
and operation of suitable internal controls. These 
risks are assessed on a continuing basis and may 
be associated with a variety of internal or external 
sources including control breakdowns, disruption 
in information systems, natural catastrophe and 
regulatory requirements. These risks are recorded 
in the risk register.
 Management reports fortnightly on operational 
issues and risks and how they are managed to 
the Management Committee. The Management 
Committee’s role in this regard is to review on 
behalf of the Authority the key risks inherent in 
the affairs of the HPRA and the system of actions 
necessary to manage such risks and to present 
their findings on significant matters via the Chief 
Executive to the Authority.
 The Chief Executive reports to the Authority 
on behalf of the executive management on 
significant changes in the work of the HPRA 
and on the external environment, which affects 
significant risks. The Deputy Chief Executive 
provides the Authority with monthly financial 
information, which includes key performance 
indicators. Where areas for improvement in the 
system are identified, the Authority considers the 
recommendations made by the Management 
Committee.
 An appropriate control framework is in place 
with clearly defined matters which are reserved 
for Authority approval only or, as delegated 
by the Authority, for appropriate Management 
Committee approval. The Authority has delegated 
the day-to-day management of the HPRA and 
established appropriate limits for expenditure 
authorisation to the Management Committee. The 
Chief Executive is responsible for implementation 
of internal controls, including internal financial 
control.
 The system of internal financial control is 
monitored in general by the processes outlined 
above. In addition, the Audit Committee of the 
Authority reviews specific areas of internal control. 
The HPRA has outsourced the internal audit 
function to an independent professional firm. 
During 2015 two reviews were conducted. The 
Audit Committee considers reports from internal 
audit and recommendations from the Comptroller 
and Auditor General arising as a result of the 
external audit.
4. The Authority have carried out a review of the 
effectiveness of internal financial control, in order 
to demonstrate compliance with the Code of 
Practice. This review was carried out at its meeting 
on 11 May 2016.
Ms. Ann Horan  
Chairman to the Authority
15 June 2016
Statement on Internal  
Financial Control
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The Authority is required by the Irish Medicines Board 
Act, 1995 to prepare financial statements for each 
financial year which give a true and fair view of the 
state of affairs of the HPRA and of its surplus or deficit 
for that period.
In preparing those statements the Authority is 
required to:
• select suitable accounting policies and apply them 
consistently;
• make judgements and estimates that are 
reasonable and prudent;
• disclose and explain any material departures from 
applicable accounting standards; and
• prepare the financial statements on a going 
concern basis unless it is inappropriate to 
presume that the HPRA will continue in existence.
The Authority is responsible for keeping proper 
accounting records which disclose with reasonable 
accuracy at any time the financial position of the 
HPRA and which enable it to ensure that the financial 
statements comply with the Irish Medicines Board 
Act, with accounting standards generally accepted 
in Ireland and with accounting directions issued by 
the Minister for Health.  It is also responsible for 
safeguarding the assets of the HPRA and hence 
for taking reasonable steps for the prevention and 
detection of fraud and other irregularities. 
 
 
On behalf of the Authority: 
 
Ms. Ann Horan
Chairman
15 June 2016
Statement of Authority  
Members’ Responsibilities
 Mr. Pat Brangan
 Authority Member
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I have audited the financial statements of the Health 
Products Regulatory Authority for the year ended 
31 December 2015 under the Irish Medicines 
Board Act, 1995. The financial statements comprise 
the statement of income and expenditure and 
retained revenue reserves, the statement of financial 
position, the statement of cash flows and the 
related notes. The financial statements have been 
prepared in the form prescribed under Section 18 of 
the Act, and in accordance with generally accepted 
accounting practice as modified by the Minister for 
Health in relation to accounting for superannuation 
costs.
 
Responsibilities of the Board of the 
Authority
The Board of the Authority is responsible for the 
preparation of the financial statements, for ensuring 
that they give a true and fair view and for ensuring 
the regularity of transactions.
 
Responsibilities of the Comptroller and 
Auditor General 
My responsibility is to audit the financial statements 
and report on them in accordance with applicable 
law.
My audit is conducted by reference to the special 
considerations which attach to State bodies in 
relation to their management and operation.
My audit is carried out in accordance with the 
International Standards on Auditing (UK and Ireland) 
and in compliance with the Auditing Practices 
Board’s Ethical Standards for Auditors.
Scope of audit of the financial 
statements
An audit involves obtaining evidence about the 
amounts and disclosures in the financial statements, 
sufficient to give reasonable assurance that 
the financial statements are free from material 
misstatement, whether caused by fraud or error. 
This includes an assessment of
• whether the accounting policies are appropriate 
to the Authority’s circumstances, and have been 
consistently applied and adequately disclosed.
• the reasonableness of significant accounting 
estimates made in the preparation of the 
financial statements, and
• the overall presentation of the financial 
statements.
I also seek to obtain evidence about the regularity 
of financial transactions in the course of audit.
In addition, I read the Authority’s annual report to 
identify material inconsistencies with the audited 
financial statements and to identify any information 
that is apparently materially incorrect based on, 
or materially inconsistent with, the knowledge 
acquired by me in the course of performing the 
audit. If I become aware of any apparent material 
misstatements or inconsistencies, I consider the 
implications for my report.
Comptroller and  
Auditor General Report  
for Presentation to the  
Houses of the Oireachtas
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Opinion on the financial statements
In compliance with the directions of the Minister 
for Health, the Authority accounts for the costs of 
superannuation entitlements only as they become 
payable. This basis of accounting does not comply 
with Financial Reporting Standard 102 which 
requires such costs to be recognised in the year the 
entitlements are earned. 
In my opinion, except for the accounting treatment 
of the Authority’s superannuation costs and liabilities, 
the financial statements have been properly prepared 
in accordance with generally accepted accounting 
practice in Ireland and give a true and fair view of the 
state of the Authority’s affairs at 31 December 2015 
and of its income and expenditure for 2015.
In my opinion, the accounting records of the Authority 
were sufficient to permit the financial statements to be 
readily and properly audited. The financial statements 
are in agreement with the accounting records.
Matters on which I report by exception
I report by exception if I have not received all the 
information and explanations I required for my audit, 
or if I find
• any material instance where money has not been 
applied for the purposes intended or where the 
transactions did not conform to the authorities 
governing them, or
• the information given in the Authority’s annual 
report is not consistent with the related financial 
statements or with the knowledge acquired by me 
in the course of performing the audit, or
• the statement on internal financial control does 
not reflect the Authority’s compliance with the 
Code of Practice for the Governance of State 
Bodies, or
• there are other material matters relating to 
the manner in which public business has been 
conducted.
I have nothing to report in regard to those matters 
upon which reporting is by exception.
 
Patricia Sheehan 
For and on behalf of the
Comptroller and Auditor General 
21 June 2016
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 Note  2015  2014
   As restated
  € €
Fee Income  3  21,654,894  21,046,800
Department of Health Funding 3  3,916,000  3,916,000
Other Income  4  585,872  784,860
   
  26,156,766  25,747,660 
Salaries and Wages  5  17,926,950  17,501,062
Other Operating Costs  6  5,486,959  4,738,449
Depreciation  2  1,648,765  1,310,329
   
  25,062,674  23,549,840
 
Surplus for the year before write
back of Superannuation contributions   1,094,092  2,197,820
 
Staff Superannuation Contributions   441,888  443,890
 
 
Surplus for the year   1,535,980  2,641,710
 
Balance brought forward  25  25,862,197  23,220,487
 
Balance carried forward  12  27,398,177  25,862,197
 
 
 
All income and the surplus for the year arises from continuing activities.
 
 
 
 
 
 
 
Chairman Authority Member
Ms. Ann Horan Mr. Pat Brangan
15 June 2016
The notes on pages 95 to 105 form part of the financial statements.
 
STATEMENT OF INCOME AND EXPENDITURE AND RETAINED REVENUE RESERVES
For the year ended 31 December 2015
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 Note  2015  2014
  € €
Fixed Assets  
Property, plant and equipment  2  25,665,558  25,574,039
 
Current Assets
Debtors and Prepayments 7  1,191,666  727,029
Inventory of Stationery  2,077  2,259
Cash at Bank and in Hand   475,265  205,531
Short Term Deposits 10 15,991,441  15,649,391 
  17,660,449  16,584,210
Creditors - Amounts falling
due within one year
Creditors and Accruals  8  8,787,819  8,362,712
Mortgage  13  793,332  793,332
   
  9,581,151  9,156,044
 
Net Current Assets   8,079,298  7,428,166
 
Creditors - Amounts falling 
due after more than one year
Mortgage  13  6,346,679  7,140,008
 
 
NET ASSETS   27,398,177  25,862,197
 
 
Reserves
Income and Expenditure Reserve  12  27,398,177  25,862,197 
  
  27,398,177  25,862,197
 
 
 
 
Chairman Authority Member
Ms. Ann Horan Mr. Pat Brangan
15 June 2016
The notes on pages 95 to 105 form part of the financial statements.
 
STATEMENT OF FINANCIAL POSITION
As at 31 December 2015
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 Note  2015  2014
  € €
Cash flows from Operating Activities
 
Surplus/(Deficit) for financial year   1,535,980  2,641,710
Depreciation of property, plant and equipment  1,648,765  1,310,329
(Profit)/Loss on Disposal of property, plant and equipment  156  61
(Increase)/Decrease in Debtors  (464,637)  (82,644)
(Increase)/Decrease in Stock  182  148
Increase/(Decrease) in Creditors - amounts  
falling due within one year   425,107  670,960
Deposit Interest   (79,548)  (131,249)
Bank Interest  243,288  355,712
Cash from Operations  3,309,293  4,765,027
Bank Interest Paid   (243,288)  (355,712)
Net Cash generated from Operating Activities  3,066,005 4,409,315
Cash flows from Investing Activities   
Deposit Interest Received  79,548  131,249
(Increase)/Decrease in Bank Deposits   (2,126,720)  (8,540,234)
Payments to acquire property, plant and equipment    (1,740,789)  (994,135)
Receipts fom sales of property, plant and equipment  352  370
 
Net cash from Investing Activities   (3,787,609)  (9,402,750)
Cash flows from Financing Activities
Repayment of Borrowings  (793,332)  (793,332)
Net cash used in Financing Activities  (793,332)  (793,332)
 
Net increase/(decrease) in Cash and Cash Equivalents   (1,514,936)  (5,786,767)
Cash and Cash Equivalents at beginning of year  3,617,069  9,403,836
 
Cash and Cash Equivalents at end of year 9  2,102,133  3,617,069
The notes on pages 95 to 105 form part of the financial statements.
 
 
STATEMENT OF CASH FLOWS 
For the year ended 31 December 2015
HPRA ANNUAL REPORT 2015 95
1. Accounting Policies
A.  General information
The Health Products Regulatory Authority (HPRA) is a public statutory body established under the Irish Medicines 
Board Act 1995 (as amended). The principal place of business is at Earlsfort Centre, Earlsfort Terrace, Dublin 2. The 
Health Products Regulatory Authority is the competent Authority for the regulation of medicines, medical devices 
and other health products in Ireland.
B.  Compliance with FRS 102
The financial statements of the HPRA for the year ended 31 December 2015 have been prepared in accordance with 
FRS 102, the financial reporting framework applicable in the UK and Ireland, with the exception of superannuation. 
By direction of the Minister for Health, the provisions of FRS102 in relation to retirement benefits are not being 
complied with. In all other respects the financial statements comply with FRS102. These are the first set of financial 
statements prepared in accordance with FRS102. The date of transition to FRS 102 is 1 January 2014. The prior year 
financial statements were re-stated for material adjustments on adoption of FRS 102. The result of this adoption can 
be seen in note 25.
C.  Basis of preparation
The financial statements have been prepared under the historical cost convention. The following accounting policies 
have been applied consistently in dealing with items which are considered material in relation to the Health Products 
Regulatory Authority’s financial statements.
D.  Critical accounting estimates and judgements
The preparation of the financial statements requires management to make judgements, estimates and assumptions 
that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for 
revenues and expenses during the year. However, the nature of estimation means that actual outcomes could differ 
from those estimates. The following may involve a higher degree of judgement and complexity:
(a)  Provisions
 Provisions for legal obligations which it knows to be outstanding at the period-end date. These provisions are 
generally made based on historical or other pertinent information, adjusted for recent trends where relevant. 
However, they are estimates of the financial costs of events that may not occur for some years. As a result of this 
and the level of uncertainty attaching to the final outcomes, the actual outturn may differ significantly from that 
estimated. 
NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2015
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E.  Revenue recognition
Revenue is measured at the fair value of the consideration received.
-  In the case of applications for marketing authorisations (new applications, variations to existing authorisations, or 
transfers) and clinical trial applications, income is recognised on a straight line basis over the specified timeline 
for the processing of the application by the Authority.
- In the case of wholesale and manufacturing licences and maintenance of marketing authorisations, fees are 
payable annually and a full year’s income is accrued in each financial year.
F.   Expenditure recognition
Expenditure is recognised in the financial statements on an accruals basis.
G. Reporting currency and currency translation
The financial statements are prepared in euros. Transactions in currencies other than euro are recorded at the rates 
ruling at the date of the transactions or at a contracted date. Monetary assets and liabilities are translated into euro 
at the balance sheet date or at a contracted date. Exchange differences are dealt with in the statement of income 
and expenditure.
H. Property, plant and equipment
Plant and equipment excluding Premises
Plant and equipment excluding premises are stated at cost less accumulated depreciation. Depreciation is calculated 
in order to write off the cost of property, plant and equipment to their estimated residual values over their estimated 
useful lives by equal annual instalments.
The estimated useful lives of property, plant and equipment by reference to which depreciation has been calculated 
are as follows:
 Fixtures and Fittings :  5 years 
 Computer Equipment :  3 years 
 Improvements to Premises :  10 years
 
Premises
The HPRA purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2 on 22 
December 2004. The value capitalised was equal to the purchase price plus those costs directly attributable to 
bringing the asset into use.
No depreciation has been calculated on the value of premises, as the remaining useful economic life is estimated to 
be greater than 50 years.
NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2015
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I. Taxation
The HPRA is exempt from liability to Corporation Tax under Section 227 of the Taxes Consolidation Act, 1997.
J. Debtors
Known bad debts are written off and specific provision is made for any amount the collection of which is considered 
doubtful.
K.  Superannuation
The superannuation scheme operated by the HPRA is in accordance with the Local Government (Superannuation Re-
vision) (Consolidation) Scheme, 1986. It is an unfunded statutory scheme and benefits are met from current income 
as they arise.
The charge to salaries and wages is stated gross of superannuation deductions of €800,889 (2014 - €748,987). The 
surplus for the year on page 92 is then shown both before and after superannuation deductions less lump sum 
amounts paid in the year. The income and expenditure reserve on the statement of financial position is split between 
retained reserves and superannuation reserves in note 12. The balance on the superannuation reserve represents the 
cumulative superannuation deductions made since 1996.
By direction of the Minister for Health, the provisions of FRS 17 as incorporated into FRS 102 are not being complied 
with.
L.  Provisions
A provision is recognised when the HPRA has a present obligation as a result of a past event, it is probable that this 
will be settled at a cost to the HPRA and a reliable estimate can be made of the amount of the obligation.
M.  Library
No value has been placed on the books, audio-visual resources and electronic databases in the library. Expenditure 
on these items is written off in the year in which it is incurred.
N.  Leases
All leases are treated as operating leases and the rentals thereunder are charged to the Income and Expenditure 
account on a straight line basis over the lease period.
O.  Loans
Loans are recognised initially at the transaction price (present value of cash payable, including transaction costs). 
Loans are subsequently stated at amortised costs. Interest expense is recognised on the basis of the effective interest 
method and is included in finance costs.
Loans are classified as current liabilities unless there is a right to defer settlement of the loan for at least 12 months 
from the reporting date.
NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2015
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2015
2. Property, plant Fixtures and Computer  Leasehold Improvements Premises Total 
 and equipment Fittings Equipment Improvements To Premises   
  € € € € € €
  Cost
  Balance as at   1,147,971  10,679,242  502,445  4,314,888  23,156,037  39,800,583
  1 January 2015  
  Additions for the year  57,005  1,636,454  -  47,330  -  1,740,789
  Disposals for the year (1,346)  (85,403)  -  -  -  (86,749)
  As at 31 December 2015  1,203,630  12,230,293  502,445  4,362,218  23,156,037  41,454,623
  Depreciation
  Balance as at  1,022,422  9,722,173  501,193  2,980,756  -  14,226,544 
 1 January 2015
  Charge for the year  59,265  1,177,734  1,252  410,514  -  1,648,765
  Disposals for the year  (1,346)  (84,898)  -  -  -  (86,244)
  As at 31 December 2015  1,080,341  10,815,009  502,445  3,391,270  -  15,789,065
  Net Book value at  
 31 December 2015  123,289  1,415,284  -  970,948  23,156,037  25,665,558
  Net Book value at 
  1 January 2015  125,549  957,069  1,252  1,334,132  23,156,037  25,574,039
3. Income
     2015     2014
     €     €
 Fee Income
 Clinical Trials  175,148  123,844
 Human Medicine - National Fees  6,439,762  6,588,544
 Human Medicine - European Fees  6,835,197  6,860,718
 Veterinary Medicine - National Fees  1,492,613  1,357,676
 Veterinary Medicine - European Fees  1,302,720  1,338,780
 Compliance Department  5,067,354  4,294,355
 Medical Devices  403,392  374,992 
  
  21,716,186  20,938,909
 Movement in deferred revenue (61,292)  107,891
  21,654,894  21,046,800
 Dept Of Health Funding (Vote 38 Subhead E1)  3,916,000  3,916,000 
 Other Income (Note 4)  585,872  784,860
  
 Total Income  26,156,766  25,747,660
 
 Certain fees, totalling €16,824,480 are required by law to be disposed of in accordance with the directions of the Minister  
 for Public Expenditure and Reform. 
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For the year ended 31 December 2015
4. Other Income
     2015     2014
     €     €
  
 Conference Fee Income  1,850  184,075
 Deposit Interest  79,548  131,249
 (Loss)/Gain on Disposal of Fixed Assets  (156)  (61)
 IT Income  504,630  469,597
   
  585,872  784,860
5. Salaries and Wages  
 
 Salaries and Wages  15,965,979  15,663,696
 Pensions  469,680  382,144
 Social Welfare Costs  1,491,291  1,455,222
   
  17,926,950  17,501,062
 
  
 The average number of staff employed during the year was 298 (2014 - 291).
 Payroll numbers at 31 December 2015 can be analysed across the following departments : -
 
 Chief Executive  11  11
 Compliance  64  62
 Finance, Corporate & International  20  19
 Human Products Authorisation & Registration  103  106
 Human Products Monitoring  47  44
 Human Resources & Change  8  8
 IT & Business Services  19  13
 Scientific Affairs  1  2
 Veterinary Sciences  25  22
 Staff  298  287
 Pensioners  34  30
   
  332  317
 
 
 Pension related deductions for Public Servants of €964,037 were deducted from staff  
 during the year and paid over to the Department of Health.
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2015
 While the HPRA does not consider that Circular 13/2014 “Management and Accountability for Grants 
 from Exchequer Funds” applies to HPRA, in the interests of transparency we are disclosing salary 
 breakdowns required under that circular: 
    Salary Band   2015     2014
  
 €0 to €60,000    197  190
 €60,001 to €70,000    48  47
 €70,001 to €80,000    14  9
 €80,001 to €90,000    20  21
 €90,001 to €100,000    9  10
 €100,001 to €110,000    6  6
 €110,001 to €120,000    2  2
 €120,001 to €130,000    1  1
 €140,001 to €150,000    1  1
   
    298  287
  
 Average Salary    €51.4K  €51.9K
 
 Higher salaries replate primarily to scientific and other professional staff e.g. clinicians, pharmacists,
 veterinarians, lawyers etc. and are in accordance with Department of Health salary scales. 
 
6. Operating Costs
     2015     2014
     €     €
  
 Accommodation Costs  1,059,592  1,048,954
 Travel, Representation and Training  939,155  730,412
 Bank Charges and Interest  246,447  363,697
 Legal & Professional Fees  427,161  106,604
 Stationery, Publications and Postage  458,007  418,624
 Other Operating Costs  2,356,597  2,070,158
   
  5,486,959  4,738,449
  
  
 Operating costs of €5,486,959 includes an amount of €4,329 related to staff hospitality.
 
7. Debtors (all due within one year) 
 
 Trade Debtors  1,013,810  303,875
 Prepayments  26,339  238,854
 Other Debtors  151,517  184,300
   
  1,191,666  727,029
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8. Creditors (amounts falling due within one year)   2015     2014
       As restated
  €    € 
 
 
 Trade Creditors  367,776  287,858
 Accruals  6,554,867  6,321,754
 Deferred Revenue  1,272,212  1,210,920
 Revenue Commissioners  592,964  542,180 
  
  8,787,819  8,362,712
9. Cash and Cash Equivalents    As At   As At
  01/01/2015  Cashflow  31/12/2015 
  
  
 Cash at Bank and in Hand  205,531  269,734  475,265
 Demand Deposits  3,411,538  (1,784,670)  1,626,868
 
  3,617,069  (1,514,936)  2,102,133
 
10. Short Term Deposits    2015     2014
      €    € 
 
 
 Demand Deposits (convertible to cash on demand)  1,626,868  3,411,538
 Short Term Deposits (not immediately convertible to cash)  14,364,573  12,237,853 
  
  15,991,441  15,649,391
 
11. Administration Expenses    
 
 Surplus for the year was calculated having charged : -   
 Auditor’s Remuneration   16,000  17,300
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For the year ended 31 December 2015
12. Movement on Income    As At   As At
and Expenditure Reserves 01/01/2015  Movement  31/12/2015 
  €  € € 
  
Retained Reserves  18,194,845  1,094,092  19,288,937
Staff Superannuation Contributions  7,667,352  441,888  8,109,240
 
  25,862,197  1,535,980  27,398,177
 
13. Long Term Liabilities      
       
  Mortgage
  On 22 December 2004 the HPRA purchased its premises at Kevin O’Malley House, Earlsfort
  Centre, Earlsfort Terrace, Dublin 2. The purchase was financed by way of a mortgage, secured
  on the premises of €20,400,000 over 20 years from Bank of Ireland Corporate Lending.
  
  The HPRA is committed to making the following capital repayments on its mortgage : 
       
 
  - within one year    793,332  793,332
  - between one and five years    3,173,328  3,173,328
  - after five years    3,173,351  3,966,680
   
     7,140,011  7,933,340
14. Interest Rate Exposure       
 
 The HPRA has taken all necessary steps to minimise its interest rate exposure by fixing 2/3s
 of the borrowings for the mortgage duration. The balance of the borrowings are fully offset
 by cash reserves. As the mortgage is at a fixed rate, the Authority has no interest rate exposure.  
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15. Financial Commitments
 Accommodation Costs (Note 6) includes expenditure of €285,984 in relation to operating leases. 
 
 On 28 January 2005, the HPRA signed a leasehold interest in respect of the 5th floor, Alexandra
 House Earlsfort Centre, Dublin 2. At 31 December 2015 this lease had 6 years and four months
 remaining.
    
    2015     2014
      €     €
 The amounts due under this lease are as follows:
 - within one year  285,984  285,984
 - between one and five years  1,143,936  1,143,936
 - after five years  381,312  667,296
   
  1,811,232  2,097,216
16. Capital Commitments    
     
 Contracted For ( Contract Signed )    1,877,410  -
 Not Contracted For  405,900  2,510,000
   
  2,283,310  2,510,000
 
17. Authority Remuneration
  
 Chairman’s Salary  20,520  20,520
 Authority Members’ Travel Expenses  9,106  5,247
   
  29,626  25,767
 Other than the Chairman, no other Authority member receives a salary.
 
18. Staff Remuneration
    
 Chief Executive’s Total Remuneration
 Basic Salary  145,749  145,985
   
  145,749  145,985
  
  
 Mr. Pat O’Mahony served as Chief Executive during the period 1 January to 4 September 2015. He received a salary  
 of  €99,535 during this period. Ms. Rita Purcell was appointed acting Chief Executive on 5 September and served in this  
 capacity to 31 December 2015. Her salary for this period was €46,214.
 
 Both Mr. O’Mahony’s and Ms. Purcell’s pension entitlements do not extend beyond the standard entitlements in the   
 model public sector defined benefit superannuation scheme.
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19. Related Party Transactions
  
 There have been no transactions with related parties which require disclosure under Financial
 Reporting Standard 102.
20. Prompt Payment of Accounts
  
 The Health Products Regulatory Authority (HPRA) confirms that it is complying with EU law in
 relation to prompt payments of account.
21. Exchange Rates
  
 The exchange rates used in preparing these financial statements were as follows : -
  
 2015 €1 = STG £0.73693
 2014 €1 = STG £0.7825
22. Provisions
  
 The HPRA has been notified of a number of legal proceedings or potential proceedings.  
 The information usually required under by FRS 102 is not disclosed as the HPRA believes 
 that to do so would be prejudicial to the outcome. 
23. Going Concern
  
 The HPRA has a reasonable expectation, at the time of appoving the financial statements,  
 that the HPRA has adequate resources to continue its operations. For this reason, the HPRA 
 continues to adopt the going concern basis in preparing the financial statements. 
24. Approval of Financial Statements
  
 The financial statements were approved by the Authority of the HPRA on 11 May 2016.
25. Transition to FRS102   As At As At
    1 Jan 2014 31 Dec 2014 
    €     €
 Reconciliation of Reserves    
 Reserves (as previously stated)    24,539,298  27,073,117
 Deferred revenue adjustment    (1,318,811)  (1,210,920)
  
 Reserves (as restated) 23,220,487  25,862,197
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 Reconciliation of surplus for the year    2014 
         €
    
 Surplus for the year (as previously stated)     2,533,819
 Movement in deferred revenue    107,891
   
 Surplus for the year (as re-stated)   2,641,710
  
  
 Adjusting items
  
 (a) Deferred revenue
  
In 2014, the HPRA, in accordance with its then accounting policy, recorded fee income in relation to applications for   
marketing authorisations on a cash receipts basis. In compliance with FRS102 all such income is now recognised on a 
straight line basis over the specified timeline for the processing of applications by the Authority. Income received   
not recognised at year end is recorded as deferred revenue and included in the Statement of Financial Position as a 
creditor.
The impact of the change is that:
-  A liability, in respect of the deferred revenue creditor, is recognised in the amount of
 €1,318,811 at the transition date and €1,210,920 at 31 December 2014.
-  Fee income and thus the Authority’s surplus for 2014 has increased by €107,891 to €21,046,800  
 and €2,641,710 respectively.
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APPENDIX 1   
2015 Committee Members
Management Committee
Mr. Pat O’Mahony (resigned 
September 2015) 
Chief Executive
Ms. Rita Purcell 
Deputy Chief Executive (Chief 
Executive Acting - September to 
December 2015)
Ms. Lorraine Nolan 
Director of Human Products 
Authorisation and Registration 
(Appointment as Chief Executive 
confirmed December 2015) 
Dr. Gabriel Beechinor 
Director of Veterinary Sciences
Dr. Catríona Fisher (appointed 
October 2015) 
Director of Quality, Scientific 
Affairs and Communications
Dr. Joan Gilvarry 
Director of Human Products 
Monitoring
Mr. Kevin Horan  
Director of Information 
Technology and  
Business Services 
Mr. John Lynch 
Director of Compliance
Dr. Mike Morris (retired 
December 2015) 
Director of Scientific Affairs
Ms. Lynsey Perdisatt  
Director Human Resources and 
Change
Authority
Mr. Michael D Hayes* – Chairman
Mr. Pat Brangan 
Mr. Wilfrid J. Higgins 
Ms. Ann Horan
Prof. Mary Horgan
Dr. Elizabeth Keane 
Mr. Noel O’Donoghue*
Prof. Caitriona O’Driscoll
Dr. Diarmuid Quinlan
*Term expired 31 December 2015
Audit Committee
Ms. Ann Horan - Chairman
Mr. Pat Brangan
Dr. Elizabeth Keane
Advisory Committee for  
Human Medicines
Prof. Mary Horgan – Chairman
Dr. Paul Browne
Dr. Kevin Connolly
Dr. Desmond Corrigan
Prof. Tom Fahey
Prof. David Kerins
Ms. Marita Kinsella
Prof. Patrick Murray
Dr. Brian O’Connell
Mr. Ronan Quirke
Dr. Patrick A. Sullivan
Prof. Peter Weedle
Advisory Committee for  
Veterinary Medicines
Mr. Pat Brangan – Chairman
Dr. Ruaidhrí Breathnach
Ms. Eugenie Canavan
Mr. Michael F. Clancy
Dr. Martin Danaher
Dr. Helena Kelly
Mr. Des Leadon
Dr. Nola Leonard
Mr. Ciaran Mellet
Mr. John Moriarty
Mr. John Underhill
Advisory Committee for  
Medical Devices
Mr. Wilfrid J. Higgins – Chairman
Dr. Gillian Carlos McDowell
Dr. Geoffrey Chadwick
Mr. Darragh Hynes
Dr. Jonathan Lyne
Prof. Fergal O’Brien
Prof. Richard Reilly
Ms. Mary Sharp
Ms. Maebh Smith
Mr. Sean Paul Teeling
Prof. Wil van der Putten
Dr. Vivion Crowley
8
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Clinical Trial Sub-
Committee of Advisory  
Committee for Human 
Medicines
Dr. Patrick A. Sullivan – Chairman
Dr. Liam Bannan
Dr. Geraldine Boylan
Dr. Paul Browne
Dr. Peter Crean
Dr. Catherine Kelly 
Dr. Thomas Peirce
Dr. Bryan Whelan
Dr. Lee Helman (CT Expert)
Dr. Filip Janku (CT Expert)
Advisory Sub-Committee 
for Herbal Medicines
Dr. Des Corrigan – Chairman
Dr. James Barlow
Dr. Kevin Connolly
Mrs. Ingrid Hook
Ms. Claudine Hughes
Ms. Anna-Maria Keaveney
Dr. Celine Leonard
Dr. Donal O’Mathuna
Dr. Camillus Power
Dr. Helen Sheridan
Ms. Anne Varley (resigned 
February 2015)
Dr. Emma Wallace
Experts Sub-Committee of 
the Advisory Committee 
for Human Medicines
Prof. Mary Horgan – Chairman
Dr. Colin Buckley (resigned 
January 2015)
Dr. Linda Coate
Dr. Kevin Connolly
Dr. James Colville
Dr. Noreen Dowd
Dr. Stephen Eustace
Dr. Stephen Flint
Dr. Tim Fulcher
Dr. Joseph Galvin
Dr. Patrick Gavin
Dr. Paul Gallagher
Dr. Kevin Kelleher
Dr. Catherine Kelly
Dr. Mary Keogan
Prof. David Kerins
Dr. Mark Ledwidge
Prof. Aidan McCormick  
(resigned January 2015)
Dr. Frank Murray
Dr. Yvonne O’Meara
Dr. Cormac Owens
Mr. Ashley Poynton
Dr. Brion Sweeney
Dr. Jogin Thakore
Dr. Gerry Wilson
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Presentations 2015
Third Level / Professional Development Presentations 
Institution Course Presentation Title
Athlone IT Pharmaceutical Sciences Authorisation of Medicines
Athlone IT Pharmaceutical Sciences Pharmacovigilance
Athlone IT Veterinary Nursing Regulation of Veterinary Medicines 
DIT Pharmaceutical QA Quality Risk Management
Dundalk IT Veterinary Nursing Regulation of Veterinary Medicines 
Griffith College Pharmaceutical Business  Good Clinical Practice Inspections 
 Operations / Data Analytics 
HSE Registered Nurse Prescribers   A Series of Presentations on the Role of the HPRA 
 - CPD Forums
IT Sligo / NUI MSc in Medical Device                          Medical Device Regulation: A Competent Authority  
Galway Regulatory Affairs Perspective 
(IMDA Skillnet) 
LAST Laboratory Animal Science and Training Directive 2010/63/EU
NUIG Nurse / Midwife Prescribing (1) The Role of the HPRA and (2) Pharmacovigilance
PEMBA /  PEMBA Postgraduate Course Regulating Drugs and Medical Devices in Ireland   
University of   and Europe 
Auburn
RCSI Nurse / Midwife Prescribing (1) The Role of the HPRA and (2) Pharmacovigilance
RCSI Pharmacy Quality Defects and Recalls
RCSI Pharmacy Regulatory Affairs and Authorities
Sligo IT Medical Biotechnology and Quality Defects / Pharmacovigilance 
 Pharmaceutical Science  
St. Johns, Cork Veterinary Nursing Regulation of Veterinary Medicines 
TCD Immunology Regulation of Biological Medicinal Products
TCD Pharmaceutical Medicine An Overview of Pharmacovigilance
TCD Pharmaceutical Medicine  Communication of Drug Safety Data
TCD Pharmaceutical Medicine Pharmaceutical Medicine Seminar
TCD Pharmaceutical Medicine Pharmacovigilance and Risk Management
TCD Pharmaceutical Medicine Quality Defects and Recalls
TCD Pharmaceutical Medicine The Paediatric Regulation
TCD Pharmacy  An Overview of Pharmacovigilance
TCD Pharmacy Authorisation of Medicines
TCD Pharmacy Quality Defects and Recalls
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TCD Pharmacy Regulation of Biological Medicinal Products
TCD Pharmacy The Role of a Pharmacist in the HPRA and    
  Pharmacovigilance
TEARAP Professional Certificate  Application Process for Authorisations
TOPRA  Introduction to Regulatory Affairs An Agency Perspective
Trinity College  Continuing Education Series (1) In Vitro Diagnostics and 
Dublin / BEAI for Clinical Engineers (2) Medical Device Vigilance
UCC  Medicine and Pharmacy  Notification of Adverse Events
UCC Pharmacy Quality Defects and Recalls
UCD Nurse / Midwife Prescribing (1) The Role of the HPRA and (2) Pharmacovigilance 
Regulatory Presentations 
Event / Organiser Presentation Title
2nd Industry Stakeholder Platform -  Post-Authorisation Safety Studies – Experience to Date 
Operation of EU Pharmacovigilance Legislation 
3rd Industry Stakeholder Platform -  Referrals – Updates from Regulators 
Operation of EU Pharmacovigilance Legislation 
4th Industry Stakeholder Platform -  Impact of Pharmacovigilance Systems 
Operation of EU pharmacovigilance legislation 
5th Industry Stakeholder Platform -   Operation of the EU Pharmacovigilance Legislation 
Operation of the EU Pharmacovigilance Legislation
Annual OMCL Network Meetings HMA Drafting Group for Risk-based Approach to  
  Product Testing
Association of Clinical Biochemistry and  Reporting of Issues in Laboratory Medicine 
Laboratory Medicine Conference 
Brazil National Health Surveillance Agency  (1) Regulatory Compliance Inspections and (2) PIC/S
China Food and Drug Administration Visit to Ireland The Role of the HPRA
CMC Strategy Forum Europe An Update on Regulatory Expectations for Biosimilars
Cosmetic Compliance Summit CPSR: Requirements and Challenges
Department of the Environment – Enforcement Forum HPRA: Enforcement Powers & Role
DIA Annual Meeting  A Series of Presentations on Pharmacovigilance 
EPA / Office of Radiological Protection Information Day Role of the HPRA and the Vigilance Reporting System for  
  Medical Devices
Ethics Committees Meeting (Department of Health) Clinical Trials Regulations: Interaction between the   
  Competent Authority and Ethics Committees
EUPATI Patient Advocacy Training Event Pharmacovigilance – Introduction to Signal Management
FakeCare International Conference Open Source Intelligence
Horse Racing Ireland Committee on Anti-Doping Veterinary Medicines
HSE / HPRA Launch of eAlert System  Driving Quality Improvement in Medical Device   
  Management through Regulation
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HSE Environmental Health Workshop Social Media and Internet Investigations
IAT Symposium  Directive 2010/63/EU: The Role of the HPRA
Informa Life Sciences Complying with the Requirements for Medical Device  
  Vigilance
International Society for Pharmaceutical Engineering Benchmarking for Pharmaceutical Regulators
Irish Association of Chemicals and Ingredients Active Substance Distribution and Importation
Irish Cosmetics Detergent & Allied Products Association Compliance with the Cosmetic Regulations
Irish Institute of Pharmacy Seminar  Supporting the Pharmacy Journey: A Healthcare Products  
  Regulatory Perspective 
Joint DIA EMA RMP Information Day Lessons learned from PRAC experience with Risk   
  Management Plans, Reflections from PRAC
Mobile Course on Process Analytical Technology (PAT) Implementation of a PAT Technology and Thoughts on  
  QbD
Organ Donation and Transplant Ireland The Role of the HPRA in the Regulation of Blood, Tissues  
  and Organs
PDA  Process Validation: Regulatory Observations
PharmaBioServ Workshop Quality Risk Management Perspective of Quality Defects
Pharmaceutical Manufacturing The Regulatory Framework: The Role of the HPRA and RSI 
Technology Centre Knowledge Day
Pharmaceutical Quality Group Quality Defect Investigations and Recalls on the Irish  
  Market
PharmaChemical Ireland Supply Chain Regulation
PharmaChemical Ireland / PDA / ISPE Conference Patient Health and Product Innovation: The Role of the 
Medicines Regulator
PharmaChemical Ireland / PDA / ISPE Conference QRM in the GMP Environment
PIC/S Expert Circle Computerised Systems and Data Integrity –  
  Inspection Tips
PIC/S Expert Circle GDP Regulatory Update
POCT Workshop  Vigilance Reporting for Devices in the Point of  
  Care Setting
Process Analytical Technology (PAT) Seminar PAT: A Regulatory Perspective
QP Forum (TCD)  Electronic Systems: Regulatory Observations
Regulatory Science Ireland  Generating Knowledge from Quality Defect Data
Swissmedic  Development of Veterinary Medicinal Law in the EU
Tissue Establishments / ART Tissue Establishments (1) Single European Code for Tissues and Cells and  
  (2) Commission Directive 2015/566
TOPRA  Content of the Dossier
TOPRA  Veterinary Regulatory Affairs
Turkish Study Visit to IBTS EU Blood Legislation: The Role of the HPRA 
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APPENDIX 3
Human Medicines Safety:   
Publications and Articles
Drug Safety Newsletters 
Edition Topics Covered
February  -  Beta interferons: Risk of thrombotic microangiopathy and nephrotic syndrome 
66th Edition -  Mycopheolate mofetil (CellCept) and Mycophenolic acid (Myfortic):  
  New warnings about the risks of hypogammaglobulinaemia and bronchiectasis 
 - Eligard (leuprorelin acetate depot injection): Risk of lack of efficacy due to incorrect   
  reconstitution and administration process 
 - Tecfidera (dimethylumarate): Progressive Multifocal Leukoencephalopathy (PML)  
  in a patient with severe and prolonged lymphopenia 
 - New Direct Healthcare Professional Communications published on the HPRA website
April -  Bisphosphonates and denosumab: Minimising the risk of osteonecrosis of the jaw (ONJ) 
67th Edition -  Risk of severe allergic reactions with ambroxol and bromhexine containing medicines  
  considered small       
 -  New restriction for hydroxyzine-containing medicines to further minimise the known  
  risk of QT prolongation 
 -  The importance of product information for medicines 
 -  New Direct Healthcare Professional Communications (DHPC) published on the  
  HPRA website 
June -  Ibuprofen: Review confirms small increased cardiovascular risk with daily doses at or  
68th Edition  above 2400mg 
 -  Codeine: Restricted use in children and adolescents for cough and cold 
 - Adverse reaction reporting - reminder 
 - EU HCP survey 
 - New Direct Healthcare Professional Communications (DHPC) published  
  on the HPRA website
July -  Systemic fusidic acid and interaction with statins: Reminder of risk of rhabdomyolysis 
69th Edition -  Risk of clinically significant arrhythmias when Harvoni or Daklinza in combination with  
  Sovaldi are given concomitantly with Cordarone X 
 -  New Direct Healthcare Professional Communications (DHPC) published on the  
  HPRA website
September - Proton Pump Inhibitors: Very rare reports of subacute erythematosus (SCLE)  
70th Edition -  Donepezil: Reports of Rhabdomyolysis.  
 -  Adverse Reaction Reporting during 2014 
 -  New Direct Healthcare Professional Communications (DHPC) published  
  on the HPRA website
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December  -  Reminder: Oral Methotrexate and risk of unintentional overdose due to medication error 
71st Edition -  Tecfidera (dimethyl fumarate): New measures to minimise the risk of PML 
 -  EU review concluded that evidence does not support that HPV vaccines cause  
  CRPS or POTS 
 -  New Direct Healthcare Professional Communications (DHPC) published on the  
  HPRA website
December  - Bisphosphonates: Small risk of osteonecrosis of the external auditory canal 
72nd Edition -  Mycophenolate mofetil (Cellcept) and Mycophenolic acid (Myfortic):  
  Risk of teratogenicity and new pregnancy prevention advice for women and men 
 -  The starting dose of thalidomide should be reduced when combined with melphalan in  
  patients over 75 years of age 
 -  New Direct Healthcare Professional Communications (DHPC) published on the  
  HPRA website
Articles in External Publications
Month Publication Topic
January MIMS / MIMS Compendium - Valproate containing medicines: Recommendation to   
   further restrict the use of valproate in women and girls 
  - Recommendation to restrict the combined use of medicines  
   affecting the renin-angiotensin (RAS) system  
   (Circulatory Section of the Compendium) 
  - Transdermal Fentanyl: Reminder about the potential for  
   life-threatening harm from accidental exposure  
   (Pain Section of the Compendium)
February IMF - Domperidone-containing medicines: Risk of cardiac adverse  
   reactions and restrictions for use 
February MIMS - Ivabradine (Procorlan): New contraindication and    
   recommendations to minimise the risk of cardiovascular events  
   and severe bradycardia
March MIMS /  - Eligard (leuprorelin acetate depot injection): Risk of lack of   
 MIMS Cardiac Supplement  efficacy due to incorrect reconstitution and administration process 
  - Ivabradine (Procorlan): New contraindication and    
   recommendations to minimise the risk of cardiovascular events  
   and severe bradycardia
April MIMS / MIMS  - Beta interferons: Risk of thrombotic microangiopathy and   
 Respiratory Supplement  nephrotic syndrome 
  - Risk of severe allergic reactions with ambroxol and bromhexine- 
   containing medicines considered small
May MIMS / MIMS  - Bisphosphonates and denosumab: Minimising the risk of   
 Oncology Supplement  osteonecrosis (ONJ)
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June MIMS - The Importance of Product Information for Medicines
July MIMS / MIMS  - Ibuprofen: Review confirms small increased     
 Diabetes Supplement  cardiovascular risk with daily doses at or above 2400mg 
  - Adverse Reaction Reporting: Reminder
August IMF - Systemic fusidic acid and interaction with statins:  
   Reminder of risk of rhabdomyolysis
August MIMS - Systemic fusidic acid and interaction with statins:  
   Reminder of risk of rhabdomyolysis
September MIMS - Codeine: Restricted use in children and adolescents  
   for cough and cold
October MIMS / MIMS  - Proton Pump Inhibitors: Very rare reports of 
 MS Supplement  subacute cutaneous lupus erythematosus (SCLE) 
  - Fingolimod (Gilenya): PML in an MS patient without previous  
   treatment with natalizumab or other immunosuppressive   
   medicines
November MIMS / MIMS  - Donepezil: Reports of Rhabdomyolysis     
 Diabetes - Risk of diabetic ketoacidosis during treatment with  
 Supplement  SGLT2 inhibitors
December MIMS / MIMS  - Adverse Reaction Reporting during 2014 
 Oncology - The starting dose of thalidomide should be reduced when   
 Supplement / MIMS  combined with mephalan in patients over 75 years 
 Compendium - Reminder: Oral methotrexate and risk of unintentional overdose  
   due to medication error
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Committee / Working Group Organisation Meetings in  
   2015
Compliance and Enforcement Working Group Competent Authorities  3 
 Working Group 
Committee of Experts Combating Risks of Counterfeit Medicines Council of Europe 2
European Pharmacopoeia Commission  Council of Europe 3
Pompidou Group – Drug Precursors Council of Europe 1
P-SC-COS (Committee of Experts on Cosmetics) Council of Europe 2
Regional Meeting of the Medicrime Convention Council of Europe 1
Medication Safety Forum Department of Health 3
Chemicals Interdepartmental / Agency Group Department of Jobs  1 
 Enterprise and Innovation 
Market Surveillance Forum - Cosmetics Department of Jobs  4 
 Enterprise and Innovation 
Official Medicines Control Laboratories - Network Meetings  EDQM 7
Committee for Advanced Therapies EMA 11
Committee for Medicinal Products for Human Use (CHMP) EMA 11
Committee for Medicinal Products for Veterinary Use (CVMP) EMA 11
Committee for Orphan Medicinal Products (COMP) EMA 11
Committee on Herbal Medicinal Products (HMPC) EMA 6
Efficacy Working Party - Veterinary EMA 3
European Surveillance of Veterinary Antimicrobial Consumption EMA 1
Expert Group on the Application of the 3Rs in Regulatory Testing EMA 2
GCP Inspectors Working Group  EMA 4
GMDP Inspectors Working Group EMA 4
Immunological Working Party - Veterinary EMA 3
APPENDIX 4   
European and National  
Committee /  
Working Group Participation
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Impact of Pharmacovigilance EMA 1
Paediatric Committee (PDCO) EMA 12
Pharmacovigilance Inspectors Working Group - Human EMA 2
Pharmacovigilance Inspectors Working Group - Veterinary EMA 2
Pharmacovigilance Risk Assessment Committee  EMA 11
Pharmacovigilance Working Party - Veterinary EMA 6
Quality Defects / Rapid Alerts Meeting EMA 1
Quality Working Party  EMA 4
Safety Working Party  EMA 4
Scientific Advice Working Party  EMA 11
Project and Maintenance Group 1 (Pharmacovigilance) EMA and National Competent Authorities 17
Health Advisory Committee Environmental Protection Agency 3
Notified Body Operations Group EU Working Group 2
Competent Authorities for Blood European Commission 2
Competent Authorities for Organs for Human Transplantation European Commission 2
Competent Authorities for Tissues and Cells European Commission 2
Cosmetic Borderline Working Group European Commission 2
Cosmetic Standing Committee and Working Group European Commission 3
Drug Precursors Working Group European Commission 2
European Commission Sub-working Group on Cosmetovigilance European Commission 2
European Surveillance Strategy European Commission 2
In-Vitro Diagnostic Technical Working Group European Commission 1
MDEG Working Group on Vigilance European Commission 2
Medical Device Expert Group European Commission 
Meeting of Expert Group on Safety Features European Commission 5
National Contact Points for the Implementation  European Commission 1 
of Directive 2010/63/EU 
PEMSAC (Platform of European Market Surveillance  European Commission 2 
Authorities for Cosmetics) Market Surveillance 
PEMSAC (Platform of European Market Surveillance  European Commission 2 
Authorities for Cosmetics) Analytical Methods 
Project Evaluation Expert Working Group (Directive 2010/63/EU) European Commission 1
Safe and Timely Access to Medicines (STAMP)  European Commission 1
SCOPE Work Package  European Commission 13
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Single European Code Working Group Meeting European Commission 1
Statistical Reporting Requirements (Directive 2010/63/EU) European Commission 2
Blood Working Group - Experts Sub-Group on Haemovigilance)  Experts Sub-Group on  1 
 Haemovigilance 
Food Fraud Task Force Food Safety Authority of Ireland 3
Patient Safety Surveillance Advisory Group HIQA 1
Clinical Trial Facilitation Group (CTFG) HMA 
Co-ordination Group for Mutual-recognition and  HMA 10 
Decentralised Procedures (Human) CMD(h) 
Co-ordination Group for Mutual-recognition  HMA 10 
and Decentralised Procedures (Veterinary) CMD(v) 
European Medicines Agencies Co-Operation of Legal  HMA 2 
and Legislative Issues 
Homeopathic Medicinal Products Working Group (HMPWG) HMA 2
Meeting of Heads of Medicines Agencies under EU Presidency  HMA 4
Network Training Centre HMA 
Pharmacovigilance Procedures Work Sharing Working Party  HMA 7
Telematics Working Groups HMA 
Working Group of Communications Professionals HMA 2
Working Group of Enforcement Officers HMA 5
Working Group of Quality Managers HMA 2
Operation Pangea Interpol 4
HPRA – UK Department for Business Innovation & Skills Ireland/UK Working Group 5
FOAM (Forum on the Advertising of Medicines) Network Meeting   MHRA 1
Meeting of Competent Authorities for Medical Devices  National Competent Authorities 2 
under European Presidency 
Cosmetic Standards Advisory Group NSAI 2
Permanent Forum on International Pharmaceutical Crime (PFIPC)  PFIPC 1
Committee of Officials  PIC/S 2
Executive Bureau  PIC/S 2
GDP Working Group PIC/S 2
QRM Expert Circle  PIC/S 1
Point of Care Testing Consultative Group RCPI 2
HEO Enforcement Forum Revenue’s Customs Service 1
Fakecare University of Trento, Italy and AEMPS, Spain 2
Fraudulent Medical Products UNODC 1
Annual National Pharmacovigilance Centres Meeting WHO 1
Board of the WHO/UMC Collaborating Centre WHO 3
Member State Mechanism on SSFFC Medical Products WHO 1
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Glossary
AED Automated External Defibrillator 
APMI Association of Pharmaceutical Manufacturers in Ireland 
ASR Annual Safety Report 
ATMP Advanced Therapy Medicinal Product
BEMA Benchmarking of European Medicines Agencies
CAMD Competent Authority for Medical Devices 
CAT Committee for Advanced Therapies 
CD Controlled Drugs 
CESP Common European Submission Portal
CHMP Committee for Medicinal Products for Human Use 
CMC Central Management Committee 
CMD(h) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human
CMD(v) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary 
CMS Concerned Member State
COMP  Committee for Orphan Medicinal Products 
CTFG  Clinical Trials Facilitation Group 
CVMP  Committee for Medicinal Products for Veterinary Use 
DCP  Decentralised Procedure 
DPP  Director of Public Prosecutions
EDQM European Directorate for Quality of Medicines 
EEA European Economic Area 
EMA European Medicines Agency 
EUDAMED European Database on Medical Devices
FSAI Food Safety Authority of Ireland
GCP Good Clinical Practice 
GDP Good Distribution Practice 
GMP Good Manufacturing Practice
GVP Good Vigilance Practice 
HIQA Health Information and Quality Authority 
HMA Heads of Medicines Agencies
HMPC Committee on Herbal Medicinal Products 
HPSC Health Protection Surveillance Centre 
HSE Health Service Executive
HTA Health Technology Assessment
IAHS Irish Association of Health Stores 
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IBTS Irish Blood Transfusion Service 
ICH International Conference of Harmonisation 
ICMRA International Coalition of Medicines Regulatory Authorities
IMDA Irish Medical Devices Association 
IMDRF International Medical Device Regulators Forum
IMF Irish Medicines Formulary
IMSTA  Irish Medical and Surgical Trade Association
IPHA Irish Pharmaceutical Healthcare Association
IVD In-Vitro Diagnostics 
MAH Marketing Authorisation Holder 
MEDDEV Medical Devices Guidance Document from the European Commission
MIMS Monthly Index of Medical Specialities 
MRP Mutual Recognition Procedure 
NBOG  Notified Body Operations Group 
NCA National Consumer Agency 
NHO National Haemovigilance Office
NSAI National Standards Authority of Ireland 
OMCL Official Medicines Control Laboratories 
OTC  Over-the-Counter 
PASS  Post Authorisation Safety Studies 
PCI Pharmachemical Ireland 
PDCO  Paediatric Committee 
PDP Performance Development Programme
PIC/S Pharmaceutical Inspection Co-operation Scheme 
PIF  Product Information File 
PRAC Pharmacovigilance Risk Assessment Committee
PSUR Periodic Safety Update Report
PSUSA EU Single Assessment Procedures
RMP Risk Management Plan 
RMS  Reference Member State 
SmPC Summary of Product Characteristics
THMP Traditional Herbal Medicinal Product
UMC Uppsala Monitoring Centre 
VHP Voluntary Harmonisation Procedures 
VMD Veterinary Medicines Directorate 
WHO World Health Organization 
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